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Abstract
Moniliformin (MON) is a mycotoxin with low molecular weight primarily produced by Fusarium fungi
and occurring predominantly in cereal grains. Following a request of the European Commission, the
CONTAM Panel assessed the risk of MON to human and animal health related to its presence in food
and feed. The limited information available on toxicity and on toxicokinetics in experimental and farm
animals indicated haematotoxicity and cardiotoxicity as major adverse health effects of MON. MON
causes chromosome aberrations in vitro but no in vivo genotoxicity data and no carcinogenicity data
were identiﬁed. Due to the limitations in the available toxicity data, human acute or chronic
health-based guidance values (HBGV) could not be established. The margin of exposure (MOE)
between the no-observed-adverse-effect level (NOAEL) of 6.0 mg/kg body weight (bw) for
cardiotoxicity from a subacute study in rats and the acute upper bound (UB) dietary exposure
estimates ranged between 4,000 and 73,000. The MOE between the lowest benchmark dose lower
conﬁdence limit (for a 5% response - BMDL05) of 0.20 mg MON/kg bw per day for haematological
hazards from a 28-day study in pigs and the chronic dietary human exposure estimates ranged
between 370 and 5,000,000 for chronic dietary exposures. These MOEs indicate a low risk for human
health but were associated with high uncertainty. The toxicity data available for poultry, pigs, and mink
indicated a low or even negligible risk for these animals from exposure to MON in feed at the
estimated exposure levels under current feeding practices. Assuming similar or lower sensitivity as for
pigs, the CONTAM Panel considered a low or even negligible risk for the other animal species for which
no toxicity data suitable for hazard characterisation were identiﬁed. Additional toxicity studies are
needed and depending on their outcome, the collection of more occurrence data on MON in food and
feed is recommended to enable a comprehensive human risk assessment.
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Summary
In a request from the European Commission, the Panel on Contaminants in the Food Chain
(CONTAM Panel) was asked to assess on the basis of the available information the risk for public
health and farm and companion animals related to the presence of moniliformin (MON) in food and
feed. The potential risks for the different animal species and speciﬁc (vulnerable) groups of the human
population should be considered.
MON is a mycotoxin with low molecular weight typically, but not exclusively, produced by several
plant pathogenic Fusarium species. It has mainly been detected in cereal grains and cereal-based food
and feed. Naturally occurring modiﬁed forms of MON have not been reported. Analytical methods for
MON in food, feed and biological samples have been mostly based on liquid chromatography coupled
to ultraviolet detection (LC-UV) and LC with tandem mass spectrometry (LC–MS/MS). Currently,
LC–MS/MS is the most widely used and preferred analytical technique. However, none of the applied
analytical methods for MON have been formally validated in inter-laboratory studies. Certiﬁed reference
materials were not available for MON but calibrants were commercially available.
Occurrence of MON in various cereal grains, such as maize, wheat, barley and oats, and in products
produced from them has been reported in the literature, and co-occurrence with other mycotoxins, in
particular with trichothecenes, enniatins, beauvericin and zearalenone, was found. Within the available
occurrence data sampled between 2001 and 2016 was a total of 3,205, 806, and 504 analytical results
of MON for food, feed and unprocessed grains of undeﬁned end-use, respectively, that fulﬁlled the
required quality criteria of EFSA. However, the proportion of left-censored data (results below the limit
of detection (LOD) or limit of quantiﬁcation (LOQ)) was high and reached 90% for MON in food, 60%
for MON in feed and 70% for MON in unprocessed grains of undeﬁned end-use. The LODs ranged
between 1 and 20 lg/kg food, 5 and 52 lg/kg feed and were equal to 8 lg/kg grains. The LOQs
ranged between 4 and 66 lg/kg food, 7 and 171 lg/kg feed and were equal to 39 lg/kg grains. The
highest mean concentrations of MON were recorded for food in the categories ‘Grains for human
consumption’, ‘Snack food’ and ‘Breakfast cereals’, for feed in the category ‘Cereal grains’ (i.e. maize
and barley) and for unprocessed grains of undeﬁned end-use in the category ‘Grains as crops’ (i.e.
wheat and oat grain).
Cleaning and sorting of grains resulted in a reduction of MON in subsequently produced products.
Milling of grains led to a redistribution of MON into different fractions. Semolina, ﬂour and feed ﬂour
contained the highest concentrations of MON. Cooking and baking generally led to reductions of MON
concentrations in contaminated samples. MON was unstable under high temperatures in combination
with alkaline conditions. In the absence of studies with feed materials, the CONTAM Panel considered
the effects of the processing of animal feeds were similar to those reported for food. Although the
effects of ensiling on MON appeared not to have been studied so far, in view of the relatively high
levels of MON reported in maize grains, plants intended for silage were considered as also potential
sources of exposure to MON for ruminant livestock.
The estimates of mean acute human exposure to MON across dietary surveys and age groups
ranged from 82 to 530 ng/kg body weight (bw) per day based on the mean upper bound (UB)
concentrations The estimates based on the UB of the 95th percentile acute exposure ranged from 202
to 1,489 ng/kg bw per day. The highest acute dietary exposures were for infants, toddlers and other
children. The estimates of mean chronic human exposure to MON across dietary surveys and age
groups ranged from 0.04 to 226 ng/kg bw per day (minimum lower bound (LB) to the maximum UB).
The estimates at the 95th percentile ranged from 0.06 to 528 ng/kg bw per day (minimum
LB–maximum UB). The highest chronic dietary exposures were for infants, toddlers, other children and
adolescents. The most important contributors to the chronic dietary exposure to MON were ‘Grains and
grain-based products’, especially ‘cereal ﬂakes’. The limited available consumption data on vegetarians
did not indicate a major difference in the dietary exposure to MON between them and the general
population.
Exposure of farm and companion animals to MON was primarily from consuming cereal grains and
cereal by-products. Levels reported for grass-based forages were generally low. For ruminants, the
estimated lowest LB and highest UB mean dietary exposures were 0.04 and 1.6 lg/kg bw per day, and
the 95th percentile exposures were 0.27 and 2.4 lg/kg bw per day, respectively. For pigs, the
estimated lowest LB and highest UB mean dietary exposures were 0.65 and 2.2 lg/kg bw per day, and
the 95th percentile exposures were 2.8 and 5.6 lg/kg bw per day, respectively. For poultry, the
estimated lowest LB and highest UB mean dietary exposures were 0.71 and 3.2 lg/kg bw per day, and
the 95th percentile exposures were 3.6 and 10 lg/kg bw per day, respectively. For horses, the
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estimated LB and UB mean dietary exposures to MON were 0.06 and 0.27 lg/kg bw per day, and the
95th percentile exposures were 0.31 and 0.68 lg/kg bw per day, respectively. For farmed ﬁsh
(salmonids and carp), the estimated lowest LB and highest UB mean dietary exposures were 0.10 and
0.51 lg/kg bw per day, and the 95th percentile exposures were 0.38 and 1.5 lg/kg bw per day,
respectively. For farmed rabbits, the estimated LB and UB mean dietary exposures were 0.39 and
1.0 lg/kg bw per day, and the 95th percentile exposures were 2.5 lg/kg bw per day (both, LB and
UB). For farmed mink, the estimated LB and UB mean dietary exposures were 0.24 and 0.33 lg/kg bw
per day, and the 95th percentile exposures were 0.99 and 1.05 lg/kg bw per day, respectively. For
dogs and cats, the estimated lowest LB and highest UB mean dietary exposures were 0.22 and
0.33 lg/kg bw per day, respectively, and the 95th percentile exposures were 0.80 lg/kg bw per day
for dogs and 0.75 lg/kg bw per day for cats (both, LB and UB).
The data on the toxicokinetics of MON in experimental animals were limited. In rats, a large portion
of MON was absorbed and excreted rapidly after administration with no apparent accumulation in any
tissue. However, the fate of at least half of the amount ingested remained unknown. In this opinion,
no data on toxicokinetics were identiﬁed for farm and companion animals. The only available study on
the transfer of MON from feed to food products of animal origin was identiﬁed for broiler chickens,
where no transfer was found.
Acute toxicity of MON was identiﬁed in rats, with oral LD50 values ranging from 19 to 25 mg
MON/kg bw. The oral acute toxicity in mice was lower with LD50 values of about 50 mg MON/kg bw.
Acute toxicity was accompanied by muscular weakness, respiratory and cardiovascular changes, the
latter including faint heart beats and cardiac arrhythmia. The CONTAM Panel identiﬁed the presence of
ultrastructural lesions in the myocardium, reduction of contractility in aorta, pulmonary artery and
terminal ileus, decreased myocardial contractile force and ventricular arrhythmia and congestive heart
failure as prominent acute adverse health effects in experimental animals. The CONTAM
Panel identiﬁed only one subacute toxicity study in rats, which allowed the identiﬁcation of a
no-observed-adverse-effect level (NOAEL) of 6 mg/kg bw per day. Cardiotoxicity was observed at
15 mg/kg bw per day and indications of cardiotoxicity were seen at doses as low as 9 mg MON/kg bw
per day. Only one subchronic toxicity study based on a limited number of rats was identiﬁed. MON
induced cardiotoxicity and mortality at 32.5 mg MON/kg bw per day and higher, while no adverse
effects were observed at the lowest dose tested (16.6 mg MON/kg bw per day), which was identiﬁed
as NOAEL for mortality. Data on haematotoxicity or myelotoxicity and on immunotoxicity were too
scarce to conclude on the hazard of MON in experimental animals. No chronic toxicity studies or any
carcinogenicity study on MON were identiﬁed in experimental animals. For developmental and
reproductive toxicity of MON, only one study in mink was identiﬁed from which the lowest dose of
0.92 mg MON/kg bw per day was identiﬁed as NOAEL. Exposure to 1.94 mg MON/kg bw per day, the
other dose tested, resulted in signiﬁcant neonatal mortality and reduced offspring body weights. There
was no evidence that MON induces bacterial reverse mutation. MON has been shown to be clastogenic
in vitro inducing chromosomal damage. No data were identiﬁed to conclude on whether in vitro
genotoxicity is caused by a direct or indirect mechanism. No data were available on genotoxicity of
MON in vivo.
No relevant human epidemiological data on MON were identiﬁed. Although it has been
hypothesised in published literature that dietary exposure to MON was involved in past incidence and
prevalence of Keshan disease (KD) in some regions in China, the CONTAM Panel noted that the
evidence for a causal relation between dietary exposure to MON and the incidence of KD was too
weak and insufﬁcient for human hazard characterisation.
Only a limited amount of data was available on the mode of action of MON and the mode was
unclear. The inhibition of enzymes involved in glucose metabolism could lead to cellular energy
deprivation and may partially explain the respiratory stress, including myocardial effects. The available
database of possible effects of combined exposure to MON and other mycotoxins was weak and
insufﬁcient to establish the nature of combined effects.
Data on adverse health effects in farm and companion animals were lacking for most of the animal
species. Information was available on poultry and, however limited, for pigs, farmed ﬁsh and farmed
mink. Mortality and reduced body weight gain were identiﬁed as chronic adverse effects both in pigs
and poultry.
From the few available studies on the toxicity of MON in pigs, reduced weight gain, adverse
haematological effects, cardiotoxicity and mortality accompanied with lesions in heart were identiﬁed
as critical adverse health effects. The NOAEL for reduced body weight gain ranged between 50 and
100 mg MON/kg feed, corresponding to 1.2 and 2.2 mg MON/kg bw per day. For haematological
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adverse effects, a NOAEL of 25 mg MON/kg feed corresponding to 1.0 mg MON/kg bw per day was
identiﬁed. A lowest BMDL05 of 0.20 mg MON/kg bw per day was calculated from the dose–response
data on the decrease of haematocrit and haemoglobin levels and this was the most sensitive endpoint
for pigs exposed to MON. Mortality was observed at a dose as low as 4.17 mg MON/kg bw per day. A
study in miniature pigs showed cardiotoxicity at 3 mg MON/kg bw per day.
In poultry, the heart was the main target organ causing heart failure at acute doses. Repeated
dietary exposure to MON not only generated cardiomegaly but also changed haematological
parameters and affected body weight gain and egg production. For 1-day-old chickens, oral LD50
values of 4.0 and 5.4 mg MON/kg bw were reported. Ascites with oedema of the mesenteries and
small haemorrhages in the proventriculus, gizzard, small and large intestine, and skin were observed in
surviving chickens. For 7-day-old ducks, an oral LD50 value of 3.7 mg MON/kg bw with increasing heart
rates followed by arrhythmia and ultimately cessation of contraction were reported. In broiler chickens,
the dose of 2.8 mg MON/kg bw per day resulted in reduced body weight gain, cardiomyopathy,
changes in the major haematological parameters and increased mortality rates, while at 1.4 mg
MON/kg bw per day no adverse effects were observed. In the only available study on laying hens, the
dose of 8.5 mg MON/kg bw per day reduced egg production and body weight gain, while 3.8 mg
MON/kg bw per day did not generate any adverse effects. In turkeys, no adverse effects were
observed at 1.6 mg MON/kg bw per day, while a dose of 3.2 mg MON/kg bw per day induced
cardiomegaly. Based on two studies on ducks, the dose of 2.8 mg MON/kg bw per day generated
cardiomegaly, while no adverse effects were observed at 2.3 mg MON/kg bw per day.
Only two studies on farmed ﬁsh were identiﬁed. Reduced weight gain was reported for channel
catﬁsh at the lowest dose of 0.8 mg MON/kg bw per day. Nile tilapia appeared to be more resistant
and no effects were observed at 1.8 mg/kg bw per day.
In farmed mink, a dose of 1.94 mg MON/kg bw per day resulted in signiﬁcant neonatal mortality
and it reduced body weight of the offspring. This dose was identiﬁed as the lowest-observed-adverse-
effect level (LOAEL), whereas 0.92 mg MON/kg bw per day was the NOAEL.
Given that no toxicity data suitable for hazard characterisation of MON were identiﬁed for ruminants,
farmed rabbits, horses, farmed ﬁsh, dogs and cats and no NOAELs/LOAELs could be determined for
these farm and companion animals, the CONTAM Panel considered the benchmark dose lower
conﬁdence limit for a benchmark response of 5% (BMDL05) of 0.20 mg MON/kg bw identiﬁed for pigs
as an indicative reference point for those. The CONTAM Panel noted that the conclusion on animals
other than poultry, pigs and farmed mink would be affected by a higher degree of uncertainty than that
on the animal species for which sufﬁcient toxicity data were available.
The CONTAM Panel could not establish an acute reference dose (ARfD) for MON due to the
limitations of the available acute and subacute toxicity data. The CONTAM Panel identiﬁed
cardiotoxicity as a critical adverse health effect of acute and subacute exposure to MON and identiﬁed
a NOAEL of 6.0 mg/kg bw from a subacute study in rats as reference point for the acute exposure of
humans to MON. The CONTAM Panel calculated the margin of exposure (MOE) between the NOAEL of
6.0 mg/kg bw from a subacute study in rats and the acute UB dietary exposure estimates. The MOEs
ranged across age groups and consumption studies from 11,000 to 73,000 at the mean and from
4,000 to 29,000 at the 95th percentile dietary exposures, respectively, indicating a low risk for human
health.
Due to limitations in the available toxicity data on chronic effects, the CONTAM Panel could not
establish a tolerable daily intake (TDI) for MON. However, haematotoxicity was the critical chronic
adverse effects of MON in pigs and the CONTAM Panel identiﬁed the lowest BMDL05 of 0.20 mg
MON/kg bw per for the decrease of the haematocrit and haemoglobin levels as reference point for
chronic exposure of humans. In order to get an indication of the possible chronic risk from MON
exposure, the CONTAM Panel calculated the MOE between the lowest BMDL05 of 0.20 mg MON/kg bw
per day calculated for haematological adverse effects from a 28-day study in pigs and the chronic
dietary human exposure estimates. The MOEs ranged across age groups and consumption studies
from 3,900 to 5,000,000 (LB) and from 880 to 25,000 (UB) at the mean exposure, and from 1,400 to
3,300,000 (LB) and from 370 to 4,500 (UB) at the 95th percentile exposure estimates. The CONTAM
Panel concluded that these MOE values were sufﬁciently large to indicate a low risk for human health
from current chronic dietary exposure to MON. However, the CONTAM Panel stressed that in the
absence of quantitative dose–response data on cardiotoxicity this risk characterisation was based on
haematological effects from very limited toxicity database. The limited data on exposure among
vegetarians did not indicate notable differences in acute or chronic dietary exposure between the
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vegetarians and the general population. Therefore, the conclusions on the general population
remained valid also for vegetarians.
The margins (MOEs) between the UB estimates of the dietary exposure and the reference point for
adverse health effects, ranged for pigs between 90 and 160 for the mean and 35 and 60 for the 95th
percentile exposure, for poultry between 430 and 1,400 for the mean and 140 and 460 for the 95th
percentile and it was 2,700 for the mean and 830 for the 95th percentile exposure in the farmed mink.
The CONTAM Panel concluded that the MOE calculated for pigs, poultry and farmed mink indicated
overall a low or even negligible risk for these animal species at the estimated exposure levels of MON
under current feeding practices. The MOEs or the other farm and companion animals for which no
toxicity data suitable for hazard characterisation of MON were identiﬁed, ranged between 120 and
1,400 for the mean and 80 and 290 for the 95th percentile exposure. The CONTAM Panel noted that
these MOEs were similar to those observed for animals for which data on adverse effects were
observed and concluded that the risk for the other farm and companion animals was low or even
negligible at the estimated exposure levels of MON under current feeding practices. The CONTAM
Panel also noted that the conclusion on animals other than poultry, pigs and farmed mink would be
affected by a higher degree of uncertainty than that on the animal species for which sufﬁcient toxicity
data were available.
The CONTAM Panel concluded that in the human risk assessment of MON overall the uncertainty
was large. The impact of the uncertainties in the risk assessment of farm and companion animals was
also large. Therefore, the CONTAM Panel recommends that a well-designed 90-day toxicity study in
rats using puriﬁed MON and according to relevant Organisation for Economic Co-operation and
Development (OECD) guidelines with special focus on the assessment of haematotoxicity, myelotoxicity
and cardiotoxicity should be performed. Furthermore, in vivo studies on the genotoxicity of MON and
more data on the mode of action of MON are needed. The CONTAM Panel also recommends
well-designed studies of the toxicokinetics and adverse effects of MON in experimental and farm and
companion animals, particularly, in animal species other than poultry. The CONTAM Panel further
recommends, depending on the outcome of the above suggested toxicity studies, the collection of
more occurrence data on MON in foods and feeds with state-of-the-art validated analytical methods,
such as LC–MS/MS, to enable a comprehensive risk assessment for humans, and farm and companion
animals.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
Moniliformin (MON) is formed in cereals by a number of Fusarium species that include
F. avenaceum, F. subglutinans and F. proliferatum and occurs as the sodium or potassium salt of
3-hydroxy-3-cyclobutene-1,2-dione. Samples of oats, wheat, maize, rye and triticale have been shown
to be contaminated with MON.
Available information (not exhaustive)
In accordance with Article 36 of Regulation (EC) No 178/2002, a report ‘Scientiﬁc information on
mycotoxins and natural plant toxicants’ has been produced following a grant agreement between the
European Food Safety Authority (EFSA) and the author(s) of the report (CFP/EFSA/CONTAM/2008/01).
The report presents information, inter alia, regarding MON in feed and food and is available on the
EFSA website (http://www.efsa.europa.eu/en/scdocs/doc/24e.pdf).
Issue
In the above mentioned report produced on the request of EFSA, it is concluded that MON is a
toxin of possible concern in animal feed (especially maize-based) but the lack of data on occurrence
and its transfer into animal products make it impossible to evaluate its signiﬁcance to animal and
human health.
Following this conclusion indicating that MON is a toxin of possible concern, the European
Commission asks EFSA to assess on the basis of the available information the risk for farm animals and
public health related to the presence of MON in feed and food in order to enable the European
Commission and the competent authorities in the Member States to consider the need for a possible
follow up including to ﬁll the knowledge gaps.
1.1.2. Terms of Reference
In accordance with Art. 29 (1) of Regulation (EC) No 178/2002, the European Commission asks the
European Food Safety Authority to provide a scientiﬁc opinion on the risks for public and animal health
related to the presence of MON in feed and food.
The assessment should, based upon the available information, assess if the presence of MON in
food and feed is a potential risk for public and animal health taking into account the toxicity of MON
and the occurrence in feed and food. For the assessment of the risks, the situation for the different
animal species and the speciﬁc (vulnerable) groups of the human population (e.g. high consumers,
children, people following speciﬁc diets, etc.) should be considered.
1.2. Interpretation of the Terms of Reference
The CONTAM Panel concluded that the terms of reference provided by the Commission were clear.
1.3. Supporting information for the assessment
1.3.1. Chemistry
Moniliformin (MON) (Figure 1) is a mycotoxin with low molecular weight (free acid: 98.00 g/mol;
molecular formula: C4H2O3; Chemical Abstract Service (CAS) number 31876-38-7) produced by several
Fusarium species (Sydenham et al., 1996) and by Penicillium melanoconidium (Hallas-Møller et al.,
2016). It was discovered in the USA while screening for toxigenic products of Fusarium moniliforme
from the damaged maize seeds which were naturally infected with southern leaf blight by Cole et al.
(1973) who assigned its trivial name moniliformin. Another Fusarium species, F. fujikuroi, which is a
complex of several Fusarium species, producing several different mycotoxins (e.g. beauvericin,
fusaproliferin, and fumonisins B1, B2 and B3) is known to produce substantial amounts of MON (Fotso
et al., 2002). Therefore, these species of Fusarium have often been used as a source of MON in
various studies (see Section 3.1). The CONTAM Panel noted that, since MON was found in 1973, there
has been taxonomic reclassiﬁcation of the MON producing Fusarium species and new evidence has
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also shown that MON is not only produced by Fusarium species (Battilani et al., 2009; Hallas-Møller
et al., 2016). Franck and Breipohl (1984) studied the biosynthesis of MON and concluded from
experimental work that MON is formed through the condensation of two acetate moieties via malonyl
coenzyme A to form 1,3 the intermediate cyclobutanedione, followed by oxidation, tautomerisation and
dehydration.
MON generally occurs in nature as the sodium (CAS number 71376-34-6) or potassium salt (CAS
number 52591-22-7) of 3-hydroxy-3-cyclobutene-1,2-dione, also known as semisquaric acid (Appell
et al., 2007; Battilani et al., 2009; Diaz Toro et al., 2015). Springer et al. (1974) elucidated the MON
chemical structure by X-ray crystallography of the potassium salt. MON is a water soluble, polar, strong
acid with a pKa value of 0.88 (Scharf et al., 1978; Franck and Breipohl, 1984; Verniest et al., 2005).
The ultraviolet (UV) absorbance of MON in distilled water has a maximum at 227 nm and a shoulder at
258 nm with molar absorption coefﬁcients (e) of 1,990 m2/mol and 540 m2/mol, respectively,
(Sydenham et al., 1996). The melting point for the crystalline acid is at 158°C (Cole and Cox, 1981)
and for the sodium and potassium salts above 320°C (Cole and Cox, 1981; Sydenham et al., 1996). In
aqueous buffer solutions, MON was most stable at pH 4. After 60 min at pH 4 and 150°C, MON was
reduced by only 5%. Heating at pH 10 caused major reduction of the concentration of MON. After
60 min at pH 10 and 100, 125 and 150°C, MON was reduced by 56, 72 and 83%, respectively
(Pineda-Valdes and Bullerman, 2000). The free acid of MON is instable in both methanol and water
(Scott and Lawrence, 1987).
The CONTAM Panel noted that at the time of development of this opinion, no naturally occurring
modiﬁed forms of MON have been identiﬁed. Chemically synthesised methyl- and phenyl forms of MON
have been reported by Mrozek (1988).
1.3.2. Methods of analysis
The analytical methodology described in this section mainly relates to the determination of MON in
food and feed. Methods of analysis used for biological samples were applied in studies described in
Sections 3.1.1 and 3.1.3.
1.3.2.1. Sampling and storage
To date, no speciﬁc recommendations concerning sampling and storage of samples intended for the
determination of MON have been established. However, to ensure the reliability of the generated
analytical data, a representative sample must be provided. Due to the possible inhomogeneous
distribution of MON in lots (of grains), sampling may contribute to a signiﬁcant extent to the variability
in analytical results. Samples should be stored under appropriate conditions (dry, preferably frozen)
prior to analysis in order to prevent the growth of fungi and associated production of toxins.
1.3.2.2. Determination of MON
Analytical methods typically consist of MON extraction from the samples with an extraction solvent,
usually followed by a clean-up step to eliminate interferences from the sample matrix, and a ﬁnal
detection/quantiﬁcation step of MON by suitable techniques. Analytical methods for MON have been
reviewed by Zoellner and Mayer-Helm (2006), Krska et al. (2007), Jestoi (2008), Battilani et al. (2009),
Cigic and Prosen (2009). Examples on the methods can be found in Table 1. Besides methods
especially developed for MON analysis (single analyte methods), MON has also been part of multi-
mycotoxin/multianalyte liquid chromatography–mass spectrometry (LC–MS) methods although it is a
highly polar acid raising a particular demand for chromatographic separation (Apfelthaler et al., 2008).
Examples are multianalyte methods including 79 fungal metabolites (Apfelthaler et al., 2008), several
mycotoxins (Sulyok et al., 2006; Herebian et al., 2009; Delgado et al., 2014), or 295 microbial
Figure 1: Chemical structure of moniliformin (MON)
Moniliformin in food and feed
www.efsa.europa.eu/efsajournal 10 EFSA Journal 2018;16(3):5082
metabolites (Malachova et al., 2014) where extracts are directly injected into the LC–MS equipment
(Kokkonen and Jestoi, 2009) or after solid-phase clean-up (Jin et al., 2010). Sometimes, high limits of
quantiﬁcation (LOQs) for MON are achieved in multi-mycotoxin LC–MS methods (Kokkonen and
Jestoi, 2009).
Analyte isolation
MON is soluble in water, but because of possible extraction of undesired impurities from the sample
matrix and because of instant swelling of cooked matrices after application, water is not suitable
as an extraction solvent (Chung et al., 2005). Therefore, extraction is generally carried out with
acetonitrile/water (84–95% acetonitrile) (Scott and Lawrence, 1987; Bosch et al., 1989; Jestoi et al., 2003;
Parich et al., 2003; Jin et al., 2010). In addition, an ion pair reagent tetra-n-butyl ammonium
hydroxide (TBAH) or tetra-n-butyl ammonium hydrogen sulfate (TBAHS) was used to facilitate
extraction (Shepherd and Gilbert, 1986; Munimbazi and Bullerman, 1998). A method combining
TBAHS and a-amylase has also been reported resulting in a higher recovery of MON and lesser
interferences from matrix (Chung et al., 2005). Clean-up steps may involve the use of strong anion
exchange columns (Munimbazi and Bullerman, 1998; Parich et al., 2003) or other solid-phase
extraction columns including MycoSepTM columns (Scarpino et al., 2013). Appell et al., 2007,
synthesised molecularly imprinted polymers to bind MON which were further used as sorbents for
molecularly imprinted solid-phase extraction to pre-concentrate and clean-up maize extracts.
Chromatographic methods
Although MON can be analysed by thin-layer chromatography (TLC), gas chromatography (Gilbert
et al., 1986) and capillary zone electrophoresis (B€ohs et al., 1995; Maragos, 2004), high-performance
liquid chromatography coupled to ultraviolet detection (HPLC-UV) or LC–MS is predominantly used.
Enzyme-linked immunosorbent assays are non-existing as no antibodies were developed against MON
(Appell et al., 2007).
For TLC analysis, MON is visualised by spraying 3-methyl-2-benzothiazolinone hydrazone (MBTH)
(Kostecki et al., 1997) or 2,4-dinitrophenylhydrazine (Kamimura et al., 1981; Jansen and Dose, 1984)
and quantiﬁed by densitometric analysis (Kamimura et al., 1981). Romer et al. (1997) used a one-step
clean-up column MycoSepTM followed by TLC as a rapid detection technique. Determination of MON in
Fusarium cultures/isolates mostly relied on TLC (Bosch et al., 1989; Desjardins et al., 1997; Kostecki
et al., 1997; Sch€utt et al., 1998).
HPLC-UV and HPLC with diode array detection (HPLC-DAD) (Parich et al., 2003; Sorensen et al.,
2007) are mainly used with ion-pair reversed-phase chromatography (Shepherd and Gilbert, 1986;
Scott and Lawrence, 1987; Thiel, 1990; Munimbazi and Bullerman, 1998) or hydrophilic interaction
(HILIC) chromatography (Sorensen et al., 2007) to achieve good chromatographic separation.
Derivatisation of MON also allows the samples to be analysed by ﬂuorescence detection (HPLC-FLD)
(Filek and Lindner, 1996).
LC–MS(/MS) has been used since more recent years (Sewram et al., 1999; Jestoi et al., 2003; Nazari
et al., 2015). MON is efﬁciently ionised in the negative mode of electrospray ionisation and atmospheric
pressure chemical ionisation (Jestoi et al., 2003; Herebian et al., 2009; Jin et al., 2010), but may have
to be derivatised in order to achieve retention on reversed phase LC columns (Zoellner and Mayer-Helm,
2006). Alternatively, ion-pairing (Sewram et al., 1999) or HILIC chromatography (Sorensen et al., 2007)
can be used for this purpose. Also, because of its low molecular weight, only one fragment ion can be
produced out of the precursor ion (Jestoi et al., 2003; Herebian et al., 2009). High-resolution mass
spectrometry for MON analysis in cereal samples was reported by von Bargen et al. (2012) who used
the isotopically labelled 13C2-MON internal standard, as well as by Lim et al. (2015).
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1.3.2.3. Analytical quality assurance: performance criteria, reference materials and
proﬁciency testing for analysis of food
While criteria for methods of analysis for the ofﬁcial control of the levels of various other
mycotoxins are laid down in the Regulation (EU) No 401/2006 of 23 February 20061, as amended by
the Regulation (EU) No 519/2014 of 16 May 20142, performance criteria for methods of analysis of
MON have not been established to date. Currently, certiﬁed reference materials were not available for
MON, but non-certiﬁed calibrant solutions of the sodium salt of MON were commercially available
(Battilani et al., 2009). The free acid of MON must not be used as an analytical standard because of its
instability in both methanol and water (Scott and Lawrence, 1987). Proﬁciency tests for the
determination of MON have not been organised.
1.3.3. Previous risk and exposure assessments on MON
No previous scientiﬁc risk assessments on MON in food and/or feed by national agencies, national
and international independent expert advisory committees were identiﬁed by the CONTAM Panel.
However, one scientiﬁc paper of Peltonen et al. (2010) proposed a tolerable daily intake (TDI) of
0.1 mg/kg body weight (bw) per day based on a preliminary no-observed-adverse-effect levels
Table 1: Typical examples of the method characteristics and limits of quantiﬁcation (LOQ) of
analytical methods used for the determination of MON in food and feed
Analytical
technique
Method characteristics
LOQ
(lg/kg)
References
TLC Screening (qualitative–semiquantitative) nr
(LOD = 50–1,000)
Kamimura et al. (1981)
Kostecki et al. (1997)
Romer et al. (1997)
HPLC-UV/DAD Conﬁrmation (semiquantitative–quantitative)
Possible multianalyte detection
25–136 Shepherd and Gilbert (1986)
Scott and Lawrence (1987)
Lauren and Agnew (1991)
Filek and Lindner (1996)
Kostecki et al. (1997)
Scudamore et al. (1998)
Munimbazi and Bullerman
(1998)
Parich et al. (2003)
Maragos (2004)
Sorensen et al. (2007)
HPLC-FLD Conﬁrmation (semiquantitative–quantitative)
Possible multianalyte detection
20 Filek and Lindner (1996)
HPLC–MS(/MS) Conﬁrmation (semiquantitative–quantitative)
Possible multianalyte detection
0.25–1,250 Sewram et al. (1999)
Jestoi et al. (2003)
Sulyok et al. (2006)
Sorensen et al. (2007)
Herebian et al. (2009)
Kokkonen and Jestoi (2009)
Jin et al. (2010)
Scarpino et al. (2013)
Delgado et al. (2014)
Nazari et al. (2015)
HPLC–HRMS Conﬁrmation (semiquantitative–quantitative)
Possible multianalyte detection
Identiﬁcation of unknown compounds
2.5 von Bargen et al. (2012)
LOQ: limit of quantiﬁcation; LOD: limit of detection; nr: not reported; TLC: thin-layer chromatography; HPLC: high-performance
liquid chromatography; UV: ultra violet; DAD: diode array detection; FLD: ﬂuorescence detection; MS: mass spectrometry;
MS/MS: tandem mass spectrometry; HRMS: high-resolution mass spectrometry.
1 Commission Regulation (EC) No 401/2006 of 23 February 2006 laying down the methods of sampling and analysis for the
ofﬁcial control of the levels of mycotoxins in foodstuffs. OJ L 70, 9.3.2006, p. 12–34.
2 Commission Regulation (EU) No 519/2014 of 16 May 2014 amending Regulation (EC) No 401/2006 as regards methods of
sampling of large lots, spices and food supplements, performance criteria for T-2, HT-2 toxin and citrinin and screening
methods of analysis. OJ L 147, 17.5.2014, p. 29–43.
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(NOAEL) of 10 mg/kg bw per day from the pathological and histopathological data on a single 28-day
rat toxicity study (toxicity data were unpublished at the time). These authors estimated that the
exposures of Finnish children and adults to MON were 5- and 45-fold lower, respectively, than this
proposed TDI. Using a worst-case scenario exposure for Norway, these authors concluded that
exposure to adults was 15-fold lower than this proposed TDI. However, the CONTAM Panel noted that
when this 28-day toxicity study was completed and published later by Jonsson et al. (2015) these
authors could not conﬁrm the suggested NOAEL. The Norwegian Scientiﬁc Committee for Food Safety
(VKM, 2013) conducted a risk assessment for Fusarium mycotoxins but due to lack of sufﬁcient
toxicological evidence no TDI could be derived for MON.
1.3.4. Legislation
In the European Union (EU) and worldwide, no legal maximum levels or guidance levels have been
set for MON in foods and feeds (FAO, 2004; Leatherhead Food Research Association, 2010; Council
Regulation (EEC) No 315/933; Commission Regulation (EC) No 1881/20064; EU Directive 2002/32/EC5;
Recommendation 2006/576/EC6).
1.3.5. Other supporting information
The CONTAM Panel also noted that several reviews on trichothecenes and Fusarium toxins
identiﬁed the possible adverse effects of MON to humans and to several farm animal species, in
particular, poultry (Ueno, 1973; Jestoi et al., 2004; Peltonen et al., 2010; Marin et al., 2013; Escriva
et al., 2015). Two recent papers of Jonsson et al., 2013 and Jonsson et al., 2015; and the recent
review of Freayman et al. (2017) conﬁrmed this.
2. Data and methodologies
2.1. Methodology of data collection for supporting information for the
assessment
2.1.1. Collection and selection of evidence (search strategy, eligibility criteria)
for supporting information
No systematic literature search was carried out for scientiﬁc evidence for the Sections ‘1.3
Supporting information for the assessment’, ‘3.3.1 Occurrence data on food and feed reported in the
available literature’ and ‘3.4 Food and feed processing’. The collected scientiﬁc evidence in these
sections, used as background information for the assessment, was limited to the most relevant
information identiﬁed by the experts of the CONTAM Panel working group on Fusarium toxins.
2.1.2. Appraisal of evidence for supporting information
The inclusion of studies for the Sections ‘1.3 Supporting information for the assessment’, and ‘3.4
Food and feed processing’ was based on consideration by the expert judgement of the CONTAM
working group (WG) on Fusarium toxins of the extent to which the study was informative and relevant
for the assessment accounting for study quality considerations. With regard to the Section ‘3.3.1
Occurrence data on food and feed reported in the available literature’, the appraisal and reporting of
selected data used for the exposure assessment were in compliance with the quality requirements of
EFSA for the occurrence data (see Section 2.3).
3 Council Regulation (EEC) No 315/93 of February 1993 laying down Community procedures for contaminants in food. OJ L 37,
13.2.1993, p. 1–3.
4 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in
foodstuffs. OJ L 364, 20.12.2006, p. 5–24.
5 Directive 2002/32/EC of the European Parliament and the Council of 7 May 2002 on undesirable substances in animal feed. OJ
L 140, 30.5.2002, p. 10–21.
6 Commission Recommendation 2006/576/EC of 17 August 2006 on the presence of deoxynivalenol, zearalenone, ochratoxin A,
T-2 and HT-2 and fumonisins in products intended for animal feeding. OJ L 229, 23.8.2006, p. 7–9.
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2.2. Methodology of data collection for hazard identiﬁcation and
characterisation
2.2.1. Collection and selection of evidence (search strategy, eligibility criteria)
for hazard identiﬁcation and characterisation
A ﬁrst systematic literature search in scientiﬁc databases aimed at identifying studies that have
been published in the open scientiﬁc literature and in scientiﬁc peer-reviewed journals until 17
November 2015. The collection of scientiﬁc studies available in the public domain was done through
searching scientiﬁc literature databases (Web of Science and PubMed) using the word ‘moniliformin’ as
key term word. The search aimed to retrieve as many studies as possible that might be relevant for
hazard identiﬁcation and hazard characterisation of MON. The search was not limited to the evidence
published in English language. The references resulting from the literature search were imported and
managed using a software package (EndNoteX8). Deletion of the duplicate references (automatically
and manually) resulted in 671 references.
The titles and abstracts were screened for the relevant evidence for hazard identiﬁcation and
characterisation of MON. Publications which were not in the ﬁeld of laboratory animals and human
health, and the health of farm and companion animal were excluded in the screening. These papers
reported in particular data on mycology, plant physiology and invasion of plant diseases linked to MON
producing fungi. Conference proceedings and abstracts which were part of the outcome of the
literature search were also reviewed and included when they provided relevant supporting scientiﬁc
information as it was, in particular, the case for the hazard characterisation of poultry.
The identiﬁed publications included in the assessment of MON in this opinion were:
• Papers that had been published in a scientiﬁc journal and were subject to an independent
scientiﬁc peer-review process (i.e. the process that scientiﬁc journals generally use to ensure
that the articles to be published represent the best information available in terms of solid
scientiﬁc soundness and quality control).
• Study reports written in English or in other languages which included an abstract in English
were considered. The only exceptions to this were the studies on human epidemiology written
fully in Chinese (without an English abstract): these were also included when their relevance of
effects of MON in humans observed in toxicosis outbreaks in Asia was clear. When identiﬁed as
relevant by the working group, these and also papers written in other languages than English
were submitted for the translation to the Translation Centre of the Bodies of the European
Union in Luxemburg. The received translation was then included for hazard identiﬁcation and
hazard characterisation of MON and this translation of the paper was indicated as footnote in
this opinion.
• Reviews and book chapters were considered as source of background information and as an
additional source of scientiﬁc evidence unless otherwise stated in this scientiﬁc opinion.
The selection process above resulted in total of 220 publications for human and animal hazard
identiﬁcation and characterisation; among them were 102 publications that contained information on
experimental animals and humans and, partially overlapping, 179 that contained information for farm
and companion animals, mainly poultry (54 publications). Ten papers on toxicosis outbreaks in humans
in Asia and only published in China were obtained from a member of WG on Fusarium toxins during
the development of the scientiﬁc opinion and considered for Section 3.1.7.
To update the published literature for the hazard identiﬁcation and characterisation of MON ﬁrst
collected up to 17 November 2015, the alerts of the table of contents of the journals within mycotoxin
area namely World Mycotoxin Journal, Food Additives and Contaminants, Food and Chemical
Toxicology, Toxicology and Applied Pharmacology, Toxicology, Toxicology Letters, Poultry Science and
Avian Diseases were monitored for relevant publications on MON up to 31 May 2017, and relevant
publications were identiﬁed. This outcome was conﬁrmed by a second systematic literature search for
the time span from 1 January 2016 to 29 May 2017.
2.2.2. Appraisal of evidence for hazard identiﬁcation and characterisation
The retrieved evidence was reviewed by the CONTAM WG on Fusarium toxins and has been used
for this assessment as considered relevant by expert judgement. Any limitations noted by the WG in
the evidence used for the risk assessment of MON in food and feed are described in this scientiﬁc
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opinion. Selection of the scientiﬁc papers considered study quality and the extent to which the study
was relevant (e.g. sufﬁcient details on the methodology, performance and outcome of the study,
information on dosing and route of administration and details of reporting).
The amount of available data on MON for different sections of the assessment varied greatly. In a
ﬁrst step, only those data from which it could clearly be concluded that the adverse effects in
experimental and farm and companion animals were associated with an oral exposure to MON alone
were included in the sections on hazard characterisation of humans and farm and companion animals.
Second, papers reporting oral co-exposure to MON and other mycotoxins were included when it was
clear from the study description and content that the co-exposure did not have a substantial impact on
toxicity of MON: e.g. (1) when the other identiﬁed mycotoxins had concentrations that were not
considered to induce or notably contribute to the observed adverse effects, or (2) when the other
identiﬁed mycotoxins were known to have speciﬁc adverse effects which could not be attributed to
MON, or (3) when the other identiﬁed mycotoxins were not expected to interact with the effects of MON.
Papers were excluded when the reported data were from experiments: (1) designed for using
naturally contaminated feed in which not only MON but also other Fusarium toxins such as fumonisins,
beauvericin or other mycotoxins not produced by Fusarium species were (or might have been) present
in the diet, or (2) the diets were prepared from fermented grains contaminated with Fusarium strains
producing MON and other mycotoxins. Papers on studies in which feed was artiﬁcially contaminated
with pure MON or with added Fusarium culture material reported to contain MON alone were
considered as of providing useful information on the adverse effects induced by MON.
With regard to the evidence on toxicokinetics in experimental animals, the CONTAM Panel decided
to report the available ex vivo data under the header of in vitro data emphasising clearly the nature of
each experiment and which information was considered.
For the study of combined effects of MON with other mycotoxins (Section 3.1.6), only those studies
were included in the assessment in which the experiment design was clearly set up to study combined
effects and in which methodologically sound conclusions were substantiated and reported on the
combined effects.
In this opinion, if not indicated in the text explicitly, the term ‘signiﬁcant’ always indicates the
presence of statistical signiﬁcance at the level of 0.05.
2.3. Occurrence data on MON used for the assessment
2.3.1. Data collection and validation
Following an European Commission mandate to EFSA, a call for annual collection of chemical
contaminant occurrence data in food and feed, including MON, was issued by the former EFSA Dietary
and Chemical Monitoring Unit (now DATA Unit)7 in December 2010 with a closing date of 1 October of
each year.8 European national authorities and similar bodies, research institutions, academia, food
business operators and other stakeholders were invited to submit analytical data on MON in food and
feed. The data for the present assessment were provided by national authorities from Finland, Italy,
the Netherlands, Norway, Sweden and the United Kingdom (UK).
The data submission to EFSA followed the requirements of the EFSA Guidance on Standard Sample
Description for Food and Feed (EFSA, 2010a); occurrence data were managed following the EFSA
standard operational procedures on ‘Data collection and validation’ and on ‘Data analysis of food
consumption and occurrence data’.
In the data validation phase, data reported as suspect samples9 were excluded from the present
analysis. Suspect samples are usually samples taken from the same site as a consequence of evidence
or suspicion of contamination, and are often taken as a follow-up of demonstrated non-compliance
with legislation. Some of the remaining samples may also have been collected in a more targeted way
(i.e. selective sampling, convenient sampling)10 (see also Section 2.3.2).
7 From 1 January 2014 onwards, Evidence Management Unit (DATA).
8 http://www.efsa.europa.eu/en/data/call/datex101217
9 Suspect sampling means ‘selection of an individual product or establishment in order to conﬁrm or reject a suspicion of
non-conformity. It’s not a random sampling, therefore there is no sample extracted from the population’. EFSA Journal 2013;
11(10):3424, 114 pp. https://doi.org/10.2903/j.efsa.2013.3424
10 For the deﬁnition of selective and convenient sampling, see EFSA Journal 2013;11(10):3424, 114 pp. https://doi.org/10.2903/
j.efsa.2013.3424
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By the end of October 2016, 2,800 analytical results of food (including one result from suspect
sampling to be excluded) and 528 results of unprocessed grains of undeﬁned end-use (including 24
from suspect sampling to be excluded) with analytical data on MON were available in the EFSA
database. Data received after the 31 of October 2016 were not included in the data set used for
further evaluation for this opinion.
In addition to the occurrence data collected from the Member States within the call for data, the
CONTAM Panel also searched the published literature for occurrence data of MON in food and feed for
possible inclusion as additional data in the occurrence data sets submitted to EFSA within the call for
data and to be used for the exposure assessment. The literature data were included when they
conformed to the most important EFSA requirements on data collection and validation, and the details
on country of origin, product, sampling, analytical method, LODs/LOQs and occurrence levels (e.g.
mean, median) were adequately reported. As an outcome of this exercise, additional occurrence data
on MON in food (i.e. 406 analytical results) were obtained from the scientiﬁc literature (Jestoi et al.,
2004; Van der Fels-Klerx et al., 2012; Lindblad et al., 2013; Scarpino et al., 2013; Uhlig et al., 2013).
Additional occurrence data on MON in feed (i.e. 191 analytical results) were obtained from the
scientiﬁc literature (Goertz et al., 2010; Van der Fels-Klerx et al., 2012). Furthermore, in the beginning
of the development of this opinion, it was brought to the attention of the CONTAM Panel that two
research groups at research institutes in Austria and Norway wished to provide recent occurrence data
on MON in feed to EFSA. These feed data on MON of 380 analytical results from Austria and 235
analytical results from Norway were also included in the occurrence data set.
After excluding 25 suspect samples, a total of 4,515 analytical results (i.e. 3,205 on food, 806 on
feed and 504 on unprocessed grains of undeﬁned end-use) were available for the exposure
assessment analysis.
2.3.2. Data analysis
Following the EFSA SOP on ‘Data analysis of food consumption and occurrence data’ to guarantee
an appropriate quality of the data used in the exposure assessment, the initial data set was carefully
evaluated applying several data cleaning and validation steps. Special attention was paid to different
parameters such as ‘Sampling strategy’, ‘Sampling method’, ‘Sampling year’, ‘Sampling country’,
‘Analytical methods’, ‘Reporting unit’, ‘LOD/LOQ’ and the codiﬁcation of the different samples under
FoodEx classiﬁcation. Non-targeted sampling (i.e. objective sampling11) had been applied for the
samples from Austria and Norway, and it was interpreted that the non-targeted sampling was also
used for the data collected from the literature.
In the analysis of MON occurrence data, the left-censored data (results below LOD or below LOQ)
were treated by the substitution method as recommended in the ‘Principles and Methods for the Risk
Assessment of Chemicals in Food’ (WHO, 2009). The same method is indicated in the EFSA scientiﬁc
report ‘Management of left-censored data in dietary exposure assessment of chemical substances’
(EFSA, 2010b) as an option in the treatment of left-censored data. The guidance suggests that the
lower bound (LB) and upper bound (UB) approach should be used for chemicals likely to be present in
the food (e.g. naturally occurring contaminants, nutrients and mycotoxins). The LB is obtained by
assigning a value of zero (minimum possible value) to all samples reported as lower than the LOD
(< LOD) or LOQ (< LOQ). The UB is obtained by assigning the numerical value of LOD to values
reported as < LOD and LOQ to values reported as < LOQ (maximum possible value), depending on
whether LOD or LOQ is reported by the laboratory.
2.4. Food consumption data
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database)
provides a compilation of existing national information on food consumption at individual level. It was
ﬁrst built in 2010 (EFSA, 2011a; Huybrechts et al., 2011; Merten et al., 2011). Details on how the
Comprehensive Database is used are published in the Guidance of EFSA (EFSA, 2011b). The latest
version of the Comprehensive Database updated in 2015 contains results from a total of 51 different
dietary surveys carried out in 23 different Member States covering 94,532 individuals.
Within the dietary studies, subjects are classiﬁed in different age classes as follows:
11 Objective sampling means ‘strategy based on the selection of a random sample from a population on which the data are
reported. Random sample is a sample which is taken under statistical consideration to provide representative data.’
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Infants: < 12 months old
Toddlers: ≥ 12 months to < 36 months old
Other children: ≥ 36 months to < 10 years old
Adolescents: ≥ 10 years to < 18 years old
Adults: ≥ 18 years to < 65 years old
Elderly: ≥ 65 years to < 75 years old
Very elderly: ≥ 75 years old
Two additional surveys provided information on speciﬁc population groups: ‘Pregnant women’
(≥ 15 years to ≤ 45 years old; Latvia) and ‘Lactating women’ (≥ 28 years to ≤ 39 years old; Greece).
For chronic exposure assessment, food consumption data were available from 44 different dietary
surveys carried out in 19 different European countries. When for one particular country and age class
two different dietary surveys were available, only the most recent one was used. This resulted in a
total of 35 dietary surveys selected to estimate chronic dietary exposure. In Appendix B, Table B.1,
these dietary surveys and the number of subjects available for the acute and chronic exposure
assessment are described.
The food consumption data gathered by EFSA in the Comprehensive Database are the most
complete and detailed data currently available in the EU. Consumption data were collected using single
or repeated 24- or 48-hour dietary recalls or dietary records covering from three to seven days per
subject. Because of the differences in the methods used for data collection, direct country-to-country
comparisons can be misleading.
2.5. Food classiﬁcation
Consumption data were classiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011c).
FoodEx is a food classiﬁcation system developed by EFSA in 2009 with the objective of simplifying the
linkage between occurrence and food consumption data when assessing the exposure to hazardous
substances. It contains 20 main food categories (ﬁrst level), which are further divided into subgroups
having 140 items at the second level, 1,261 items at the third level and reaching about 1,800 end-
points (food names or generic food names) at the fourth level.
In 2011, a new version of FoodEx, named FoodEx2 was developed and is described in the scientiﬁc
document ‘Report on the development of a Food Classiﬁcation and Description System for exposure
assessment and guidance on its implementation and use’ (EFSA, 2011c). The last release of FoodEx2
complements the previous hierarchical classiﬁcation system of basic codes with more detailed food
levels and gives the possibility of reporting additional information through the use of facets and facet
descriptors (EFSA, 2015).
2.6. Feed consumption data
MON is predominantly found in cereal crops, cereal grains and in by-products of cereal processing,
all of which are widely used as feed for farm animals in Europe. They may be included as ingredients
of manufactured complete feedingstuffs, or fed directly as individual feeds to livestock. In 2015, more
than 90 million tonnes of cereals and cereal by-products were used in the manufacture of compound
feeds, accounting for 60% of all feed materials used, almost all of which (> 95%) are grown or
produced in the EU.12 In addition, a further 51 million tonnes of cereal grains and by-products were
fed in on-farm mixes or as single ingredients. However, there are no industry data on the partition of
these cereal grains between livestock species (cattle, pigs, poultry, etc.).
There is considerable variation in both the feeds used and the feeding systems adopted for farm
livestock, companion animals and ﬁsh throughout Europe. This variation is largely due to the
availability of feeds and market demands for speciﬁc animal products, the quality of the feeds available
and nutritional needs of the animals concerned.
Details of feed consumption of farm and companion animals and the rations used in this opinion
are given in Appendix B.
12 Source: FEFAC Feed and Food Statistical Yearbook 2015. www.fefac.org
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2.7. Methodology for exposure assessment for MON
2.7.1. Methodology for exposure assessment for MON in humans
The CONTAM Panel considered it appropriate to estimate acute and chronic exposure to MON for all
age groups (see Section 3.5). The food categories represented by either very low number of samples
(≤ 5 samples) or by all data left-censored were considered not being suitable and were not used in
exposure calculation.
As reported in Section 3.3.2, quantiﬁed results were reported for ‘Grains and grain-based products’
and for ‘Snack, desserts and other foods’. The proportion of left-censored data was 80% for ‘Grains
and grain-based products’, 25% for ‘Snack, desserts and other foods’ and 100% for the other food
categories. The chronic dietary exposure cannot be performed accurately if a large proportion of left-
censored data is included (WHO, 2009; EFSA, 2011b). Therefore, the large proportion of left-censored
data and the limited available data add uncertainty to the chronic dietary exposure assessment. Since
this was the case for most of the food categories, the results of the present assessment should be
interpreted with caution. It should be noted that with a high proportion of left-censored data, the
exposure is likely to be underestimated with the LB approach, whereas it may be highly overestimated
with the UB approach (see also Section 4).
2.7.1.1. Acute dietary exposure
Acute dietary exposure to MON was estimated using a probabilistic approach. For calculating acute
dietary exposure to MON, food consumption and body weight data at the individual level were
accessed in the Comprehensive Database. The acute dietary exposure to MON was calculated for each
reporting day, since individual meals are recorded for only a few countries in the consumption
database. The preferred option is, therefore, to use individual days of consumption. Days of
consumption offer a conservative estimate of the exposure, since it will sum the contribution of all
meals during the same day. Acute exposure was assessed for each reporting day by multiplying the
total consumption amount for each food category by an occurrence level randomly drawn among
individual results available for that food category. Respective intakes of the foods consumed that day
were summed and ﬁnally divided by the individual’s body weight. This process was iterated 100 times
for each day of consumption reported by each participant. For the calculations, occurrence data
estimated using the UB approach was used. The UB approach is a conservative approach which better
reﬂects the purpose of an acute exposure compared to the LB approach. For each of these endpoints,
the 95% conﬁdence interval was deﬁned as the 2.5th and 97.5th percentiles obtained from the 1,000
iterations. All analyses were run using the SAS Statistical Software (SAS enterprise guide 5.1),
including the modelling of the probabilistic acute exposure.
2.7.1.2. Chronic dietary exposure
As suggested by the EFSA WG on Food Consumption and Exposure (EFSA, 2011b), dietary surveys
with only 1 day per subject were not considered for chronic exposure as they are not adequate to
assess repeated exposure. Similarly, subjects who participated only 1 day in the dietary studies, when
the protocol prescribed more reporting days per individual, were also excluded for the chronic
exposure assessment. Not all countries provided consumption information for all age groups, and in
some cases the same country provided more than one consumption survey. For calculating chronic
dietary exposure to MON, food consumption and body weight data at the individual level were
accessed in the Comprehensive Database. Occurrence data and consumption data were linked at the
lowest (most detailed) FoodEx level possible. In addition, the different food commodities were grouped
within each food category to better explain their contribution to the total dietary exposure to MON.
The mean and the high (95th percentile) chronic dietary exposures were calculated by combining
MON mean occurrence values for food samples collected in different countries (pooled European
occurrence data) with the average daily consumption for each food at individual level in each dietary
survey and age class. Consequently, individual average exposures per day and body weight were
obtained for all individuals. On the basis of distributions of individual exposures, the mean and 95th
percentile exposure were calculated per survey and per age class. Dietary exposure was assessed
using overall European LB and UB mean occurrence of MON.
The contribution (%) of each food category to overall mean chronic exposure of MON was
calculated for each age group and dietary survey. Estimations of chronic exposure using the LB
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approach, which is considered to be less inﬂuenced by results below LOD/LOQ, were used to explain
the contribution of the different food categories.
All analyses were run using the SAS Statistical Software (SAS enterprise guide 5.1).
2.7.2. Methodology for exposure assessment for MON in farm and companion
animals
MON generally occurs in cereals crops, cereal grains and by-products of cereal processing, both for
human food and biofuel production, and as reported in Section 3.3, these may account for 60% or
more of the diet of farm and companion animals. Diets do include a wide range of other feed
materials, particularly vegetable proteins, but since no data are available on levels of MON in these
feeds, it has been assumed that they make no contribution to exposure to MON.
No data on levels of MON in compound feeds have been reported. For forages, data on
concentrations of MON in 42 samples of maize silage were provided for the EFSA database (see
Section 3.3.2.3). Limited data were available for cereal straws, but levels of MON are generally low
while the number of samples reported is insufﬁcient to include the data in estimates of exposure.
A large variety of feed materials are used to formulate diets for livestock and companion animals in
the EU, and information on levels of MON in these feeds is necessary if reliable estimates of exposure
are to be derived. However, as reported in Section 3.3, only data on the major cereal grains (wheat,
barley, oats, rice and maize), and limited data for maize silage and cereal straw, have been available
to assess exposure. As a result, the estimates reported below are likely to be underestimates of
exposure. For certain categories of feeds, e.g. oilseed meals and cakes, the effect of this omission is
likely to be small, since the crops from which these are derived, and the feeds themselves, have not
been reported to be sources of MON. However, by-products derived from cereal grains are also widely
used as animal feeds. In 2015, it was estimated that over 17 million tonnes of cereal by-products were
used in the manufacture of compound feeds,13 representing 11% of all ingredients used, and
therefore, the absence of data on levels of MON in these feed materials on the underestimation is
likely to be greater.
Estimates of exposure to MON by farm and companion animals are based on levels of MON in feed
and the amount of feed consumed. For many livestock in Europe, part or all of the daily ration is
provided in the form of manufactured compound feeds, but for this opinion data on levels of MON in
species-speciﬁc compound feeds were not available. Therefore, intakes of individual feed materials by
farm and companion animals, using example diets (Appendix B), have been used to estimate
exposure. It should be stressed that these do not represent either ‘average’ or ‘extreme’ diets, nor are
the feeding systems ‘typical’ for all of Europe. Instead, the diets are used to estimate levels of
exposure to MON that might be indicative. They are based on published guidelines on nutrition and
feeding (AFRC, 1993; Carabano and Piquer, 1998; NRC, 2007a,b, Leeson and Summers, 2008;
McDonald et al., 2011; EFSA FEEDAP Panel, 2012; OECD, 2013), and expert knowledge of production
systems in Europe. Details of the rations used feed intakes and live weights assumed are given in
Appendix B.
For all species, the mean and 95th percentile (high) exposures have been estimated based on the
mean and the 95th percentile LB and UB concentrations, respectively. According to EFSA, 2011c,
caution is needed when calculating acute exposure (95th percentile) where data on less than 60
samples are available, since the results may not be statistically robust. Therefore, in this Opinion
estimates of the 95th percentile have not been made where data on < 60 samples are available. It
should be noted that the estimates at the 95th percentile concentrations were calculated in order to
characterise the farm and companion animals health risk associated with chronic dietary exposure to
MON when high concentrations of MON are found in the feed, e.g. due to favourable growing season
for MON production.
2.8. Methodology for risk characterisation
The CONTAM Panel applied the general principles of the risk assessment process for chemicals in
food as described by WHO (2009), i.e. hazard identiﬁcation and characterisation, exposure assessment
and risk characterisation. Several EFSA guidance documents were applied in the assessment of MON in
food and feed listed in Appendix A.
13 Food and Feed Statistical Yearbook 2015. www.FEFAC.org
Moniliformin in food and feed
www.efsa.europa.eu/efsajournal 19 EFSA Journal 2018;16(3):5082
3. Assessment
3.1. Hazard identiﬁcation and characterisation
3.1.1. Toxicokinetics in experimental animals and humans
In vitro studies
Behrens et al., 2015, studied the transfer of MON through a monolayer of primary porcine brain
capillary endothelial cells as a model for a blood–brain barrier. The transfer of MON across the monolayer
was 1.07 9 106 cm/s in 48 h, which was about four times the transport of the negative control sucrose
(0.23 9 106 cm/s). In addition, the authors incubated the cell system with equimolar concentrations of
MON (200 nM) on both the apical and basolateral side of the monolayer for 48 h. At the two sides, no
signiﬁcant differences in concentrations were observed during the 48 h and the authors concluded that
MON is not a substrate for the efﬂux proteins since the toxin was not enriched in any compartment.
In vivo studies
Only two in vivo studies on the toxicokinetics of MON were identiﬁed.
Urine and faeces were collected 24 h pre-exposure and 6, 12, 24, 48, 168 and 336 h after the
single oral dosing of Sprague–Dawley rats (n = 3 per group) with 5 mg MON/kg bw (Jonsson et al.,
2013). The study was designed according to OECD guideline 42314 and is described in Section 3.1.4
below. During the ﬁrst 6 h, a mean of 38% of the total administered MON was recovered from the
urine, which increased up to 42% at 24 h after exposure. MON was detectable in the urine from
24–48 h post-dosing but not at the remaining collection times of 168 h (7 days) and 336 h (14 days)
with LOD/LOQ of 0.4/0.9 lg/mL. Less than 1% of the administered MON was recovered in faeces
(same LOD/LOQ as in urine). Animals at higher doses survived much less than 14 days and excretion
data were not reported. However, the authors noted that the fate of more than 50% of the
administered MON remained unknown and might have accumulated in body compartments or, more
likely been biotransformed or degraded to metabolic products.
Five groups of Sprague–Dawley rats were exposed by gavage once per day for 28 days at the dose of
3, 6, 9, 12 and 15 mg MON/kg bw using the OECD guideline 40715 (Jonsson et al., 2015) (see details of
the study in Section 3.1.4). Three animals per dose group were kept in metabolic cages, and faeces and
urine samples were collected. All urine and faeces samples were analysed daily for the ﬁrst week. Samples
were collected on days 1, 3 and 6 in the following weeks. In the ﬁrst week, the administered dose of MON
recovered in urine during the following 24 h ranged from 21% to 37%. The daily excretion remained
between 20% and 32% of the daily dose during the following weeks with no signiﬁcant difference
between dose groups. MON was not detected in the two satellite groups16 during 14 days post-dosing.
Less than 2% of the administered dose of MON was recovered in faeces during the overall period of the
study and only minor traces (not quantiﬁed by the authors) of MON conjugates were found in the urine
samples. The fate of more than 60% of the administered MON remained unknown in the study. The tissue
concentrations were not measured. The authors of the paper speculated that in the animals MON might
be biotransformed and then excreted in urine to some unknown form, e.g. by an opening of the so called
‘squaric’ ring structure of MON and carboxylation by a carboxylase into CO2 and possibly to acetate.
Conclusions
Limited data from two studies indicate that a large portion of MON was rapidly absorbed and
excreted after administration with no apparent accumulation in any tissue. The urinary recovery was
20–37%, while less than 2% of the administered MON was recovered from faeces. However, the fate
of more than half of the amount of MON ingested remained unknown.
3.1.2. Toxicokinetics in farm and companion animals
No data on toxicokinetics were identiﬁed for ruminants, pigs, poultry, farmed rabbits, farmed ﬁsh,
horses, farmed mink, dogs and cats.
14 OECD Guidelines for the Testing of Chemicals, Test No. 423 (2002): Acute Oral toxicity - Acute Toxic Class Method. Available
online: http://www.oecd-ilibrary.org/environment/test-no-423-acute-oral-toxicity-acute-toxic-class-method_9789264071001-en
15 OECD Guidelines for the Testing of Chemicals, Test No. 407 (2008): Repeated Dose 28-day Oral Toxicity Study in Rodents.
Available online: http://www.oecd-ilibrary.org/environment/test-no-407-repeated-dose-28-day-oraltoxicity-study-in-rodents_
9789264070684-en
16 The term satellite group is used by OECD guideline 407 http://www.oecd.org/chemicalsafety/testing/37477972.pdf
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3.1.3. Transfer
Data on transfer were identiﬁed in poultry only. A trial was carried out by Zollitsch et al. (2003)
using a total of 180 one-day-old broiler chickens. Maize grain naturally contaminated with
deoxynivalenol was inoculated by F. subglutinans producing beauvericin and MON to generate
contaminated maize feed material. This material was mixed with uncontaminated maize grain at
different percentages to prepare the diets at levels of 0, 0.9, 1.8 and 2.7 mg MON/kg feed. No
residues of MON were detected in carcass (muscles from breast, legs and wings) and selected internal
organs (heart, liver, bursa of Fabricius and spleen).
The only available study on MON indicated no transfer from feed to food products of animal origin
in broiler chickens. For other farm animals, no information on transfer from feed to food products of
animal origin was identiﬁed.
3.1.4. Toxicity in experimental animals
3.1.4.1. Acute toxicity
The CONTAM Panel identiﬁed four studies to characterise the acute oral toxicity of MON in rodents
with LD50 values which are summarised in Table 2.
Mice
White mice were exposed to MON by intragastric intubation (0.5 mL of MON diluted in water at
doses equal to 0, 10, 20, 40 or 80 mg/kg bw as reported by the authors (number of mice per group
not reported). Deaths occurred within 12 h and survivors appeared to be healthy for 14 days after
dosing. An oral LD50 of 47.6 mg/kg bw for MON in white mice was calculated by Burmeister et al.
(1980), with a 95% conﬁdence interval of 95% (CI: 34.6–67.2 mg/kg bw).
Rats
The oral LD50 of chemically pure MON in diet was 50.0 and 41.6 mg/kg bw, in male and female
inbred BD IX black rats, respectively (Kriek et al., 1977). The authors stated that MON was chemically
pure but did not report the percentage of purity. The administered single doses were 25, 40, 63 and
100 mg MON/kg bw, including a control group. Deaths occurred within 3 h and the authors reported
for those rats, in particular rapidly progressive muscular weakness, respiratory distress and terminal
coma, also sternal recumbence and abdominal respiration. At autopsy, generalised congestion and
cyanosis and effects on the liver, pericardium and thorax were also observed. Survivors recovered,
Table 2: Acute toxicity studies associated to oral exposure of MON in rodents
Species
(gender)
Origin and purity of
MON
Doses tested
(mg/kg bw)
LD50 (mg/kg bw) Reference
White mice
(breed not
speciﬁed)
(female)
Puriﬁed from Fusarium
extract, purity not
reported
0, 10, 20, 40 and 80 47.6
95% CI: 34.6–67.2
Burmeister et al. (1980)
Rats, inbred
BD IX black
(male and
female)
Puriﬁed from Fusarium
extract, stated as
‘pure’ by the authors
0, 25, 40, 63 and 100 Male: 50.0
95% CI: 38.5–64.9
Female: 41.6
95% CI: 33.1–52.1
Kriek et al. (1977)
Rats, Sprague
–Dawley and
Wistar
(female)
Puriﬁed from Fusarium
extract, 99% purity
0, 2.5, 5, 10, 20, 40,
60, 80 and 100
18.5(a)
Lower bound: 13.1
Abbas et al. (1990)
Rats, Sprague
–Dawley
(male)
Synthetic potassium
salt of MON, 99%
purity
0, 5, 10, 25, 40 and
50
25
LD50 cut-off value
(b)
Jonsson et al. (2013)
bw: body weight; LD50: oral median lethal dose.
(a): No effects observed until 20 mg/kg bw where 4/5 rats died. At all higher doses 100% mortality was reported. The LD50 was
calculated by the CONTAM Panel applying the BMD approach with a BMR of 50% (see Appendix C.1) with a lower 95%
conﬁdence bound of 13.1 mg MON/kg bw.
(b): LD50 cut-off value determined according to the Globally Harmonized System (GHS) for the classiﬁcation of chemicals that
cause acute toxicity.
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apart from mild myocardial lesions, to clinical normality within 12 h. The authors noted that severity of
histological lesions varied between the four dose groups. They provided comprehensive qualitative
histopathological data illustrating dose-dependent toxicity, but no quantitative dose–response data on
the total of 50 animals used to calculate the two LD50 values.
In 20-day virgin female rats, mainly of the Sprague–Dawley rats mixed with some Wistar rats
(weight of the animals not reported), gastric intubation of MON induced haemorrhage of the small
intestine and lead to death within 16 h in 5 of 5 rats exposed to 40, 60, 80 or 100 mg MON/kg bw
and in 4 of 5 rats exposed to 20 mg/kg bw (Abbas et al., 1990), but no adverse effects were observed
in the groups of 5 rats exposed to 0, 2.5, 5 or 10 mg MON/kg bw. Applying the benchmark dose
(BMD) approach with a BMR of 50%, the CONTAM Panel identiﬁed an LD50 of 18.5 mg/kg bw for rats
from this study with a lower 95% conﬁdence bound of 13.1 mg/kg bw based on the ﬁt of the
log-logistic model (see Table 2). These results were supported by a BMD50 interval of 13.5–17.6 mg/kg
bw obtained from model averaging which is, however, not an established method for acute toxicity
data. For details, see Appendix C.
The acute oral toxicity of MON was assessed in Sprague–Dawley male rats administered by gavage
according to OECD Guideline 423 by Jonsson et al. (2013), applying the Globally Harmonized System
(GHS) for the classiﬁcation of chemicals which cause acute toxicity. The stepwise procedure started
with the low dose of 5 mg MON/kg bw and the high dose of 50 mg MON/kg bw each administered to
rats (n = 3), the latter expected to produce mortality. Three additional rats (only one per group used
to reduce the number of experimental animals) were exposed to 10, 25 or 40 mg MON/kg bw to assist
to assess the appropriate dose levels for future studies on the subacute toxicity of MON. Health
condition of the animals was monitored at least twice a day for the next 13 days and complete
necropsy with evaluation of macroscopic changes was performed for each rat in major organs, most
detailed in the high-dose group. At predeﬁned time points (24 h pre-exposure, 6 h, 12 h, and 1, 2, 7
and 14 days post-exposure), urine and faeces samples were collected (see Section 3.1.1 above). The
observed outcomes were:
• The three animals in the high-dose group of 50 mg MON/kg bw died at 48, 60 and 83 min
post-administration, respectively. These rats showed signs of toxicity such as decreased activity
(at 5–10 min after exposure), altered body position, respiratory and cardiovascular changes
(including faint heart beats in two and cardiac arrhythmia in one animal) and muscular
weakness. The heart was unevenly contracted in two rats and there was marked congestion in
the liver. Microscopically, there was mild multifocal oedema and lymphocytic inﬁltration in the
heart muscle in all three animals.
• The one rat, at the dose of 40 mg MON/kg bw, showed muscular weakness, respiratory
distress, cardiovascular changes and sudden death after 75 min, all observations attributable
to cardiac arrest and general toxic signs such as decreased activity and altered body position.
• The one rat at the dose of 25 mg MON/kg bw showed symptoms resembling those observed
at the high dose and died after 60 min.
• The surviving rat at the dose of 10 mg MON/kg bw showed also decreased activity, respiratory
changes, trembling and piloerection up to 3 h post-dosing.
• No clinical signs were seen at the low dose of 5 mg MON/kg bw. The activity of animals was
slightly decreased but it was similar in the control group. The authors related this to the 12-h
fasting period before the start of treatment.
Based on the GHS for the classiﬁcation of chemicals (OECD Guideline 423), the authors concluded
that MON was acutely toxic to rats and identiﬁed 25 mg MON/kg bw as cut-off value of for the LD50.
Conclusions
MON showed high acute toxicity in rats with oral LD50 values ranging between 18.5 and 25 mg
MON/kg bw per day in experiments with 99% pure MON. The oral acute toxicity in one study in mice
was lower with an LD50 of about 50 mg MON/kg bw per day.
3.1.4.2. Subacute toxicity
Only studies on cardiotoxicity were identiﬁed in the available literature.
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Mice
In addition to the experiment on the acute toxicity (see Section 3.1.4.1), Burmeister et al. (1980)
exposed young white mice in groups of n = 7 for 3 weeks to MON dissolved in distilled water at
concentrations of 0, 0.1 and 0.5 mg/mL (initial weights ranging from 13.5 to 19.9 g) consumed on
average 0, 0.7 and 2.9 mg MON daily in drinking water, respectively. All of the animals survived with
an average daily water consumption and average weight gain to be calculated as of 7.0, 7.2 and
5.8 mL and 7.8, 7.2 and 5.8 g for the three groups, respectively (statistically signiﬁcant reduced only in
the high-dose group based on an analysis of variance). The authors reported a slight but insigniﬁcant
reduction in weight gain at the low concentration but a signiﬁcant one at the high when compared to
controls. The consumption of MON at the high concentration of 0.5 mg/mL was estimated to be
2.9 mg MON per day which was, however, three times higher than estimated consumption of 1.0 mg
MON /per day at the LD50 of 47.6 mg MON/kg bw derived from the author’s a subtrial on the acute
toxicity, see Section 3.1.4.1 (assuming a bw of 20 g). The authors argued that the mice of 21-day
study either might have excreted MON readily or an efﬁcient deactivating mechanism might occur
since no deaths were observed. Because of the discrepancies between the two subtrials the CONTAM
Panel did not consider these data for the risk assessment of MON.
Rats
A subacute oral toxicity study was conducted in Sprague–Dawley rats (n = 5 per group,
9–10 weeks old, 217–307 g), adapting the OECD guideline 407 (Jonsson et al., 2015). Groups of ﬁve
male rats were daily exposed by gavage to 0, 3, 6, 9, 12 or 15 mg MON/kg bw per day for 28 days.
The synthetic potassium salt of MON (purity > 99.8%) was used. Each animal was subject to a
comprehensive check of its health conditions twice a day including movement, behaviour, respiratory,
circulatory functions and excretion. Two satellite groups were treated identically with the two
experimental groups at the two highest doses (12 and 15 mg MON/kg bw per day) and were kept
alive for additional 14 days without treatment to study the potential reversibility of the adverse effects
observed in the animals of the main part of the study. Complete necropsy was performed for each rat
with macroscopic examination of all organs. Tissue samples were collected from the liver, spleen,
kidneys, lungs, adrenal glands, thymus, heart, stomach, intestine, testicles and brain. There were no
treatment-related differences between control animals, treated animals or animals of the satellite
groups for body weight, feed and water consumption, organ weights or measured blood parameters
(such as red blood cell counts (RBC), white blood cell counts, haemoglobin (Hb), haematocrit (HCT)
and platelet counts). Within the ﬁrst 3 weeks after start of treatment, the mean excretion of MON in
urine varied between the ﬁve dose groups ranging from 20% to 36% however without showing a clear
dose dependence. There was also considerable interindividual variability per dose group with standard
deviation (SD) values ranging between 5% and 13%). The authors noted that about 15% of the rats
showed decreased excretion to less than 5% over a few days before they resumed excretion to normal
levels possibly due to intersubject variation of metabolic enzyme activity. Overall, total mean excretion
remained around 30% during for the ﬁrst 3 weeks but decrease after 4 weeks to about 20%.
Decreased phagocytic activity of neutrophils (luminol-ampliﬁed chemiluminescence assay) was
observed in all treated groups, including the two satellite groups and this activity did not recover.
Compared with the control group, the decrease was 59% at the lowest dose and on average 48%.
However, the number of neutrophils and the total number of leucocytes stayed within normal ranges
and weights of lymphoid organs (thymus and spleen) remained unaffected such that the authors
excluded dystrophic and dysplastic effects for MON. The CONTAM Panel noted that the neutrophil
scoring method was not described and that the assay was performed on whole blood dilution. There
was also a large variability of neutrophil counts in the control group (15  12.5%; expressed by
dividing the whole blood activity by neutrophil number) and the potential macrophage phagocytic
activity was not taken into consideration in this calculation. Therefore, the CONTAM Panel decided not
to consider these data for human hazard characterisation of MON.
In contrast, the CONTAM Panel summarised the clinical observations in the ﬁve experimental dose
groups of 3, 6, 9, 12 or 15 mg MON/kg bw per day over the 28 days in comparison with the controls
as follows:
• Two rats died at the highest dose and at 12 MON/kg bw per day one rat died and one was
euthanised due to respiratory distress immediately after gavage, among the 36 rats in the
experimental groups, before the end of the study.
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• The two rats in the experimental group of 15 MON/kg bw per day died with acute heart failure
on the 4th and 21st day after presenting strongly decreased activity or somnolence. They had
a normal nutritional condition, however macroscopically, some blood-stained contents were
observed in the small intestine in one of them, although the gastrointestinal contents were
otherwise normal. Microscopically, there was an acute congestion and leucostasis in the lungs.
The other rat had no speciﬁc macroscopic or microscopic organ changes.
• The two animals with premature deaths at the next lower dose of 12 MON/kg bw per day
exhibited acute pulmonary congestion. The rat that died had notably little digesta in the
stomach. The CONTAM Panel noted that the sacriﬁce of the one rat because of signs of
respiratory distress just after gavage could be due to a technical error in administration by
gavage when MON suspension reaches the airways. This suspicion of the CONTAM Panel is
supported by dyspnea, wheezing and body secretion from nostrils or mouth in 7 of the 35
treated rats noted by the authors.
• One rat in the 9 mg MON/kg bw dose group showed repeatedly symptoms (decreased activity,
withdrawal and somnolence), which were similar to those seen at the two highest doses, but
recovered until the end of the study.
• At the three highest doses of 9–15 mg/kg bw (no dose-speciﬁc information reported) 23% of
the animals had a weak grip at the front legs compared to controls and to rats exposed to 3
MON mg/kg bw per day which showed normal grip. Grip strength at 6 MON mg/kg bw per day
was not speciﬁed.
• Otherwise, no other adverse health effects were reported for the doses up to 9 mg MON/kg
bw. These animals were reported as clinically healthy without impairment of weight gain. A
transient decrease in activity and occasionally respiratory changes and bloody nostril secretion
was reported for a total of eight rats (20%) of all dose groups but also for controls; without
detailed dose information given.
Accounting for the effects seen in one rat at 9 mg MON/kg bw dose the CONTAM Panel considered
that at doses of 9 mg/kg bw per day and higher acute heart failure cannot be excluded for rats
exposed to MON and identiﬁed 6 mg/kg bw per day as a NOAEL for adverse health effects of MON
from this subacute study.
Conclusions
Very few subacute studies on MON were available in the literature. MON was well tolerated in a
28-day study on rats at doses lower than 9 mg/kg bw per day, and a NOAEL of 6 mg/kg bw per day
was identiﬁed. Cardiotoxicity was observed at 15 mg/kg bw per day and could not be excluded at
doses as low as at 9 mg/kg bw per day.
3.1.4.3. Subchronic toxicity
Only two in vivo subchronic toxicity studies on MON in rats were identiﬁed.
Rats
Groups of four male and four female inbred BDIX black rats were fed ad libitum for 12 weeks with
feed containing 0%, 2%, 4%, 8%, 16% and 32% of mouldy feed contaminated with Fusarium culture
material producing MON (Kriek et al., 1977). The diet was not analysed for other mycotoxins, but the
CONTAM Panel noted that the presence of MON was characterised by appropriate analytical techniques
available at the time. All 16 animals fed with the two highest %-proportions of mouldy feed in their
diets died early (at concentration of 16% within 15–18 days and at 32% concentration within
11 days). Feed consumption of the controls and the groups given 2%, 4% or 8% of mouldy feed was
determined over a 5-day period (from day 15 to day 20) and intake decreased with increasing
concentration. At 0%, 2%, 4% and 8% of mouldy feed mean feed intake was 19.1, 17.6, 18.2 and
6.9 g/day and 14.7, 12.9, 11.3 and 5.3 g/day for male and female rats, respectively. From these data
and the available mean weights per %-proportions of mouldy feed in the diet and sex (also declining
with increasing %-proportions of mouldy feed in the diet), the authors calculated doses of 0, 16.6,
34.6 and 32.5 mg MON/bw per day and 0, 16.5, 32.9 and 34.5 mg MON/bw per day for males and
females, respectively. Early deaths prevented the calculation of doses at the two highest
concentrations. The CONTAM Panel noted that the feed intake at the level of 8% of mouldy feed in the
diet was drastically reduced such that practically only two different dose regimes were applied in this
experiment, one around 17 mg MON/kg bw and another between 32 and 35 mg MON/kg bw. Mortality
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was high in male and females at the 8% mouldy feed (4 males and 3 females died with mean time-to-
death of 49 and 42 days, respectively) and at 4% mouldy feed in males (3 males died mean time-to-
death of 62 days) but no deaths were among the females at that concentration, nor among females
and males at the 2% mouldy feed concentration. The most conspicuous and prominent effect in all
exposed groups were lesions in the myocardium and depending on survival time myocardial
degeneration, necrosis and ﬁbrosis were evident.
• Rats exposed to 32% mouldy feed in the diet showed acute degenerative lesions with
pronounced granularity of the sarcoplasm and focal Zenker’s degeneration and necrosis in 3 of
the 8 animals, in particular, in papillary muscles and left ventricular (LV) subendocardium.
• Similar lesions were seen at the exposure to 16% mouldy feed in a diet with more prominent
Zenker’s necrosis.
• Rats exposed to 8% mouldy feed in the diet showed widely distributed Zenker’s necrosis
manifesting fragmentation and macrophage inﬁltration alternating with focal areas of myolysis
and ﬁbrosis in the papillary muscles, LV subendocardium, right ventricular wall and
intraventricular septum.
• Abnormalities in rats which died when being exposed to 4% mouldy feed were similar to those
at 8% mouldy feed however less extended in the surviving rats (1 male and 4 females). There
were also focal Zenker’s necrosis, macrophage aggregates, and focal areas of early myocardial
ﬁbrosis in 6 out of the total 8 rats.
• Beyond the myocardial lesions mentioned above, no speciﬁc other lesions were described for
exposure to 2% mouldy feed in the diet.
• No comparable lesions were observed in the controls; also not in the survivors and in two of
the three males exposed to 4% mouldy feed that died before 12 weeks.
Lesions in other organs than the heart were rated by the authors as fairly mild and commonly
non-speciﬁc and not differentiated regarding the doses. However, it was noted that in one male rat
exposed to 4% mouldy feed/kg diet, focal haemorrhage occurred on the rugae in the gastric fundus
and that severe generalised atrophy was observed in males and females exposed to 8% or 16%
mouldy feed/kg diet. Generalised venous congestion and cyanosis were evident in all the animals that
died. In two animals, the myocardium was characterised according to the authors by being ‘parboiled’.
Furthermore, focal or linear erosions and mild haemorrhage in the rugae of the gastric fundus were
observed. The two groups of males and females exposed to 32% mouldy feed/kg diet also showed
mildly emphysematous lungs, focal pulmonary haemorrhage and generalised venous congestion. The
CONTAM Panel concluded that the results of Kriek et al. (1977) were relevant for the hazard
characterisation of MON since they showed a qualitative dose–response relationship of the severity of
adverse cardiac effects of MON in rats over the range of exposures from 2 to 32% mouldy feed/kg
diet. There was also a quantitative dose–response relationship of the mortality of the rats exposed up
to 8% mouldy feed/kg diet. No quantitative dose–response data were identiﬁed for any other and/or
possibly milder toxicity endpoint of this study. Since myocardial lesions were observed at the lowest
exposure level tested, no NOAEL for adverse cardiac health effects was identiﬁed and the dose of
16.6 mg MON/kg bw in this study was identiﬁed as a LOAEL for the cardiotoxicity of MON.
Furthermore, based on the association of the severity of cardiac toxicity with the mortality, the
CONTAM Panel considered the mortality of the rats as directly related to the cardiac toxicity of
MON and identiﬁed 16.6 and 32.5 mg MON/kg bw per day for male rats as NOAEL and LOAEL,
respectively. Since the dose at which no female rat died (32.9 mg MON/kg bw per day) was very close
to that at which three of the four females rats died (34.5 mg MON/kg bw per day), no NOAEL or
LOAEL was determined for female rats. Overall, the toxicity of MON appeared to be lower in female
rats compared to the males.
Conclusions
Only one 12-week subchronic study in rats was available for hazard characterisation, in which
treated rats were fed diets contaminated with MON at levels of 2–32% mouldy feed/kg diet. The
CONTAM Panel noted a clear qualitative dose–response relationship of the severity of adverse cardiac
effects of MON in rats over that range diet and identiﬁed 17 mg MON/kg bw as a LOAEL for the
cardiotoxicity of MON. Considering mortality, the CONTAM Panel identiﬁed for male rats a NOAEL of 17
and a LOAEL of 33 mg MON/kg bw per day. Toxicity of MON in rats appeared to be lower in female
than males.
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3.1.4.4. Chronic toxicity
No data were identiﬁed.
3.1.4.5. Developmental and reproductive toxicity
Reproductive effects in mink exposed to MON were investigated by Morgan et al. (1998). In the
reproductive study, groups of pastel, adult female mink (n = 12) were fed diets containing 0, 8.1 and
17.0 mg MON/kg feed, equivalent to 0, 0.92 and 1.94 mg MON/kg bw per day as calculated by the
CONTAM Panel using the body weights and dry weight feed consumption data for female mink from
NRC (1982).17 These data from NRC were considered by the CONTAM Panel as the most appropriate
to use, although it should be noted that there is high uncertainty in the CONTAM Panel’s calculated
results. First, the NRC feed intake was given as dry matter and a conversion was applied (93) for the
feed in the Morgan et al. study. Second, minks in the study of Morgan et al. were pregnant which may
affect feed intake. Treatment with MON was from 2 weeks prior to the breeding season, and continued
until the offspring (no data on their food consumption reported) were 8 weeks old. There were no
signiﬁcant differences of feed consumption, body weights, breeding performance, gestation, litter size
and offspring sex ratios among the groups of dams. The number of offspring that were stillborn or
died within 24 h postpartum was signiﬁcantly higher in the high-dose group (41%) compared to the
low-dose group (7.3%) and the controls (6.1%). Signiﬁcant effects on the body weights of offspring
were observed. At birth, the offspring in the high-dose group weighed signiﬁcantly less than those
from the control group. At 3 weeks, they weighed less than offspring from the low-dose group. No
offspring weight differences were seen at 6 weeks but at 8 weeks offspring from the high-dose group
weighed less than both the low-dose and the control group. In the high-dose group, the mortality of
offspring increased markedly between 6 and 8 weeks, reaching 72.4% at 8 weeks. An increase in
offspring mortality was not seen in the low-dose or control groups. The CONTAM Panel considered that
toxicity observed in the offspring at 6 weeks and above might not be reproductive effects as the
offspring were offered the same experimental diet as their dams at 3 weeks of age. No gross or
histological lesions or alterations in liver, lung or heart tissues were found in 8-week-old offspring from
the high-dose and control groups.
Conclusions
The dose of 1.94 mg MON/kg bw per day resulted in signiﬁcant neonatal mortality and reduced
offspring body weights in mink. The lowest dose of 0.92 mg MON/kg bw per day was identiﬁed as a
NOAEL.
3.1.4.6. Genotoxicity
Wehner et al. (1978) showed that MON was inactive in the Salmonella Typhimurium bacterial
mutation assay (Ames test) using strains TA98, TA100, TA1535 and TA1537 (0.25–250 lg MON/plate)
with and without metabolic activation with an induced rat liver S9 fraction. Takahashi et al. (1992) also
showed that MON (10 and 100 lg/plate) was inactive in the S. Typhimurium assay with TA100. MON
was also subsequently tested by Knasm€uller et al. (1997) using S. Typhimurium strains TA98 and
TA100 (0.7–500 lg MON/plate) with and without S9, and it did not induce mutations. The CONTAM
Panel was not able to use these data from Knasm€uller et al. (1997) as there were inconsistencies in
the reported results. For example, the positive control caused fewer mutations than the negative
control, whereas MON caused a very high level of mutations at one dose.
MON was studied in differential DNA repair assays with Escherichia coli K-12 strains (343/753, uvrB/
recA and 343/765, uvr+/rec+) at concentrations ranging from 0.7 to 500 lg/mL. In the absence of
metabolic activation, a signiﬁcant effect of MON on induction of reparable DNA damage was found at
concentrations of 55 lg/mL and above. Addition of S-9 mix reduced this effect (Knasm€uller et al.,
1997). MON showed no activity in the rec assay with Bacillus subtilis (Ueno and Kubota, 1976).
Among the responses induced in E. coli by DNA-damaging agents is a set of functions known as
the SOS-responses (Quillardet et al., 1982). The genotoxicity of MON in E. coli was investigated by
Auffray and Boutibonnes (1986) using the SOS spot test, which is a plate diffusion assay to detect the
SOS response. No activity was detected. Also, an SOS chromotest of MON was conducted in E. coli
17 Assuming a female mink eats 38 g dry weight feed/kg bw per day (equivalent to 38 g 9 3 = 114 g wet weight feed/kg bw
per day) and the consumption of feed containing 8.1 mg MON/kg feed (17.0 mg MON/kg feed) this is equivalent to an intake
of 0.114 kg 9 8.1 mg MON/kg feed = 0.92 mg MON/kg bw per day (0.114 kg 9 17.0 mg MON/kg feed = 1.94 mg MON/kg
bw per day).
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strain PQ 37 by Auffray and Boutibonnes (1987) and the compound showed no SOS inducing activity,
either with or without metabolic activation. The maximal concentration of MON that was tested was
5.0 lg/mL. Knasm€uller et al. (1997) also showed that MON did not show activity in the SOS
chromotest with E. coli strain PQ 37 (5–500 lg MON per assay) with and without S9.
Isolated primary rat hepatocytes were exposed to MON (5.0–500 lM) and unscheduled DNA
synthesis (UDS) was determined by autoradiography after incubation of the cells with [3H]-thymidine
(Norred et al., 1992). MON caused no effects on UDS at concentrations of 5, 10, 50 and 500 lM, and
a marginal effect at 100 lM. MON was not cytotoxic at any of the concentrations studied. The
CONTAM Panel considered MON not to be active in this assay.
Knasm€uller et al., 1997; observed that MON (0.01–100 lg/mL for 3-h) induced chromosome
aberrations (CAs) in primary cultures of rat hepatocytes. The largest effects on CAs were seen at MON
concentrations of 1 lg/mL and 10 lg/mL, where the CA rate was approximately nine-fold over the
background level. CAs declined at the higher concentration evaluated (100 lg/mL), possibly due to
inhibition of cell division. The mitotic index decreased after treatment of the cells with MON, the
difference becoming signiﬁcant at the concentration of 100 lg/mL. Micronuclei (MN) were also studied
in the same cells using the same concentration range of MON, and no statistically signiﬁcant effects
were observed (Knasm€uller et al., 1997).
In the study of Celik et al. (2009), human peripheral blood lymphocytes were treated for 48 h with
MON (sodium salt of MON) (2.5–25 lM equals to 0.3–3.0 lg/mL as calculated by the CONTAM Panel).
CAs, MN and sister chromatid exchange (SCE) increased in a concentration-dependent manner.
Statistically signiﬁcant effects on CAs were seen at MON concentrations of 1.2 lg/mL and above. The
structural aberrations observed were chromatid breaks, which were most common, chromosome
breaks and chromatid exchanges. Numerical aberrations (polyploidy) were also observed. SCEs and
MN increased signiﬁcantly at MON concentrations of 1.8 lg/mL and above. The cytokinesis-block
proliferation index was not affected by MON treatment.
The CONTAM Panel noted that mode of action of MON in the in vitro studies were not investigated.
No in vivo investigations of genotoxicity were identiﬁed.
Conclusions
There is no evidence that MON induces bacterial reverse mutation. MON has been shown to be
clastogenic in vitro inducing chromosomal damage (CAs, MN). No data were identiﬁed to conclude on
whether in vitro genotoxicity is caused by a direct or indirect mechanism. No data are available on
genotoxicity in vivo.
3.1.4.7. Carcinogenicity
No data were identiﬁed.
3.1.5. Adverse effects in farm and companion animals
3.1.5.1. Ruminants
The toxicities of several isolated Fusarium species with different toxin production capabilities were
analysed by Lamprecht et al. (1986). Sheep (n = 1 per group, 6–10 months of age, 29–36 kg) were
dosed by gavage with either 5 g culture material/kg bw per day or a single dose of 10 mg MON/kg bw
in crystalline form (98% pure). The animals who received single doses of 21.0 or 24 mg MON/kg bw18
in culture material died within 2 and 18 h, respectively. The dose of 5.2 mg/kg bw per day in culture
material resulted in death within in 48 h, and the administration of 10 mg crystalline MON/kg bw
within 18 h. Culture material with small concentrations of MON (< 0.1 mg/kg bw per day) showed no
effects on sheep. The culture material contained also small concentrations of diacetoxyscirpenol, but
no zearalenone, deoxynivalenol and T-2 toxin. The main pathological change observed in the perished
sheep was the degeneration of the proximal tubules of the kidneys. The CONTAM Panel considered
that these data were too scarce to characterise the hazard of MON in sheep. No other data on adverse
effects of MON in ruminants were identiﬁed.
Conclusions
Among the ruminants, only one study on sheep was identiﬁed. A dose of 5.2 mg MON/kg bw per
day resulted in death within in 48 h and a dose of < 0.1 mg MON/kg bw did not show any adverse
18 Doses calculated by the CONTAM Panel from the data reported by the authors.
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health effects in sheep. However, the CONTAM Panel considered that the data were too scarce to
characterise the hazard of MON in sheep.
3.1.5.2. Pigs
Only few studies on adverse effects of MON in pigs were available.
The effects of MON on the cardiac function in miniature pigs were studied by Qiao et al. (199319)
for up to 16 days in one experimental group of seven weaned piglets, each receiving a dose of 3 mg
MON/kg bw per day mixed into a small portion of feed given in the morning and a control group of
four weaned piglets. Total feed intake per pig and day was reported as of 0.5 kg without giving details
on body weights and type of housing. Four animals died after 4 and 5 h and after 5 and 6 days,
respectively, in the experimental group. The carotid blood pressure in the three surviving exposed pigs
(mean: 198.7 mmHg; SD: 10.8) was statistically signiﬁcantly higher than in controls (mean:
118.3 mmHg; SD: 7.3). A statistically signiﬁcant decrease of glutathione peroxidase was found in ﬁve
pigs (surviving day 1) by an intra-individual comparison before and after exposure, but no information
was provided for the time span between the measurements in those exposed animals and for the
controls. The histopathological ﬁndings in the pigs of the experimental group indicated various
changes in all major organs examined, i.e. the gastrointestinal tract, liver, kidney, lung and the adrenal
gland. Varying degrees of degeneration were reported for heart papillary muscles, the atrial and
ventricular muscles and the conducting cells of the Purkinje type. The cardiac effects in the
experimental group included tachycardia and arrhythmia, myocardial ischemia accompanied by
hyperkalaemia, multiple ventricular premature beats and myocardial injury. Minor myocardial effects
were mentioned for the control group from staining myocardial ﬁbres with acidic fuchsin. The authors
concluded that the pathological changes and characteristics seen at 3 mg MON/kg bw per day in the
miniature pigs were ‘very similar to those of Human Keshan disease’. Considering the missing
information on feed intake and body weight, the unbalanced sample size, the missing details on the
methods applied to describe the of effects in experimental and control pigs, the CONTAM
Panel considered this study insufﬁcient to assess the effects against a control group. The Panel also
noted that cardiomyopathy, myopathy and osteoarthropathy have been also associated of with
selenium deﬁciency (Loscalzo, 2014; Oropeza-Moe et al., 2015)—see also Section 3.1.7.
The impact of MON on the humoral immune response of piglets was studied by Wei et al., 2010.
The animals were immunised with swine fever vaccine at the age of 25 and 60 days. At 47 days of
age, the animals (average weight 12  0.5 kg, n = 6 per group) were fed for 42 days either the
control diet or a MON contaminated diet where MON extract from Fusarium culture material (30 mg
MON/kg) was added to the feed. The swine fever antibody levels in the MON group decreased
signiﬁcantly from the 61 days of age compared to the control group. Dose calculation was impossible
since the amount of extract added was not reported and information on the occurrence of other
mycotoxins was missing. Therefore, the CONTAM Panel decided not to further consider the study for
the hazard characterisation of MON.
Two feeding studies (denoted by the authors as experiment 1 and 2) based on the same design
(apart from the change of the dose range) were performed by Harvey et al. (2001) on growing
barrows for 28 days consecutively with graded amounts of MON from Fusarium culture material
produced as reported by Ledoux et al. (1995). The concentrations of aﬂatoxin, zearalenone, ochratoxin
A and cyclopiazonic acid were < LOD of 10 lg/kg in a control diet and fumonisins < LOD of 5 mg/kg in
control diet. The pigs were fed ad libitum and feed consumption was recorded weekly per pen but not
reported. Although six barrows (mean body weight 17.8–17.9 kg) per group were fed diets containing
0, 25, 50 and 100 mg MON/kg feed in the ﬁrst experiment, the same number of pigs (mean body
weight 15.1–15.3 kg) were fed diets containing 0, 50, 100 and 200 mg MON/kg feed in the second
experiment. Compared with controls, the pigs at concentration of 100 mg MON/kg feed showed in
both experiments reduced ﬁnal body weight and reduced body weight gain according to the authors’
analyses. Reductions in the number of RBC, and reductions of HCT and Hb levels were statistically
signiﬁcantly lower at concentrations of 50 mg MON/kg feed and higher. They showed a similar
concentration–effect relationship in both experiments. With increasing concentrations the levels of
serum cholesterol decreased and those of creatinine increased however without reaching statistical
signiﬁcance even at the high concentrations (100 mg MON/kg feed in the ﬁrst and at 100 and 200 mg
MON/kg feed in the second experiment). The levels of cholesterol and creatinine were higher in the
ﬁrst experiment compared with the second. In contrast, for the levels of phosphorous,
19 Original paper in Chinese, text based on the translation to English.
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ƴ-glutamyltransferase (GGT) and mean corpuscular haemoglobin (MCH) were lower in the ﬁrst
experiment compared to the second. In both experiments, one of the six pigs assigned to 100 mg
MON/kg feed group died, while ﬁve of six pigs died in the group of 200 mg MON/kg of the second
experiment. As the most striking gross abnormality, a straw-coloured ﬂuid in the pericardial sacs was
reported for the pigs dying acutely within 1 week. Cardiomegaly was the most consistent post-mortem
ﬁnding. No gross lesions were seen in other pigs necropsied at day 29. Furthermore, the relative heart
weight, only reported for the second trial, was higher in pigs fed the 200 mg MON/kg diet (mean
(standard error of the mean SEM) of 0.75 (0.06) g/100 g bw) compared with controls and pigs
exposed up to 100 mg MON/kg diet (mean (SEM) of 0.48–0.55 (0.02–0.03) g/100 g bw). The
CONTAM Panel identiﬁed from this study of Harvey et al. (2001) 50 mg MON/kg feed and 100 mg
MON/kg feed as a NOAEL and LOAEL, respectively, for reduced body weight gain in pigs. Regarding
haematological changes, a NOAEL of 25 mg MON/kg feed and a LOAEL of 50 mg MON/kg feed were
identiﬁed.
Using the reported mean body weights of each concentration group available at start of exposure
and after 90 days for each of the two experiments and assuming a mean feed intake of 1,200 g/day
for pig, the CONTAM Panel calculated from the concentrations 25, 50 and 100 mg MON/kg feed of the
ﬁrst experiment and from the concentrations 50, 100 and 200 mg MON/kg feed of the second
experiment, the doses of 1.00, 2.22 and 4.17, and 1.20, 5.07 and 11.48, respectively (see Table C.3 in
Appendix C.2). Therefore, the NOAEL for reduced body weight ranged between 1.20 and 2.22 and the
LOAEL between 4.17 and 5.07 mg MON/kg bw per day, respectively. For haematological adverse
effects, the NOAEL was calculated as 1.00 mg MON/kg bw per day (the lowest dose of the ﬁrst
experiment), whereas the LOAEL ranged between 1.20 and 2.22 mg MON/kg bw per day based on the
two experiments. Regarding mortality and relative heart weights, only the pigs at the highest dose
level of 200 mg MON/kg diet showed a statistically signiﬁcant difference compared with controls.
Therefore, the CONTAM Panel identiﬁed a NOAEL of 4.6 mg MON/kg bw per day and a LOAEL of
9.2 mg MON/kg bw per day for cardiotoxicity of MON in pigs from this study.
The dose–response data on RBC, HCT and Hb were considered suitable for an evaluation with the
BMD approach using the data of these two consecutive experiments with overlapping dose ranges.
The factor ‘experiment’ was included as covariate to account for differences in location and shape of
the dose–response curves in the BMD analysis of the combined data of the two experiments. While the
two blood parameters HCT and Hb could be ﬁtted well, the ﬁt of the RBC was inconclusive and the
outcome could not be used to derive a reference point for haematological changes, see Table 3 and
Appendix C. The CONTAM Panel identiﬁed from these results the lowest BMDL05 of 0.20 mg MON/kg
bw per day as reference point for haematological effects in pigs.
Table 3: Dose–response analysis of critical haematological endpoints HCT and Hb in pigs based on
the combined data from two experiments of Harvey et al. (2001) using the PROAST
software for the BMD approach
Best ﬁtting model
HCT
BMD05 BMDL05–BMDU05
mg/kg bw per day
Experiment 1
Exponential model family E5 1.14 0.55–2.05
Hill model family H5 1.30 0.59–2.01
Experiment 2
Exponential model family E5 0.50 0.23–1.04
Hill model family H5 0.59 0.25–1.00
Best ﬁtting model
Hb
BMD05 BMDL05–BMDU05
mg/kg bw per day
Experiment 1
Exponential model family E5 0.92 0.45–1.56
Hill model family H5 0.97 0.45–1.79
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In another study the same group of authors (Harvey et al., 2002) studied under similar
experimental conditions effects of MON in six 7-week-old crossbred barrows (mean initial body weight
11.1 kg) per group. Animals were provided 0 or 100 mg MON/kg feed ad libitum for 28 days. The
MON group showed an acute mortality of 33% (2 animals died 5 and 6 days after start of exposure),
one of them with clear straw-coloured ﬂuid in the pericardial sac and/or moderate interstitial oedema
and necrosis of the myocardium. The weight gain in the group of 100 mg MON/kg feed (mean (SEM)
of 12.3 (2.1) kg) was reduced compared with controls (mean (SEM) 18.9 (4.2) kg) but no apparent
effects on serum biochemical and haematological values were reported. Mortality was 33% at 100 mg
MON/kg feed and therefore higher than the 17% observed in Harvey et al., 2001; at the same
concentration, however not statistically signiﬁcant different given the small group sizes. Therefore the
CONTAM Panel concluded that the data of Harvey et al. (2002) support the ﬁndings above.
Conclusions
Only few studies on the toxicity of MON in pigs were available and reduced weight gain, adverse
haematological effects and mortality accompanied with lesions in heart were identiﬁed as critical on
adverse health effects for pigs. The NOAEL for reduced body weight gain ranged between 1.20 and
2.22 and the LOAEL between 4.17 and 5.07 mg MON/kg bw per day, corresponding to the MON
concentrations of 50 mg MON/kg and 100 mg MON/kg, respectively. The NOAEL for haematological
adverse effects of 1.00 mg MON/kg bw per day was based on the lowest dose of the ﬁrst experiment
and the LOAEL ranged between 1.20 and 2.22 MON/kg bw per day, corresponding to MON
concentrations in feed of 25 mg MON/kg and 50 mg MON/kg, respectively, based on both
experiments. The lowest dose at which mortality was observed was 4.17 mg MON/kg bw per day. The
CONTAM Panel identiﬁed haematological adverse effects as most sensitive adverse effects and
identiﬁed the lowest BMDL05 of 0.20 mg MON/kg bw per day as reference point for pigs. The
cardiotoxicity observed in a study in miniature pigs exposed to 3 mg MON/kg bw per day supported
these conclusions.
3.1.5.3. Poultry
Previously, Jestoi et al. (2003), Conkova et al. (2003) and Peltonen et al. (2010) reviewed the
adverse effects caused by MON in poultry. Based to the selection criteria (see Section 2.2.1), this
section describes the data on experiments on adverse effects associated with the oral exposure of
MON alone. The toxicity data from the exposure to MON in combination with other mycotoxins is
described in Section 3.1.6.
Data on acute toxicity were only identiﬁed for 1-day-old broiler chickens and 7-day-old ducks.
Cole et al. (1973) reported an LD50 of 4.0 mg/kg bw in cockerels exposed orally to puriﬁed MON
(isolated from Fusarium culture material) in sterile water solution (purity of MON, number of animals
and range of oral doses were not reported). An oral dose of 6.25 mg MON/kg bw was lethal to all the
animals and some cockerels receiving a dose of 3.12 mg MON/kg bw died within 24 h (number of
animals not reported). Those birds which survived the dose of 3.12 mg MON/kg bw recovered after
24 h and did not show apparent adverse effects. Above 3.12 mg MON/kg bw, increasing the dose
decreased the time to death until a dose of 40 mg MON/kg bw which resulted in death within 45 min.
The birds which died within 2 h given doses of 12.5 and 25.0 mg MON/kg bw showed no lesions in all
major organs. However, ascites with oedema of the mesenteries and small haemorrhages in the
proventriculus, gizzard, small and large intestine, and skin were observed in cockerels surviving for 2 h
Best ﬁtting model
Hb
BMD05 BMDL05–BMDU05
mg/kg bw per day
Experiment 2
Exponential model family E5 0.42 0.20–0.77
Hill model family H5 0.46 0.21–0.89
BMD05: benchmark dose response of 5%; BMDL05/BMDU05: 95% lower/upper conﬁdence limit for the benchmark dose response
of 5%; bw: body weight; HCT: haematocrit; Hb: haemoglobin.
Note: The two-sided 90% conﬁdence intervals (BMDL05–BMDU05) of the BMD05 of the best ﬁtting models deﬁned by the Akaike
Information Criterion (AIC) are reported for the exponential and the Hill family following the EFSA guidance (EFSA Scientiﬁc
Committee, 2017).
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at doses of 6.25 and 12.5 mg MON/kg bw. Cockerels in the control group and the birds in the two
lowest dose groups of 3.12 and 1.56 mg MON/kg bw showed no lesions.
The study of Burmeister et al. (1979) applied MON extracted and puriﬁed (estimated purity 93%)
from Fusarium culture material to chickens. In the ﬁrst experiment, 1-day-old chickens (seven birds
per dose) were dosed once by gavage at 0, 1, 2, 4, 8 and 16 mg MON/kg bw. A LD50 value of 5.4 mg
MON/kg bw was reported. Surviving chickens showed no adverse effects at any time during the 4-day
observation period. In a second experiment, 4-day-old chicken embryos (25 per treatment levels) were
injected once in the air sac with MON and an LD50 of 2.8 lg/egg was identiﬁed. No overt gross
teratogenic effects were reported for the survivors.
Another acute toxicity study was performed by Kriek et al. (1977) in ducks using chemically
semipuriﬁed MON (purity and information on the occurrence of other mycotoxins was not reported)
which was isolated from Fusarium culture material. Thirty 7-day-old Pekin ducklings were randomly
divided into ﬁve groups of six each. They were dosed by crop intubation once with pure MON
dissolved in distilled sterile water in appropriate concentrations to provide the doses of 0.0 (as
control), 0.5, 1.4, 3.7 and 10.0 mg MON/kg bw. The authors identiﬁed LD50 of 3.7 mg MON/kg bw.
In the study by Zhang and Li (1989) MON was isolated from mouldy corn contaminated with
Fusarium fungus (information on the occurrence of other mycotoxins was not reported) and collected
from the Keshan disease (KD) region in China (see also Section 3.1.7). Three Pekin ducklings of 3- to
4 days old (weight 50–60 g) were reported treated by gavage with 12 mg pure MON per animal.
However, purity (%) was not reported and missing information on the occurrence of other mycotoxins
and mode of treatment raised questions on the actually applied dose. Normal electrocardiogram (ECG)
prior to MON administration was compared to ECG after MON administration in the same animal. At
approximately, 4 min after MON administration, the heart rate increased from the previous range of
240–300 bpm to 360–480 bpm, and then gradually slowed down, followed by arrhythmia and
ultimately cessation of contraction. An increase in blood potassium at the time of MON introduction
caused hyperkalaemia, with enlargement of the atrium due to myocardial ischemia. Myocardial injury
was followed by a development of left and right ventricular dilatation in addition to atrial enlargement.
Meanwhile, blood potassium levels remained excessively high, quickly leading to ventricular ﬁbrillation
and cardiac arrest causing death. The three tested ducklings all died within 14–54 min.
In conclusion, for 1-day-old chickens, oral LD50 values of 4.0 and 5.4 mg MON/kg bw were
identiﬁed and ascites with oedema of the mesenteries and small haemorrhages in the proventriculus,
gizzard, small and large intestine, and skin were observed in surviving chickens. For 7-day-old ducks,
an oral LD50 value of 3.7 mg MON/kg bw was reported. Three-day-old ducklings receiving probably a
high dose of 12 mg of pure MON (240 mg/kg bw) by gavage showed increased heart rates followed
by arrhythmia and ultimately cessation of contraction generating the death.
Data on subchronic and chronic toxicity on MON were available for broiler chickens, laying hens,
turkeys, ducks and quails, and are described below. No data were identiﬁed for other poultry species.
Broiler chickens
Allen et al. (1981) performed two trials using groups of 10 chickens (a mixture of growing Ross
male and Arbor Acre female broiler chickens) for 3 weeks. In the ﬁrst trial, MON was extracted and
puriﬁed (98% pure) from Fusarium culture material and added to the feed to provide 0, 8 or 16 mg
MON/kg of diet. In the second trial, Fusarium culture material containing MON was incorporated to the
diet to provide 8, 16 and 64 mg/kg feed (information on the occurrence of other mycotoxins was not
reported). The birds were examined for feed consumption, body weight and symptoms (e.g. muscular
weakness, respiratory distress, cyanosis) during the conduct of the experiment. At the end of the
study, they were necropsied and examined for the presence of lesions. Exposures to concentrations of
8 and 16 mg MON/kg feed (from both feed preparations) generated no adverse effects. Three of the
10 chickens fed 64 mg MON/kg diet died and surviving birds showed reduced body weight gain and
reduced feed consumption. No lesions were found upon necropsy at this concentration. The authors
reported that the oral dose of 64 mg MON/kg feed corresponded to 9.7 mg MON/kg bw.
In an experiment of Engelhardt et al. (1989) four groups of 10 one-day-old broiler chickens were
fed MON-contaminated feed for 14 days. The feed was prepared by mixing the Fusarium culture
material producing MON at a concentration of 1.15 g MON/kg with maize applied in dietary
percentages of 0, 12.5, 25 and 50% of feed equivalent to 0, 144, 288 and 575 mg MON/kg feed
(information on the occurrence of other mycotoxins was not reported). No adverse effects were
observed in controls but in the other three groups all birds died except two out of the ten birds fed
144 mg MON/kg feed which were still alive after 10 days. Adverse effects observed before death
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included dyspnoea, cyanosis and reluctance to move. All birds that died had cyanosis and variable
amounts of ascetic and pericardial ﬂuid. Microscopic alterations were limited to the heart and liver.
Myocardial degeneration and necrosis were present indicating cardiovascular toxicosis. In the liver,
alterations of multifocal vacuolation and swelling of hepatocytes were accompanied by scattered
necrotic individual hepatocytes. The body weight of the surviving birds was lower than the controls.
Javed et al. (1993) fed a control and two dose groups of 10 one-day-old broiler chickens (Columbia
x New Hampshire) from 1 to 14 days with MON, which was extracted and puriﬁed (91% minimum
purity) from Fusarium culture material. Compared with the controls, the birds fed diets at 27 and
154 mg MON/kg feed were affected at day 7 and day 5 of the experiment, respectively. In both
experimental groups, adverse effects started with ataxia, decreased feed intake and body weight gain,
and were followed by a transient increase in water intake and seeking the heat source (within 24 h).
Mortality was 40% and 70% in groups fed diets at 27 and 154 mg MON/kg feed, respectively. A
further analysis of the serohaematological and immunological data by Javed et al. (1995) showed
statistically signiﬁcant changes of major haematological parameters in both experimental groups
compared with controls: elevated levels of cholesterol, sodium, alkaline phosphatase, aspartate
aminotransferase (AST), alanine aminotransferase, lactate dehydrogenase (LDH), GGT were
interpreted by the authors to indicate both hepatic and renal damage, and signiﬁcant decrease of
glucose concentrations was interpreted by the authors to indicate pancreatic damage. Immunological
changes included impaired anti-Newcastle disease antibody haemagglutination inhibition titres
associated with relative decreases in total serum for globulins and increases in albumin/globulin ratios.
Hall et al. (1995) analysed vitamin A concentrations in the serum samples of the four birds fed 154 mg
MON/kg feed and three control animals from the experiment of Javed et al. (1993, 1995) and noted
that the vitamin A concentrations in serum were decreased in birds fed 154 mg MON/kg feed.
Based on the same experimental design used by Javed et al. (1993, 1995) (10 one-day-old broiler
chickens fed diets at 27 and 154 mg of puriﬁed MON/kg feed during 14 days), Javed et al. (2005)
observed prominent gross lesions in affected birds including ascites, hydropericardium, hepatopathy,
nephropathy, cardiomyopathy, pneumonitis, gizzard ulceration and enlarged bursa of Fabricius ﬁlled
with caseous material. The two concentrations of MON (27 and 154 mg MON/kg feed) produced
lesions in the two groups. Histopathological changes included haemorrhage, leucocytic inﬁltration, fatty
change or inﬁltration, individual cell necrosis and ﬁbrosis in liver, kidneys, lungs, heart, intestines,
gizzard, bursa of Fabricius and pancreas. Oedema and haemorrhage were prominent in brains of
treated birds. Ultrastructural changes included cytoplasmic and nuclear enlargement of cells in affected
liver, lungs, kidneys, heart and pancreas. There were thickened membranes of the smooth
endoplasmic reticulum, dilation of the rough endoplasmic reticulum with loss of ribosomes and
vacuolated or deformed mitochondria.
The CONTAM Panel identiﬁed from the studies of Javed et al. (1993, 1995, 2005) and Hall et al.
(1995) a LOAEL of 27 mg MON/kg feed, the lowest concentration tested. At this concentration,
adverse effects such as mortality, reduced body weight gain, cardiomyopathy and changes in the
major haematological parameters were observed. No NOAEL was possible to identify from these
studies.
Six groups of ﬁve 1-day-old broiler chickens were fed diets containing 0, 25, 50, 75, 100, 150, 200,
250 and 300 mg MON/kg feed for 21 days (Ledoux et al., 1995). MON was obtained by incorporating
different percentages of a Fusarium culture material in the feed (information on the occurrence of
other mycotoxins was not reported). Compared with the controls a statistically signiﬁcant increased
mortality of 8/30, 17/30 and 25/30 occurred at the three highest concentrations of 200, 250 and
300 mg MON/kg feed, respectively. Birds fed diets at concentrations of 100 mg MON/kg feed or higher
had lower body weight gain than controls. Mortality occurred in chickens fed 200 (8 of 30), 250 (17 of
30) and 300 (25 of 30) mg MON/kg feed. Increased heart weight was observed in birds fed diet
concentrations equal and above 50 mg MON/kg feed and increased liver weight was observed in birds
fed diet concentrations equal and above 100 mg MON/kg feed. Cardiomegaly was observed in
chickens fed 50–300 mg MON/kg feed. Histopathology revealed a generalised and high incidence of
large shaped cardiomyocyte nuclei, and a loss of cardiomyocyte cross-striations in chickens fed diet
levels equal and above 75 and 200 mg MON/kg feed, respectively. From these data, the CONTAM
Panel identiﬁed the dietary concentration of 50 mg/kg feed generating cardiomegaly as LOAEL and
25 mg MON/kg feed where no adverse effects were observed as NOAEL.
Zhao et al. (1996) fed 10-day old Roman chickens a control (30 birds) and a contaminated diet (30
birds) at a level of 77 mg MON/kg feed for 30 days (provided by adding Fusarium culture material to
control feed. Information on the occurrence of other mycotoxins was not reported). Seventy per cent of
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treated birds died with deaths starting at day 5 and peaking at 8–10 days. Surviving birds grew slowly,
pathologic changes such as pulmonary congestion, severely damaged myocardium (coagulation, necrosis
and interstitial oedema) were observed. Histology of myocardium showed mitochondrial hyperplasia,
nucleus shape changes and decrease of myoﬁlaments.
In addition to above data in broiler chickens, the CONTAM Panel noted results from scientiﬁc
abstracts of Wu and Vesonder (1997), Nagaraj et al. (1997) and Bailey et al. (1997) that supported a
LOAEL for cardiomegaly in broiler chickens at a dietary concentration of 50 mg MON/kg feed.
In the study of Kubena et al. (1997), six groups of male broiler chickens (six per group) from day-
of-hatch to 3 weeks were fed diets containing 0 or 100 mg MON/kg feed. MON was obtained as
described by Ledoux et al. (1995). When compared with controls, body weight gain was reduced by
29% in the birds of the experimental group. The efﬁciency of feed utilisation was adversely affected,
and decreased relative weights of the bursa of Fabricius, increased relative weights of the heart,
concentrations of creatinine and calcium in serum, activities of alkaline phosphatase and alanine
aminotransferase, and changes in haematological values were reported.
MON from Fusarium culture material was used to prepare two dietary treatments containing 0 and
100 mg MON/kg feed (information on the occurrence of other mycotoxins was not reported) (Harvey
et al., 1997). Two pens of six 1-day old broiler chickens per dietary treatment were grown to 21 days
of age. Body weight gain and feed consumption were reduced by feeding 100 mg MON/kg feed, while
relative heart weight was increased. Increased alanine transferase and aspartate transaminase
activities and creatinine concentration and decreased mean corpuscular volume, mean corpuscular
haemoglobin and mean corpuscular haemoglobin concentration were observed. The MON diet
decreased glucose, haemoglobin and mean corpuscular haemoglobin concentration. Histopathological
lesions from the MON diet were limited to the kidney and consisted of extensive renal tubular epithelial
degeneration plus luminal mineralisation.
Susceptibility to infection was studied in one day-old broiler chickens fed 0, 50, 75 and 100 mg
MON/kg diet prepared by mixing Fusarium culture material (10,000 mg MON/kg) with the feed
(information on the occurrence of other mycotoxins was not reported) Li et al. (2000a). In the ﬁrst
experiment, 6 groups of two chickens were treated for 3 weeks and injected intravenously (i.v) with
E. coli on day 21. Chickens fed 100 mg MON/kg feed had lower feed intakes and body weight gains
than controls by that time and chickens fed 75 and 100 mg MON/kg diet had higher numbers of E. coli
colonies in the circulation, liver and spleen 180 min after the injection. In the second experiment,
chickens were treated for 4 weeks and were injected with 0.5 mL Newcastle disease virus vaccine
intramuscularly on weeks 2 and 3. Chickens fed 75 and 100 mg MON/kg diet had reduced feed intakes
and body weight gains during the 4-week test period. Chickens fed 100 mg MON/kg diet had lower
secondary antibody titres than controls 7 days after each injection. The observed decreased feed
intake and body weight gain and lower secondary antibody titres against Newcastle disease virus
suggest a reduced immune response in chickens fed 75 mg MON/kg diet.
One-day-old Cornish cross broiler chickens were treated at concentrations of 0, 25 and 50 mg
MON/kg diet (each group with 30 birds) for 7 weeks (Broomhead et al., 2002). The dietary MON was
obtained as described by Ledoux et al. (1995) (information on the occurrence of other mycotoxins was
not reported). Compared with controls, and birds fed 25 mg MON/kg feed, reduced feed intake,
reduced body weight gain, increased relative heart and increased proventriculus weights were
observed after 2 weeks for birds fed 50 mg MON/kg feed. Broiler chickens fed 25 and 50 mg MON/kg
also had increased serum GGT activities. In another experiment performed by the same group, each
three groups of ﬁve broiler chickens were given 0, 100 and 200 mg MON/kg diet (Ledoux et al., 2003).
The dietary MON was obtained as described by Ledoux et al. (1995) (information on the occurrence of
other mycotoxins was not reported). Compared with controls, both feed intake and body weight gain
were decreased at 100 mg MON/kg and 50–65% mortality occurred in chickens fed diets of 200 mg
MON/kg feed. Surviving birds had increased kidney and liver weights. Heavier heart weights, larger
pleomorphic cardiomyocyte nuclei, loss of cardiomyocytes and mild focal renal tubular mineralisation
were observed at both concentrations. From the study of Broomhead et al. (2002), the CONTAM
Panel identiﬁed the dietary concentrations of 50 mg MON/kg feed and 25 mg MON/kg feed to use to
calculate LOAEL and NOAEL for reduced body weight gain, respectively.
In conclusion, except for one experimental design in which adverse effects were observed in broiler
chickens fed a diet at 27 mg MON/kg feed (Javed et al., 1993, 1995, 2005), all the studies above on
broiler chickens, and particularly Ledoux et al. (1995) and Broomhead et al. (2002) supported by the
abstracts of Wu and Vesonder (1997), Nagaraj et al. (1997) and Bailey et al. (1997) reported that the
level of 50 mg MON/kg feed generated adverse effects such as mortality, reduced body weight gain,
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cardiomyopathy and changes in the major haematological parameters in broiler chickens. Among the
above studies, in one study (Allen et al., 1981) and in two others studies (Ledoux et al., 1995;
Broomhead et al., 2002) levels of 16 mg and 25 MON/kg feed did not generate any adverse effects,
respectively. Considering that Allen et al. (1981) used 10 birds per group for 3 weeks and Broomhead
et al. (2002) used 30 birds per group for 7 weeks, the level of 25 mg MON/kg feed was identiﬁed
from the Broomhead et al. study supported by the Ledoux et al. study as the level not generating
adverse effects for broiler chickens. Using the reported mean body weight and mean feed
consumption by the authors (Ledoux et al., 1995; Broomhead et al., 2002), the CONTAM
Panel converted the dietary concentrations of 50 and 25 mg MON/kg feed to an overall LOAEL of
2.8 mg MON/kg bw per day and an overall NOAEL of 1.4 mg MON/kg bw per day for broiler chickens.
Laying hens
Beginning at 24 weeks of age, white Leghorn laying hens (six birds per group) were fed 0, 50 and
100 mg MON/kg feed for 14 months (Kubena et al., 1999). Then, the hens were fed again the control
diet for an additional 2 months. The dietary MON was obtained as described by Ledoux et al. (1995)
(information on the occurrence of other mycotoxins was not reported). Twenty per cent of the hens
fed the 100 mg MON/kg diet died. This group of hens was the only group which had signiﬁcantly
lower body weights than controls and which egg production was reduced by 50% by the end of the
second 28-day laying period and remained at the reduced level for the 420 days. After the hens were
fed the control diet for 60 days, the egg production returned to the level of controls or above. Egg
weights were reduced during the ﬁrst three 28-day laying periods before they returned to the weights
comparable with controls. The hens were artiﬁcially inseminated with semen from males fed control
diets, but the fertility was not affected by MON exposure. From these data, the CONTAM
Panel identiﬁed the dietary concentrations of 50 and 100 mg MON/kg feed to calculate a NOAEL and
LOAEL, respectively, for decreased egg production, egg weight and body weight in laying hens. Using
the body weights and feed consumptions reported by the authors, a NOAEL of 3.8 mg MON/kg bw per
day for laying hens were calculated.
Turkeys
In the same experiment on broiler chickens (above), Engelhardt et al. (1989) treated 4 groups of
10 one-day-old turkey poults. The feed was prepared by mixing the Fusarium culture material
producing MON at a concentration of 1.15 g MON/kg maize to obtain dietary percentages of 0%,
12.5%, 25% and 50% of feed equivalent to 0, 144, 288 and 575 mg MON/kg feed (information on the
occurrence of other mycotoxins was not reported). While no adverse effects were observed in control
birds, among the three other groups only two birds fed 288 mg MON/kg feed were still alive after
10 days. The body weights of the surviving birds were lower than the controls and the observed
adverse effects were similar to the broiler chickens (see above).
Nine groups of 20 one-day-old female turkey poults were fed diets of 0, 25, 50, 75, 100, 150, 200,
250 and 300 mg MON/kg feed for 3 weeks (Bermudez et al., 1997). MON was from Fusarium culture
material and information on the occurrence of other mycotoxins was not reported. Statistically
signiﬁcant mortality occurred from 200 mg MON/kg feed onwards in 6/20 to 9/20 birds. From 100 mg
MON/kg feed and above, the feed intake and body weight gain were reduced compared to the
controls and from 50 mg MON/kg feed and above heart weight was increased with gross lesions of
cardiomegaly and focally extensive to generalised loss of cardiomyocyte cross striations (granular
change). Numerous large cardiomyocyte nuclei were observed at 100 mg MON/kg feed. The diets
containing MON at levels greater than or equal to 50 mg MON/kg feed induced cardiomegaly in turkey
poults. From this study, the CONTAM Panel identiﬁed the dietary concentration of 25 and 50 mg
MON/kg feed inducing cardiomegaly in turkeys to calculate the NOAEL and LOAEL, respectively.
Using a similar study design, Morris et al. (1999) conﬁrmed the ﬁndings of Bermudez et al. (1997)
by feeding 24 growing turkey poults two diets containing either 0 or 100 mg MON/kg for 3 weeks.
Five groups of turkeys (6 pens of 10 birds) were fed 0, 12.5, 25, 37.5 and 50 mg MON/kg feed for
14 weeks (MON from Fusarium culture material was added to a maize–soybean diet. Information on
the occurrence of other mycotoxins was not reported) (Broomhead et al., 2002). Feed intake, body
weight gain and feed conversion of turkeys were slightly affected at week 6 but not affected at week
14 in the end of the experiment for animals fed 50 mg MON/kg diet. Lesions in the heart were
observed only in turkeys fed 50 mg MON/kg feed, where a loss of cardiomyocyte cross-striations,
increased cardiomyocyte nuclear size and an increased number of cardiomyocyte mitotic ﬁgures were
also observed.
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From the above studies of Bermudez et al. (1997), Morris et al. (1999) and Broomhead et al.
(2002) performed by the same group of researchers, the CONTAM Panel noted that the dietary
concentration of 50 mg MON/kg was cardiotoxic to turkeys, and identiﬁed the dietary concentration of
25 mg MON/kg feed to calculate a NOAEL and 50 mg MON/kg feed to calculate a LOAEL for
cardiomegaly in turkeys. By using the body weights and feed consumptions reported by the authors, a
NOAEL of 1.6 mg MON/kg bw per day and a LOAEL of 3.2 mg MON/kg bw per day were calculated for
cardiotoxic effects in turkeys by the CONTAM Panel.
Susceptibility to infection was studied in four replicates of four 1-day-old turkey poults fed a control
diet and 100 mg MON/kg diet (Li et al., 2000b). MON contaminated diet was prepared by mixing
Fusarium culture material with the feed (information on the occurrence of other mycotoxins was not
reported). In a Trial-1, poults were fed for 4 weeks and were injected with 0.25 mL Newcastle disease
vaccine (NDV) on weeks 2 and 3. Anti-NDV antibody titres were measured 7 days after each injection.
Turkey poults exposed to MON had statically lower primary and secondary antibody response, and
decreased relative bursa and spleen weights were observed. In a Trial-2, poults were fed for 3 weeks
and injected with E. coli on day 21. Signiﬁcantly higher numbers of E. coli colonies were observed in
the blood and tissue homogenates of poults fed MON. In both experiments, feed intake and body
weight gains were statically lower in turkeys poults fed MON containing diets. The level of 100 mg
MON/kg feed suppressed immune response and decreased performance.
Ducks
In the above trial for LD50 determination Kriek et al. (1977), also conducted another trial (see
above), in which four Pekin ducklings either 1-day-old or 7-day-old were fed 6.1, 9.7 and 11.3 g
MON/kg feed (no control in the study). MON-contaminated diets were prepared by mixing Fusarium
culture material with commercial chicken mash. Both 1-day-old and 7-day-old ducklings died within
2–48 h depending of the diet levels and ages of the birds.
In the same experiment on chickens and turkeys described above, Engelhardt et al. (1989) also
studied four groups of 10 one-day-old ducklings. The feed was prepared by mixing the Fusarium
culture material producing MON at a concentration of 1.15 g MON/kg with maize to obtain dietary
percentages of 0%, 12.5%, 25% and 50% of feed equivalent to 0, 144, 288 and 575 mg MON/kg
feed (information on the occurrence of other mycotoxins was not reported). The control birds did not
show adverse effects but all the other birds died before 10 days. Adverse effects observed before
death were similar to the chickens and turkeys (see above).
In the ﬁrst trial of the study of Vesonder and Wu (1998), groups of 4 one-day-old ducklings were
provided diets of 0, 195, 308 and 1,169 mg MON/kg feed for 7 days. The control diet of corn–soy
bean chick mash did not contain detectable amounts of aﬂatoxin B1, T-2 toxin, deoxynivalenol,
zearalenone and fumonisin B1 (LODs: 0.02 mg/kg for aﬂatoxin, 0.5 mg/kg for other toxins). MON was
obtained from Fusarium culture material (information on the occurrence of other mycotoxins was not
reported) which was mixed with control diet to provide MON concentrations in the diets. Mortalities of
50%, 67% and 100% were observed in less than 6 h at 195, 308 and 1,169 mg MON/kg feed,
respectively. After 3 days, 100% mortality was observed at 195 mg MON/kg diet, whereas mortality
remained unchanged for the 308 mg MON/kg diet. The CONTAM Panel noted that this observation
could be due to uncertainties in the feed intake by one duck and small number of birds per group. In
the second trial, groups of six 1-day-old ducklings were provided with either a test or control diet for
2 days. The control diet was identical to the ﬁrst trial but the test diets were prepared by adding
puriﬁed MON (98% purity) to the control diet to provide diets of 15, 44, 133, 400 and 1,200 mg
MON/kg feed. Mortalities were observed for only birds in the groups fed 133, 400 and 1,200 mg
MON/kg feed in which 0%, 25% and 75% birds died in less than 12 h. On the day 2, deaths of 25 and
50% of birds fed diet 133 and 400 mg MON/kg feed were observed, whereas the 75% death for the
birds fed 1,200 mg MON/kg feed remained unchanged. No mortality within the 2-day experiment was
observed for both groups fed 15 and 44 mg MON/kg feed. However, because of the short period of
time of the experiment (2 days), the CONTAM Panel did not consider these two lowest levels as
NOAEL for risk assessment.
In absence of any other suitable data on adverse effects in ducks, the CONTAM Panel also noted
that results from two experiments reported in two scientiﬁc abstracts of Broomhead et al. (1996) and
Morris et al. (1997). Broomhead et al. (1996) (abstract), randomly allotted 140 one-day-old male Pekin
ducklings to the groups of 0, 25, 50, 75, 100, 125 and 150 mg MON/kg feed. The dietary MON was
from Fusarium culture material (information on the occurrence of other mycotoxins was not reported).
Each dietary treatment was fed to 4 pen replicates of 5 ducklings per pen for 17 days. Ducklings fed a
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diet with 100 mg MON/kg had lower relative heart and higher relative kidney weights compared with
controls. No signiﬁcant differences in serum glucose, albumin, cholesterol, total protein, globulin, AST
and GGT levels were observed. Cardiomegaly was observed in ducklings fed from 75 mg MON/kg diet
and above. From these data, the CONTAM Panel identiﬁed the dietary concentration of 75 mg MON/kg
feed generating cardiomegaly in ducklings to use for LOAEL calculation. At the dietary concentration of
50 mg MON/kg feed, no adverse effects were observed.
The group of Broomhead et al., 1996 (abstract), assigned ﬁve replicate pens of 5-day-old male
Pekin ducklings to diet groups of 0, 50, 100 and 200 mg MON/kg feed (Morris et al., 1997, abstract).
Dietary MON was obtained from Fusarium culture material (information on the occurrence of other
mycotoxins was not reported). Compared to controls, feed intake was reduced in all groups, body
weight gain was reduced in the group fed 100 mg/kg feed and statistical mortality occurred in the
group fed 200 mg MON/kg feed.
The CONTAM Panel also noted a 14-day study of Leslie et al. (1996) on 1-day-old Pekin ducklings
for testing the toxicity of 20 cultured fungal strains. Their ability for mycotoxin production was
analysed only for fumonisins and MON (ranged 85–10 345 mg/kg culture material). Mouldy feed was
mixed with commercial chicken mash (50%/50%) and fed ducklings (4 per group). A toxicity index
was calculated by multiplying the amount of feed intake (g) by the mean day of death to obtain an
inverse measure of toxicity for cultures. The authors concluded that MON levels were not strongly
correlated with this toxicity index on ducklings due to the possible production of other non-identiﬁed
toxins interfering with the toxicity. For this reason and because no details were reported on time delay
of death, body weights and feed intakes for animals, the CONTAM Panel did not consider this study
further for risk assessment.
In conclusion, in the absence of any other suitable data, the CONTAM Panel identiﬁed from the
abstract of Broomhead et al. (1996), the dietary concentrations of 75 mg MON/kg feed to use to
calculate a LOAEL for generating cardiomegaly in ducklings, and from the abstracts of Broomhead
et al. (1996) and Morris et al. (1997), the dietary concentration of 50 mg MON/kg feed to calculate a
NOAEL. Because body weight and feed intake were not reported by the authors, the body weight and
feed intake from Appendix C, Table C.2 were used to calculate the doses of 2.8 and 2.3 mg MON/kg
bw per day as LOAEL and NOAEL, respectively, for cardiomegaly in ducks.
Quail
A control group of 75 one-day-old quail chicks (Coturnix coturnix japonica) were fed quail mash
and another group of 105 birds were fed a diet of 100 mg MON/kg feed (corresponding to 5.9 mg
MON/kg bw per day) for 35 days (Sharma et al., 2008, 2012). MON was from Fusarium culture
material (information on the occurrence of other mycotoxins was not reported). Birds fed MON-diet
exhibited signs of poor feathering and decreased feed and water consumption and reduced body
weight gain, anorexia and diarrhoea and increased AST, LDH and creatine kinase (CK) values. The
changes in AST and LDH values were attributed to liver damage, while changes in CK were attributed
to kidney damage. Since only one concentration was tested no reference point could be identiﬁed.
Gross and microscopic observations of the heart were also reported. Cardiomegaly was observed in
the group fed MON. Microscopically, hypertrophy of cardiomyocytes was observed in the group fed
MON as early as after 7 days of the experiment.
Conclusions
For 1-day-old chickens, oral LD50 values of 4.0 and 5.4 mg MON/kg bw were reported and ascites
with oedema of the mesenteries and small haemorrhages in the proventriculus, gizzard, small and
large intestine, and skin were observed in surviving chickens. For 7-day-old ducks, an oral LD50 value
of 3.7 mg MON/kg bw was reported and increasing heart rates followed by arrhythmia and ultimately
cessation of contraction generating the death.
From the available database on broiler chickens, the CONTAM Panel identiﬁed a LOAEL of 50 mg
MON/kg feed corresponding to the dose of 2.8 mg MON/kg bw per day for generating adverse effects
such as some mortalities, reduced body weight gain, cardiomyopathy, changes in the major
haematological parameters in broiler chickens and a NOAEL of 25 mg MON/kg feed corresponding to
the dose of 1.4 mg MON/kg bw per day. From data from only one available study on laying hens,
the CONTAM Panel identiﬁed the NOAEL of 50 mg MON/kg feed corresponding to the dose of 3.8 mg
MON/kg bw per day and the LOAEL of 100 mg MON/feed corresponding to the dose of 8.5 mg
MON/kg bw per day for reduced egg production and reduced body weight gain. For turkeys, the
CONTAM Panel identiﬁed the NOAEL of 25 mg MON/kg feed corresponding to the dose of 1.6 mg
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MON/kg bw per day and the LOAEL of 50 mg MON/kg feed corresponding to the dose of 3.2 mg
MON/kg bw per day for inducing cardiomegaly. From the two studies (available as abstracts) on
ducks, the CONTAM Panel considered the LOAEL of 75 mg MON/kg feed corresponding to the dose of
2.8 mg MON/kg bw per day generating cardiomegaly and the NOAEL of 50 mg MON/kg feed
corresponding to the dose of 2.3 mg MON/kg bw per day in ducks. The only identiﬁed study on quails
supported the ﬁndings in other poultry for dietary MON generating cardiomegaly.
Overall, it can be concluded that the heart is the main target organ for poultry causing heart failure
at acute doses. Chronic dietary exposure to MON generated cardiomegaly in poultry but also changed
haematological parameters and affected zootechnical parameters such as reduction of body weight
gain and egg production.
3.1.5.4. Solipeds
In one donkey, daily i.v. administration of 1 mg MON/kg bw per day (purity of MON not reported)
resulted in acute death after 26 days accompanied by microhaemorrhages, satellitosis and neuronophagia
(Buck et al., 1980). No studies on oral administration were identiﬁed for donkeys. No data on horses were
identiﬁed. The CONTAM Panel noted a few studies (Marasas et al., 1976; Buck et al., 1980) on the
exposure of F. moniliforme associated with horses suffering from equine leucoencephalomalacia.
However, no MON was quantiﬁed in these studies. It should be noted that at the time these studies were
published, fumonisins were unknown (discovered in the end of 1980s) and currently it is known that
equine leucoencephalamalacia is typically associated with the exposure to fumonisins.
3.1.5.5. Farmed rabbits
No data were identiﬁed.
3.1.5.6. Farmed ﬁsh
Channel catﬁsh with an average initial weight of 1.5 g (35 ﬁsh/aquarium, 3 aquariums/dose) were
given feed containing 0, 20, 40, 60 and 120 mg MON/kg feed (estimated to correspond to 0.8, 1.7,
3.2 and 8.7 mg MON/kg bw per day by the CONTAM Panel based on data on weight and feed
consumption reported in the paper) for 10 weeks (Yildirim et al., 2000). The feed was prepared by
mixing MON-containing Fusarium culture material into the feed (information on the occurrence of other
mycotoxins was not reported). MON did not affect the mortality. A dose-dependent reduction in weight
gain was observed and the weight gain was signiﬁcantly reduced compared to control even in the
lowest dose group (20 mg MON/kg feed). The feed conversion ratio (determined as grams of feed
consumed per gram of ﬁsh wet weight gain) was signiﬁcantly increased in the highest dose group. The
only effect found in histopathological examinations of liver and heart was smaller nuclei in liver cells
from ﬁsh given 60 or 120 mg MON/kg feed. Haematocrit was signiﬁcantly lowered and serum pyruvate
signiﬁcantly increased by 60 mg MON/kg feed.
Tuan et al. (2003) fed Nile tilapia diets containing 0, 10, 40, 70 and 150 mg MON/kg feed (3
aquariums/dose; 40 ﬁsh/ aquarium) for 8 weeks from a mean weight of 2.7 g. The doses were
estimated to correspond to 0.4, 1.8, 3.9 and 9.4 mg MON/kg bw per day by the CONTAM Panel based
on data on weight gain and feed conversion reported in the paper. The MON-contaminated diets were
produced by mixing Fusarium culture material (10,000 mg MON/kg) with the feed (information on the
occurrence of other mycotoxins was not reported). MON did not increase the mortality rate or cause
any histopathological lesions. Fish fed 70 or 150 mg MON/kg feed had a signiﬁcantly (p < 0.05) lower
weigh gain than controls. MON signiﬁcantly increased the serum pyruvate levels in all dose groups
(0.1217, 0.1254, 0.1270 or 0.1419 mmol pyruvate/L, respectively) compared to control (0.1089 mmol
pyruvate/L), but there were no differences between the groups fed 10, 40 and 70 mg MON/kg feed.
Haematocrit was reduced in ﬁsh fed 70 or 150 mg MON/kg feed.
Conclusions
The available data on effects of MON on ﬁsh were limited and only two feeding experiments one
with channel catﬁsh and one with Nile tilapia were identiﬁed. A reduction in weight gain was reported
for ﬁsh given feed with 20 mg MON/kg, corresponding to 0.8 mg MON/kg bw per day, which was the
lowest concentration used in the channel catﬁsh feeding study. Nile tilapia may be more resistant as
no effects on feed intake and weight gain were observed at 40 mg MON/kg feed, corresponding to
1.8 mg MON/kg bw per day in this species. However, serum pyruvate levels were increased in Nile
tilapia at 10 mg MON/kg feed, the lowest dose tested. Due to the limited database, no critical adverse
effect levels of MON for ﬁsh could be identiﬁed.
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3.1.5.7. Farmed mink
Three groups of pastel, adult female mink (n = 12) were fed diets (from 2 weeks prior to the
breeding season, and continued until the offspring were 8 weeks old) containing 0, 8.1 and 17.0 mg
MON/kg (equivalent to 0, 0.92 and 1.94 mg MON/kg bw per day as calculated by the CONTAM
Panel using the body weights and feed consumption data from NRC, 1982, see Section 3.1.4.5) (Morgan
et al., 1998). MON was from Fusarium culture material (approximately 10,000 mg MON/kg) which was
mixed with the diet. The culture material contained no detectable fumonisins (LOD 0.5 mg/kg) and the
cereals in the diet contained no detectable concentrations of aﬂatoxins, zearalenone and deoxynivalenol
(LODs were 0.004 mg/kg for aﬂatoxins B1, B2, G1 and G2, 0.2 mg/kg for zearalenone, and 0.4 mg/kg for
deoxynivalenol). Throughout the trial, there were no marked differences in feed consumption or body
weights of the 0.92 and 1.94 mg MON/kg bw groups compared to the controls when recorded daily and
weekly, respectively. No gross lesions or alterations were observed at necropsy and there were no
signiﬁcant differences in brain, liver, kidney, heart, lung and adrenal gland weights (expressed as
absolute weight or as percent of body weight) among the groups. The only signiﬁcant difference was
observed for the leucocyte differential cell counts. The percentage of segmented neutrophils in the high-
dose group was lower and the percentage of lymphocytes was larger in the high-dose group when
compared to the control and low-dose groups. The reproductive effects reported in this paper are
described in Section 3.1.4.5, and from this study, the CONTAM Panel identiﬁed the reproductive effects,
neonatal mortality and reduced offspring body weights, as adverse effects in farmed mink. The LOAEL
and NOAEL were calculated as 1.94 and 0.92 mg MON/kg bw per day, respectively, by the CONTAM
Panel.
At birth and 3, 6, and 8 weeks afterwards, the mean body weight of the surviving offspring was in
the high-dose group 8.6, 94, 259, and 462 g (SEM: 0.4, 3.1, 12.6 and 17.8 g). This was lower than in
controls with means 9.8, 99, 261, and 521 g (SEM 0.4, 2.9, 11.9 and 15.7 g) and in the low-dose
group with means 9.5, 106, 270, and 525 g (SEM: 0.3, 2.6, 10.8 and 14.2 g). The difference was
statistically signiﬁcant at birth and 8 weeks later. The mortality up to 8 weeks was over the ﬁrst time
points statistically signiﬁcant, higher (74%) in the high-dose group compared to controls and the low-
dose group (11% and 16%, respectively). The authors interpreted these ﬁndings as indications of a
higher sensitivity of young mink compared with adults. However, the CONTAM Panel noted that the
design of this study was limited since only two dose groups were used, with clear effects only at the
highest dose. Furthermore, the study covered at the same time reproductive and developmental
toxicity which would not allow a robust investigation of the sensitivity to exposure to MON of young
animals in comparison to older ones, in particular, when the three groups differed substantially at birth
and litter effects could not be excluded.
Conclusions
The dose of 1.94 mg MON/kg bw per day resulted in signiﬁcant neonatal mortality and reduced
offspring body weights in farmed mink and was identiﬁed as LOAEL. The NOAEL was 0.92 mg MON/kg
bw per day for farmed mink.
3.1.5.8. Dogs and cats
No data were identiﬁed.
3.1.6. Combined effects of MON with other mycotoxins
Co-exposure to more than one mycotoxin in animals and humans through food and feed has been
reported (reviewed in Grenier and Oswald, 2011; Streit et al., 2012). Several in vivo experiments were
performed to analyse the effect of MON when present with other mycotoxins. No in vitro data were
identiﬁed on the combined effect of MON and other mycotoxins (Alassane-Kpembi et al., 2017). This
chapter reports only studies in which the experimental design was set to study combined effects and
in which the conclusions were drawn by the authors on the combined effects (Table 4). All of these
experiments were performed on farm animals. The CONTAM Panel noted that because of the lack of
dose–response data, it is difﬁcult to perform a reﬁned statistical analysis and to draw deﬁnitive
conclusion.
Conclusions
The available database describing possible effects of combined exposure to MON and other
mycotoxins was weak and insufﬁcient for establishing the nature of combined effects.
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Table 4: Possible combined effects between MON and other mycotoxins in vivo
MON/Tested
mycotoxin
Species (exposure
period)
Concentrations
(MON/tested
mycotoxin)
(mg/kg feed)
Additive or synergistic
combined effects(a)
Antagonistic combined effect(a) Reference
MON/Aﬂatoxin
Chicken
(21 days)
100/3.5 – inorganic phosphorus
– body weight gain
– relative weight (heart)
– number of red blood cell
– albumin
– creatinine
– alanine aminotransferase
– relative weight (gizzard, kidney, bursa of Fabricius)
– total protein
– cholesterol
– calcium
– alkaline phosphatase
Kubena et al. (1997)
MON/FB
Turkey
(21 days)
100/200 – feed intake (P)
– relative weight (liver)
– aspartate aminotransferase
– body weight gain
– mortality
– glucose
– lactate dehydrogenase
Bermudez et al. (1997)
MON/FB
Pig
(28 days)
100/100 – feed intake
– creatinine (P)
– number of red blood cell
– body weight gain
– mortality
– glucose
– inorganic phosphorus
– aspartate aminotransferase, alkaline phosphatase, lactate
dehydrogenase, gamma-glutamyltransferase
– total iron
Harvey et al. (2002)
MON/FB
Laying hens
(420 days)
50/100 – relative weight (pancreas)
– albumin
– aspartate aminotransferase
– mortality
– cytokine
– relative weight (liver, kidney)
– uric acid
– egg production
– egg weight
Kubena et al. (1999)
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MON/Tested
mycotoxin
Species (exposure
period)
Concentrations
(MON/tested
mycotoxin)
(mg/kg feed)
Additive or synergistic
combined effects(a)
Antagonistic combined effect(a) Reference
MON/FB
Chicken
(21 days)
100/100 – relative weight (heart) – feed intake
– mortality
– aspartate aminotransferase
– body weight gain
Ledoux et al. (2003)
200/100 – no parameter tested – relative weight (heart, kidney, liver)
– albumin, total protein
– mortality
– aspartate aminotransferase
100/200 – relative weight (liver, kidney)
– albumin, total protein
– relative weight (heart)
– feed intake, body weight gain
– mortality
– aspartate aminotransferase
200/200 – relative weight (kidney, liver) – relative weight (heart)
– albumin
– mortality
– aspartate aminotransferase
– total protein
MON/FB
Turkey
(21–28 days)
100/200 – antibody to New Castle diseases virus – feed intake, body weight gain
– relative weight (thymus, bursa of Fabricius, spleen)
– lymphocytes stimulation
– bacteria in tissue and blood, mortality
Li et al. (2000a,b)
MON/FB
Quail
(35 days)
100/200 – body weight
– mortality
– total protein
– cholesterol
– alanine aminotransferase, aspartate aminotransferase
– albumin
– lactate dehydrogenase, cytokine
– creatinine
– delayed type hyposensitivity reaction
Sharma et al. (2008)
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MON/Tested
mycotoxin
Species (exposure
period)
Concentrations
(MON/tested
mycotoxin)
(mg/kg feed)
Additive or synergistic
combined effects(a)
Antagonistic combined effect(a) Reference
MON/FB
Fish
(70 days)
40/20 – size of hepatocyte nuclei – body weight gain, feed intake
– Sa/So liver
Yildirim et al. (2000)
40/40 – body weight gain
– serum pyruvate
– size of hepatocyte nuclei
– feed intake
– Sa/So liver
MON/DON
Turkey
(21 days)
100/20 – feed intake
– globulin
– relative weight (kidney)
– body weight gain
– relative weight (heart)
– calcium
Morris et al. (1999)
MON/FB1
Chicken
(14 days)
27–154/
27–154
– alkaline phosphatase
– gamma glutamyltransferase
– aspartate aminotransferase,
– lactate dehydrogenase
– cholesterol
– sodium
– red Blood Cell
– haemoglobin
– packed cell volume
Javed et al. (1995)
No parameter tested: In a given study, there was no parameter tested that demonstrated synergistic, additive or antagonistic combined effect.
(a): As concluded by the authors.
Moniliformin in food and feed
www.efsa.europa.eu/efsajournal 41 EFSA Journal 2018;16(3):5082
3.1.7. Human data
No study in humans was identiﬁed that associated adverse effects and exposure to MON. However, in
several reports an association was suggested between the occurrence of MON in grains and the
prevalence of an endemic disease in China, called KD (International Classiﬁcation of Diseases, ICD-10
E5920) Zhang and Li (1988 and) Zhang and Li (1989); Liu (1996). KD is characterised by cardiomyopathy,
with acute or chronic heart disorder. The ﬁrst reported outbreak occurred Keshan county of Helongjiang
province in China in 1935. The fatal KD reached a peak in 1960–1970 with reported death rates from
7.6% to 34%, and 49,408 cases and 9,614 deaths were attributed to KD between 1950 and 1982 in
Helongjiang province alone. KD gradually disappeared in these regions by the 1980s.
Studies in the endemic regions conﬁrmed that selenium deﬁciency was a necessary but not sufﬁcient
causative factor for KD. All KD endemic regions had low selenium levels in the soil, while no KD was
found in areas with high selenium in the soil. In addition to selenium deﬁciency, MON has been
postulated as a contributing factor in KD aetiology. This was based on several ﬁndings of Liu (1996):
• Pigs fed with MON exhibited pathological changes of myocardial lesion similar to those
observed in humans with KD (Qiao et al., 1993; described in Section 3.1.5.2),
• MON concentrations in staple food from KD endemic regions were found to be higher than
those in the non-KD region,
• MON concentrations in rice samples were lower than in other cereals which corresponded to
less acute KD in areas where rice was the staple food,
• the occurrence of KD was associated with both high prevalence of MON and low selenium
content in cereals.
However, it has been suggested more recently that KD was due to a combination of viral infections
and nutrient deﬁciency (Beck et al., 2003).
The CONTAM Panel noted that a study of Xiong et al. (1998)21 investigated effects of MON and
selenium on the articular cartilage of Chinese mini-pigs.
Conclusions
No human epidemiological data on MON were identiﬁed. It has been hypothesised that dietary
exposure to MON was involved in past KD prevalence in some regions in China. However, the CONTAM
Panel noted that the evidence for a relation between dietary exposure to MON and KD is limited.
3.1.8. Biochemical mode of action
The mode of action of MON is unclear and only a limited amount of data was available. MON and
pyruvate show structural similarity, and the primary mode of action of MON seems to be the inhibition
of thiamine pyrophosphate-dependent enzymes, which compromises the tricarboxylic acid cycle. MON
has been shown to impair oxidation of pyruvate and a-ketoglutarate, and to inhibit pyruvate
dehydrogenase in vitro (Thiel, 1978; Burka et al., 1982; Gathercole et al., 1986). Later, Pirrung and
Nauhaus (1996) demonstrated that several enzymes sharing thiamine as common cofactor (pyruvate
dehydrogenase, a-ketoglutarate dehydrogenase, pyruvate decarboxylase and acetohydroxy acid
synthase) were inhibited by MON. This could lead to cellular energy deprivation and may partially
explain the respiratory stress, including myocardial effects. It could even cause mortality of test
animals exposed to MON (Jonsson et al., 2015). MON may also interfere with carbohydrate metabolism
through the inhibition of gluconeogenesis and aldose reductase (Deruiter et al., 1993). In rat
myoblasts, MON induces an inhibition of glutathione peroxidase and glutathione reductase suggesting
an implication of free radicals in the toxicity (Chen et al., 1990).
Haematotoxicity of MON was tested on human lymphocytes and on the human leukaemia cell line
K-562. The cultures were incubated for 48 h at 37°C with ~ 5% of CO2, before being examined by the
MTT colorimetric assay. IC50s were equal to 22 lM and > 100 lM, respectively (Visconti et al., 1991).
Myelotoxicity of MON was tested on human haematopoietic progenitor cells in culture at
concentrations equal to 0.1, 1, 5, 10, 20, 60 and 100 lM MON (Ficheux et al., 2012). Cytotoxicity,
proliferation and differentiation capacities were measured. MON was cytotoxic at 10 lM for red blood
cells progenitors, but not cytotoxic at tested concentrations for white blood cells progenitors and
platelet progenitors. MON had no effect on proliferation from 5, 0.1 and 0.1 lM for white blood cells
20 http://www.who.int/classifications/icd/en/
21 Original paper in Chinese, text based on the translation to English.
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progenitors, platelet progenitors and red blood cells progenitors, respectively. The IC50 was equal to
31, 39 and 4.1 lM for white blood cells progenitors, platelet progenitors and red blood cells
progenitors, respectively. MON disturbed also red blood cell progenitors’ differentiation from 2 lM
MON, when viability was equal to 83%. Furthermore, MON was cytostatic for megakaryocytic
progenitors. A general decrease in large platelet progenitors’ colony number compensated by an
increase in small colony number was observed from 60 lM MON, when viability was equal to 52%.
Based on these in vitro results, the authors suggested a putative in vivo production of immature red
blood cells induced by MON and subsequent anaemia, and an in vivo decrease in platelet production,
and consequently coagulation troubles. From this study, the CONTAM Panel concluded that MON
caused cytostatic effects on platelet progenitors in vitro and platelet production was decreased. The
CONTAM Panel noted that a low number of platelets could induce coagulation troubles in vivo.
Only one identiﬁed in vitro study investigated immunotoxicity of MON. Ficheux et al. (2013)
observed that up to 80 lM MON induced 20% of mortality on human immature and on mature
dendritic cells while no mortality was observed on human macrophages exposed to 80 lM MON. In
dendritic cells, 45% of cells presented endocytosis ability in the presence of 80 lM MON. After 5 days
of exposure to 80 lM MON, the expression of CD1a, a phenotypic marker of immature dendritic cells
was also decreased by 59% compared to non-treated cells. Monocytes-derived macrophages exposed
to MON during the differentiation process also presented a decrease of endocytosis ability, and a
decrease of transferin receptor (CD71) and HLA-DR expression. Expression of CD11a, CD80 and CD54
was not modiﬁed in the presence of 80 lM MON. These results showed that MON disturbs human
monocytes differentiation process into macrophages and inhibits human monocytes differentiation
process into immature dendritic cells, and suggested that MON could induce a decrease of immune
response in case of infection. The immunotoxicity of MON was further conﬁrmed in vivo on poultry
(see Section 3.1.5.3).
Conclusions
Only a limited amount of data was identiﬁed on the mode of action of MON. The inhibition of enzymes
involved in glucose metabolism could lead to cellular energy deprivation and may partially explain the
respiratory stress, including myocardial effects. In vitro, scarce observations described cytotoxic effects
on platelet progenitors and disturbances in differentiation process of monocytes in dendritic cells.
3.2. Consideration of critical effects, dose–response analysis and
derivation of reference points for human and farm and companion
animal risk assessments
3.2.1. Critical effects and derivation of reference points for human risk
assessment
The toxicological database of MON for chronic studies in experimental animals was scarce. Only very
few subacute and subchronic studies of sufﬁcient quality were available for hazard characterisation, and
no data on adverse health effects in humans were found. To augment the database for human hazard
characterisation the CONTAM Panel examined a subchronic study on pigs (Harvey et al., 2001) and one
study on developmental and reproductive toxicity in mink (Morgan et al., 1998).
3.2.1.1. Acute effects
Acute and subacute studies in rats indicate that the heart and the cardiovascular system is a central
toxicity target of MON. Acute cardiac effects were observed in rats at doses as low as 10–25 mg/kg
bw (Jonsson et al., 2013). Severity increased at 40 mg/kg bw and already at 50 mg/kg bw death of
rats was attributed to muscular weakness, and respiratory and cardiovascular changes. This
observation was in agreement with results in Kriek et al. (1977), who observed congestive heart failure
at 50 mg MON/kg bw in rats. Furthermore, Zhao et al. (1993) reported ultrastructural lesions in the
myocardium of rats and mice at 6 and 25 mg/kg bw. On the other hand, no adverse effects were seen
in a study of acute toxicity of MON in rats at doses ranging from 2.5 to 10 mg/kg bw (Abbas et al.,
1990) and the LD50 values for rats ranged from 18.5 to 50 mg MON/kg bw. In pigs, the dose of 17 mg
MON/kg bw (1/6 deaths in the ﬁrst experiment) was the lowest one where mortality was observed
(Harvey et al., 2001), see Section 3.1.5.2. The CONTAM Panel considered the available mortality data
and LD50 values from experimental animals unsuitable for derivation of an acute reference dose (ARfD)
for MON, due the large uncertainties of these data and the severity of the outcome.
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The CONTAM Panel identiﬁed the subacute (28 days) study in rats, performed in accordance with
OECD guidance with ﬁve dose groups (3, 6, 9, 12 or 15 mg/kg bw per day) and a control group, as
pivotal study for the study of cardiotoxicity in experimental animals (Jonsson et al., 2015). Acute heart
failure occurred at 15 mg MON/kg bw on the 4th and 21st day after presenting strongly decreased
activity or somnolence. Signs of toxicity such as decreased activity, withdrawal and somnolence were
observed at 9 mg MON/kg bw and were similar to those seen at the two highest doses. Also, a weak
grip at the front legs was reported at a dose of 9 mg MON/kg bw per day. No other adverse health
effects were reported for the doses up to 9 mg MON/kg bw, and the study NOAEL identiﬁed as of
6 mg MON/kg bw was considered as reference point of acute adverse health effects of MON.
Accounting for the limited database with only one suitable subacute study in only one species of
experimental animals, its limited number of animals and its limited information on cardiac effects in the
lower dose range, the CONTAM Panel considered the available information on acute adverse health
effects too limited to establish an ARfD. Therefore, the CONTAM Panel decided to assess the acute
human health risk of exposure to MON by comparing the NOAEL of 6 mg MON/kg bw from the
subacute study in rats with the estimated acute exposure of humans by calculating a margin of
exposure (MOE) (see Section 3.7). Accounting for the severity of cardiotoxicity with the potential of
acute death at only slightly higher doses, the CONTAM Panel considered this MOE as indicative to
inform on the potential health concern for humans acutely exposed to MON.
3.2.1.2. Chronic effects
Only one subchronic study of MON was available in experimental animals (Kriek et al., 1977) to
characterise the chronic hazard of MON. Groups of male and female rats were exposed for 12 weeks
to 5 concentrations of mouldy feed containing MON and were examined for general toxicity and
pathological changes in major organs, including necropsy at death or ﬁnal sacriﬁce. Lesions in the
myocardium and myocardial degeneration, necrosis and ﬁbrosis were observed at all concentrations
and an increase in severity with dose was demonstrated (see Section 3.1.4.3).
Because of high mortality and absence of dose information for the two highest concentration
groups, the CONTAM Panel considered only the controls and the three concentrations 2%, 4% and 8%
MON/kg feed (corresponding to 16.6, 34.6 and 32.5 mg MON/kg bw in males and to 16.5, 32.9 and
34.5 mg MON/kg bw in females) for dose–response evaluation. The CONTAM Panel concluded that the
clearly increasing severity of adverse health effects over the three doses can be considered as causative
for the observed mortality, for which a steep quantitative dose–response relationship could be
identiﬁed. However, several limitations of the mortality data in male rats were noted in the study of
Kriek et al. (1977):
• The data set was small, since only a total of 16 animals (n = 4 animals per group) were
available for the evaluation of the mortality.
• The calculated doses at the concentration groups of 4% and 8% MON/kg diet were almost
identical, probably due to lower feed consumption at 8% MON/diet. In effect, only two dose
groups were available for dose–response, one in the range of 17 mg MON/kg bw per day and
another in the range of 32–34 mg MON/kg bw per day.
In the absence of suitable dose–response data of experimental animals for hazard characterisation,
the CONTAM Panel decided to augment the database for human hazard characterisation by available
toxicity data on pigs. Therefore, the Panel identiﬁed the subchronic study on pigs (Harvey et al., 2001) as
being of relevance for human hazard characterisation and identiﬁed cardiac toxicity together with
haematotoxicity of MON as sensitive chronic adverse effects in the growing barrows exposed to 0, 25, 50,
100 and 200 mg MON/kg feed in two feeding experiments of this study. The Panel noted that
co-exposure with other mycotoxins was quantiﬁed as below the LOQ/LOD such that general adverse
effects (reduced feed intake and body weight gain), changes in biochemical and haematological
parameters and the increase of relative heart weight and mortality related to cardiotoxicity, in particular
cardiomegaly, were considered as being clearly dose related and reported as statistically signiﬁcant at the
highest dose of 200 mg MON/kg feed. Based on the reported body weights (dose-speciﬁc means) given
in the publication, and assuming a daily feed intake of 1.2 kg feed, the CONTAM Panel identiﬁed NOAELs
of 1.20–2.22, 1.00 and 4.6 mg MON/kg bw per day for reduced body weight gain, haematological
adverse effects (as decreased of haematocrit and haemoglobin levels) and cardiotoxicity, respectively
(see Section 3.1.5.2). Furthermore, the Panel evaluated the dose-dependent decrease of haematocrit
and haemoglobin using the BMD approach and identiﬁed the lowest BMDL05 of 0.20 mg MON/kg bw per
day for haematotoxicity in pigs as a reference point for chronic effects of MON for humans.
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The only available information on developmental and reproductive toxicity of MON was from a
study in farmed mink exposed to two doses (calculated by the CONTAM Panel as 0.92 and 1.94 mg
MON/kg bw per day). Statistically signiﬁcant mortality was observed during the ﬁrst 24 h after birth in
offspring from dams exposed to the highest dose. The CONTAM Panel identiﬁed the signiﬁcant
increase of the number of still births and mortality within the ﬁrst 24 h postpartum at the high dose as
a possible reproductive effect of MON. Effects observed in offspring postpartum, such as reduced
weight gain and early mortality after weaning, could possibly be related to postnatal MON exposure,
since the kits were exposed during that period to the same dose of MON as the dams, see also
Section 3.1.5.7. Therefore, these data were not considered as relevant for developmental effects but
would support a reference point in the low mg MON/kg bw per day range.
Accounting for the limited database, with only one limited subchronic study in rats and a 28-day study
in pigs, and in the absence for long-term toxicity studies, the CONTAM Panel considered the available
information on chronic adverse health effects too limited to establish a TDI. Therefore, the CONTAM
Panel decided to assess the chronic human health risk of exposure to MON by comparing the reference
point of 0.20 mg MON/kg bw per day for haematotoxicity in pigs with the estimated chronic exposure of
humans and by calculating a MOE. Accounting for the severity of cardiotoxicity with the potential of acute
death at higher doses, and the limitations of the study in pigs, the CONTAM Panel considered this MOE as
an indicative on the potential health concern for humans chronically exposed to MON.
3.2.2. Consideration of critical effects and derivation of reference points for farm
and companion animal risk assessment
Because of the limited data on MON for some farm and companion animals, NOAELs and/or
LOAELs for adverse effects of MON were only identiﬁed for poultry, pigs and farmed mink (see
Section 3.1.5). While several studies on adverse effects were available for poultry that allowed the
identiﬁcation of NOAELs, the NOAELs identiﬁed for pigs and farmed mink were based on data on
adverse health effects reported from one study only for each of the two species. The dose–reponse
data available for pigs allowed the calculation of a BMDL as reference point based on the
haematotoxicity of MON in that farm animal species.
3.2.2.1. Pigs
From the study on pigs (28 days of MON exposure), the CONTAM Panel identiﬁed reduced body
weight gain, adverse haematological effects and mortality accompanied with lesions in heart as main
adverse health effects. NOAELs were between 1.20 and 2.22 mg MON/kg bw per day for reduced body
weight gain, 1.00 mg MON/kg bw per day for haematological adverse effects and 4.17 mg MON/kg bw
per day for mortality.
The CONTAM Panel identiﬁed haematological adverse effects as critical effects and used the lowest
BMDL05 of 0.20 mg MON/kg bw per day as a reference point for pigs.
3.2.2.2. Poultry
For broiler chickens, the CONTAM Pane noted that oral LD50 values of 4.0 and 5.4 mg MON/kg
bw were reported. Ascites with oedema of the mesenteries and small haemorrhages in the
proventriculus, gizzard, small and large intestine, and skin were observed in surviving chickens. The
CONTAM Panel identiﬁed an overall NOAEL of 1.4 mg MON/kg bw per day and an overall LOAEL of
2.8 mg MON/kg bw per day for generating adverse effects such as some mortalities, reduced body
weight gain, cardiomyopathy and changes in the major haematological parameters in broiler chickens.
From the only available study on laying hens, the CONTAM Panel identiﬁed an overall NOAEL of
3.8 mg MON/kg bw per day and an overall LOAEL of 8.5 mg MON/kg bw per day for reduced eggs
production and reduced body weight gain.
The CONTAM Panel noted that the dose of 3.2 mg MON/kg bw per day did not affect body weight
gain and feed intake in turkeys but cardiotoxicity was observed. Based on the data from two studies,
the CONTAM Panel identiﬁed an overall NOAEL of 1.6 mg MON/kg bw per day and an overall LOAEL of
3.2 mg MON/kg bw per day for cardiotoxic effects in turkeys.
For ducks, the CONTAM Panel noted that the oral LD50 of 3.7 mg MON/kg bw was reported. High
doses of MON generated heart arrhythmia and ultimately cessation of contraction causing the death.
From the two studies on ducks (available as abstracts), the CONTAM Panel identiﬁed an overall NOAEL
of 2.3 mg MON/kg bw per day and an overall LOAEL of 2.8 mg MON/kg bw per day for generating
cardiomegaly.
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3.2.2.3. Farmed mink
From the one subacute study reporting developmental effects on mink, the CONTAM
Panel identiﬁed a NOAEL of 0.9 mg MON/kg bw per day and a LOAEL of 1.9 mg MON/kg bw per day
for neonatal mortality.
3.2.2.4. Ruminants, farmed rabbits, horses, farmed ﬁsh, dogs and cats
Since no toxicity data suitable for hazard characterisation of MON were identiﬁed for ruminants,
farmed rabbits, horses, farmed ﬁsh, dogs and cats, no NOAELs/LOAELs could be determined for these
farm and companion animals. In order to obtain an indication on the risk of MON for these species,
the CONTAM Panel considered the range of NOAELs of 1–4 mg MON/kg bw per day identiﬁed for pigs,
poultry and farmed mink, and considered, in particular, the reference point of 0.20 mg MON/kg bw per
day for haematotoxicity of MON in pigs as indicative for potential adverse health effects of MON. The
CONTAM Panel noted that the range of NOAELs of 1–4 mg MON/kg bw identiﬁed for pigs, poultry and
farmed mink was at least one order of magnitude lower than then LD50 values identiﬁed for
experimental animals, but only slightly lower than the LD50 values identiﬁed for the poultry species, for
which the LD50 values were available. Therefore, the CONTAM Panel identiﬁed the BMDL05 for pigs of
0.20 mg MON/kg bw per day as an indicative reference point for adverse health effects of MON in
rabbits, horses, farmed ﬁsh, dogs and cats for which data on adverse effects were not available or
insufﬁcient. The Panel noted that this value may largely overestimate the possible hazard of MON for
some, if not all, species in this group and that toxicity data are needed for the hazard identiﬁcation of
MON in ruminants, farmed rabbits, horses, farmed ﬁsh, dogs and cats.
3.3. Occurrence of moniliformin in food and feed
3.3.1. Occurrence data on food and feed reported in the available literature
Data on the occurrence of MON in food and feed have been published in the literature, in particular
in the last decade. MON has been reported to co-occur with many other mycotoxins, in particular
Fusarium toxins including type-A trichothecenes, type-B trichothecenes, enniatins, beauvericin and
zearalenone and related compounds (Uhlig et al., 2013) (see also Section 3.1.6). This section reports
only the literature data obtained by LC–UV and LC–MS/MS techniques and published from 2002
onwards in line with the occurrence data reported to EFSA (see Section 3.3.2), and only data relating
to the European market. Data from previous years were not considered, due to limitations in the
performance of the analytical methods used before 2002 and to ascertain a representative picture,
because changes in environmental conditions and agricultural practices might have inﬂuenced MON
formation by Fusarium species. The occurrence data from the literature are reported in Table 5 for
food and Table 6 for feed.
3.3.1.1. Occurrence data on food reported in the available literature
MON has been reported in the literature to occur in particular in grains (maize, wheat, barley, oats
and triticale). Incidentally MON was found in asparagus (Knaﬂewski et al., 2008; Karolewski et al.,
2011) and in pineapple juice (Stezpien et al., 2013). The occurrence data of MON in food and food
products, sampled from 2000 to 2014 (reported in the literature from 2004 to 2017) were summarised
in Table 5.
Ten studies reported the occurrence of MON in various grains, one study reported the occurrence
of MON in asparagus and one study reported the occurrence of MON in ethnic foods (as classiﬁed by
the authors). Most data were from grains and mostly from northern Europe. Altogether, data were
reported from 1,683 samples, of which 108 samples of maize, 541 samples of wheat, 356 samples of
barley, 397 samples of oats, 1 sample of rye, 40 samples of asparagus and 240 samples of ethnic
foods. It was noted by the CONTAM Panel that some articles provided only limited information which
sometimes made their interpretation of the analytical data difﬁcult. Concerning grains, the highest
values reported for maize, wheat, barley and oats were 2,606, 2,078, 522 and 220 lg/kg, respectively.
For asparagus, the highest reported value was 585 lg/kg, while for ethnic food the highest reported
value was 25.5 lg/kg. Mean values ranged from 89 to 1127 lg/kg for maize, from 5.7 to 373 lg/kg
for wheat, from < LOQ to 391 lg/kg for barley and from < LOQ to 166 lg/kg for oats.
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Table 5: Published occurrence data on MON in grains and foods
Country Sampling
Type of
sampling
Product N
LOD
lg/ kg
LOQ
lg/ kg
Samples
greater
than
LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples (a)
lg/kg
Mean (not
speciﬁed)
(b) lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
Finland 2001 Random Barley 14 10 20 4 (106) n.r. n.r. n.r. (< LOQ) 290 Jestoi et al.
(2004)Wheat 7 3 (373) n.r. n.r. n.r. (< LOQ) 810
Rye 1 0 n.r. (< LOQ) n.r. (< LOQ) (< LOQ) < LOQ
2002 Barley 8 6 (391) n.r. n.r. n.r. (< LOQ) 750
Oats 1 1 (84) (84) n.r. (84) (84) 84
Spring wheat 7 6 (72) n.r. n.r. n.r. (< LOQ) 96
Italy 2008 Random Maize (not
reported
whether for
food or feed
use)
16 1 4 16 n.r. n.r. 1127 n.r. 33 2606 Scarpino
et al. (2013)2009 16 13 n.r. n.r. 106 n.r. < LOD 527
2010 40 39 n.r. n.r. 262 n.r. < LOD 920
2011 36 33 n.r. n.r. 89 n.r. < LOD 409
Nether-
lands
2009 At harvest Winter wheat 86 n.r. 6.6 23 n.r 5.7(c) n.r. n.r. (< LOQ) 326 Van der
Fels-Klerx
et al. (2012)
Preharvest 21 5 n.r 6.7(c) n.r. n.r. (< LOQ) 97
Norway 2000 Random Oats 20 40 130 1 n.r. n.r. n.r. < LOD (< LOQ) 70 Uhlig et al.
(2004)Barley 19 1 n.r. n.r. n.r. < LOD (< LOQ) 43
Wheat 13 6 n.r. n.r. n.r. < LOD (< LOQ) 87
2001 Oats 26 3 n.r. n.r. n.r. < LOD (< LOQ) 88
Barley 23 4 n.r. n.r. n.r. < LOD (< LOQ) 380
Wheat 35 27 n.r. n.r. n.r. 69 (< LOQ) 420
2002 Oats 26 19 n.r. n.r. n.r. 59 (< LOQ) 210
Barley 33 14 n.r. n.r. n.r. < LOD (< LOQ) 230
Wheat 35 30 n.r. n.r. n.r. 120 (< LOQ) 950
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Country Sampling
Type of
sampling
Product N
LOD
lg/ kg
LOQ
lg/ kg
Samples
greater
than
LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples (a)
lg/kg
Mean (not
speciﬁed)
(b) lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
Norway 2002 Random/
targeted (d)
Organic
wheat
35 40 n.r. n.r. n.r. n.r. 98 60 n.r. n.r. Bernhoft
et al. (2010)
Conventional
wheat
35 n.r. n.r. n.r. 211 124 n.r. n.r.
2003 Organic
wheat
30 n.r. n.r. n.r. 71 < LOD n.r. n.r.
Conventional
wheat
30 n.r. n.r. n.r. 59 < LOD n.r. n.r.
2004 Organic
wheat
27 n.r. n.r. n.r. 52 < LOD n.r. n.r.
Conventional
wheat
27 n.r. n.r. n.r. 47 < LOD n.r. n.r.
Norway 2011(e) Random Barley 20 n.r. n.r. 20 n.r. n.r. n.r. 86 n.r. 522 Uhlig et al.
(2013)Oats 28 28 n.r. n.r. n.r. 57 n.r. 220
Wheat 28 28 n.r. n.r. n.r. 88 n.r. 400
Norway 2014 Random Oats 7 20 66 2 n.r. n.r. 116 (< LOQ) n.r. 165 Ivanova et al.
(2017)
Poland 2007 Targeted Asparagus
spears
40(f) n.r. n.r. n.r. n.r. n.r. 121 n.r. (< LOQ) 585 Waskiewicz
et al. (2010)
Sweden 2009 Random Winter wheat 31 n.r. 15 23 n.r. n.r. n.r. 53 (< LOQ) 497 Lindblad
et al. (2013)2011 33 12 n.r. n.r. n.r. < LOQ (< LOQ) 255
2010 Spring wheat 28 20 n.r. n.r. n.r. 61 (< LOQ) 1066
2011 33 21 n.r. n.r. n.r. 27 (< LOQ) 2078
Sweden 2010 Random Oats 50 n.r. 15 21 n.r. n.r. n.r. < LOQ (< LOQ) 156 Fredlund
et al. (2013)2011 43 18 n.r. n.r. n.r. < LOQ (< LOQ) 215
UK 2002–2003 Random Barley 239 n.r. 10 5 n.r. < LOQ(g) n.r. < LOQ n.r. 45 Edwards
(2007)Oats 196 0 n.r. < LOQ(g) n.r. < LOQ n.r. < LOQ
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Country Sampling
Type of
sampling
Product N
LOD
lg/ kg
LOQ
lg/ kg
Samples
greater
than
LOQ
Mean of
positive
samples
lg/kg
Mean of all
samples (a)
lg/kg
Mean (not
speciﬁed)
(b) lg/kg
Median
lg/kg
Min
lg/kg
Max
lg/kg
Reference
UK 2012 Random ethnic food(h) 240 5 10 2(i) 23 n.r. n.r. n.r. (< LOQ) 25.5 FSA (2013)
n.r.: not reported; N: number of samples; LOD: limit of detection; LOQ: limit of quantiﬁcation.
Note: Values in brackets were calculated by the CONTAM Panel based on the data provided in the papers.
(a): Mean values of all samples are calculated by setting samples in which the compounds were not detected to 0 and trace value below LOQ to LOD.
(b): It was not reported in the paper whether the mean was calculated for all samples or for positive samples only.
(c): Contamination levels < LOQ were set to zero.
(d): Farms producing organic cereals were randomised, but conventional cereal farms were selected relatively randomly on the basis of neighbouring the producer of the organic cereal sampled
(e): Exceptionally wet summer indicated.
(f): 20 Asparagus spears with brown spots (fusariosis) and 20 asparagus spears with no disease symptoms. Mycotoxins were determined in basal parts, results were not differentiated between the
two types of asparagus samples.
(g): Means based on imputation of 1.667 (LOQ/6) for all samples below LOQ (10 lg/kg).
(h): Herbs, spices and seeds, legumes, cereals and cereal products, dairy products and root vegetables classiﬁed by the authors as ethnic foods.
(i): Positive samples were from the category ‘cereals and cereal products’.
Moniliformin in food and feed
www.efsa.europa.eu/efsajournal 49 EFSA Journal 2018;16(3):5082
3.3.1.2. Occurrence data on feed reported in the available literature
The studies identiﬁed by the CONTAM Panel on the occurrence of MON in feeds for farm animals
are summarised in Table 5. The studies speciﬁcally relating to levels of MON in feeds reveal
considerable variation between cereal types in the occurrence and maximum concentrations. Generally,
concentrations tend to be higher in maize (corn) grains than in other cereals (Uhlig et al., 2004) and
are lowest in oats (Edwards, 2009).
As reported below (Section 3.4), processing can result in changes in concentrations of MON in the
different fractions produced. Krysinska-Traczyk et al. (2001) analysed 10 samples of stored wheat grain
and 10 samples of settled grain dust released during machine threshing of wheat grain were collected
on 10 farms located in Lublin province (eastern Poland). MON was detected in 4/10 samples of grain
(highest 200 lg/kg) but in 8/10 samples of grain dust (maximum 780 lg/kg).
Only one report of levels of MON in complete feedingstuffs has been identiﬁed. Labuda et al.
(2005) analysed 50 samples of poultry feed from farms in Slovakia. MON was detected in 26 of the
samples, with concentrations ranging from 42 to 1,214 lg/kg (mean 217 lg/kg) (LOD = 39 lg/kg).
The European corn borer (ECB) is a major pest of maize (corn), and strategies to control it have
included the development of genetically modiﬁed maize (Bt maize). A study by Magg et al. (2003)
examined concentrations of MON in maize grains from genetically modiﬁed maize (Bt maize) and
non-genetically modiﬁed maize across ﬁve locations. The mean concentration in grains from the
insecticide-protected plants was 66.2 lg MON/kg, while that for the non-GM (Fusarium-infested) maize
grains was 296.0 lg MON/kg. In a 4-year study of maize plants in north-west Italy, Scarpino et al.
(2013) also reported an increase in levels of MON in grains associated with an increasing incidence of
the ECB.
Forages are important – and frequently the sole – feeds for ruminant livestock, and may be fed fresh
or preserved (e.g. as hay or silage). MON has been reported particularly in maize plants and maize
silage (Sorensen et al., 2007; Storm et al., 2010). In view of the relatively high levels of MON reported
in maize grains, it might be expected that whole maize plants intended for silage are also potential
sources of exposure for ruminant livestock. However, Sorensen et al. (2007) did not detect MON in any
of the 28 samples analysed from whole plants intended for ensiling. Van Asselt et al. (2012) also
analysed maize cobs intended for ensiling; of the 42 samples only one had a level of MON (332 lg/kg)
greater than the LOD. In the current occurrence data on feed provided to EFSA, 31% per cent of the 42
samples of maize silage reported were blow LOD, and there was a maximum of 44 lg/kg, suggesting
that maize silage is not likely to be a major contributor to exposure to MON by farm animals
(see Section 3.3.2.3).
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Table 6: Summary of MON concentrations in animal feed reported in the literature
Country
Sampling
year(s)
Cereal
Samples
(n)
LOD
lg/kg
n > LOD
LOQ
lg/kg
n > LOQ
Minimum
lg/kg
Maximum
lg/kg
Mean
lg/kg
Sampling Reference
Cereal grains
Norway 2000–2002 Barley 75 nr nr 130 53 < LOQ 380 nr Uhlig et al. (2004)
Austria ns Maize ns nr nr 39 ns 160 1,030 nr Grain from ﬁelds Parich et al. (2003)
Denmark ns Maize 28 nr nr 12 0 < LOQ < 12 nr Whole maize plant Sorensen et al. (2007)
Germany 2006 Maize 44 nr nr 10 19 nr 3,330 280 Goertz et al. (2010)
Germany 2007 Maize 40 nr nr 10 18 nr 1,850 110 Goertz et al. (2010)
Italy 2008 Maize 16 1 nr 4 16 33 2,606 1,127 Maize grain (not
reported whether for
food or feed use)
Scarpino et al. (2013)
Italy 2009 Maize 16 1 nr 4 13 < LOQ 527 106
Italy 2010 Maize 40 1 nr 4 39 < LOQ 920 282
Italy 2011 Maize 36 1 nr 4 33 < LOQ 409 89
Netherlands 2010 Maize
cobs
42 50 1 25 nr < LOD 332 nr Cobs from standing
plants intended for
silage
Van Asselt et al. (2012)
Finland 2001–2002 Oats 1 nr nr 20 1 nr 84 nr Jestoi et al. (2004)
Norway 2000–2002 Oats 73 nr nr 130 38 < LOQ 210 nr Uhlig et al. (2004)
UK 2002–2003 Oats 196 nr nr 10 0 nr < 10 nr Grain from
commercial feed
manufacturers
Edwards (2009)
Norway 2000–2002 Wheat 83 nr nr 130 76 < LOQ 950 nr Grain from ﬁelds Uhlig et al. (2004)
Netherlands 2009 Wheat 86 nr nr 6.6 23 6.8 119 5.5 Grain from ﬁelds Van der Fels-Klerx
et al. (2012)
Poland ns Wheat 10 ns 4 ns nr nr 200 nr Grain from ﬁelds Krysinska-Traczyk
et al. (2001)
Poland 1993 Wheat 25 25 7 nr nr nr 198 63 Grain from ﬁelds Grabarkiewicz-Szczesna
et al. (2001)
Complete feeds
Slovakia 2003–2004 Poultry
feed
50 nr nr 39 26 nr 1214 nr Commercial
compound feed
Labuda et al. (2005)
N: number of samples; LOD: limit of detection; LOQ: limit of quantiﬁcation; nr: not reported.
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3.3.2. Occurrence data in food, feed and unprocessed grains of undeﬁned end-
use used for the assessment
3.3.2.1. Analytical methods
Considering all the available analytical results (i.e. the results submitted to EFSA by Member States
and the results extracted from the published literature), where classiﬁcation of the analytical method
used for determination of MON in food/feed/crops was reported by the Member States, results were
obtained by LC–MS based methods (70%) and by HPLC (10%). For the remaining 20% of the data, no
information on analytical methods was reported.
3.3.2.2. Food occurrence data used for the assessment
The 2,799 analytical results submitted to EFSA were available from two European countries
(Section 2.3.1) namely the Netherlands reported 84% of the MON data and UK the remaining 16%.
Data were reported on samples collected between the years 2002 and 2015, with the majority of the
data collected in 2014 and 2015. In addition to the data submitted to EFSA by the Netherlands and UK
the data on the 406 samples extracted from the scientiﬁc literature (Section 2.3.1) were from Italy
(n = 108), the Netherlands (n = 86), Sweden (n = 91), Norway (n = 83) and Finland (n = 38), and
referred to samples collected between 2001 and 2015 (the majority collected in 2009–2011).
Overall, 3,205 analytical results on MON in food were included in the exposure assessment analysis.
These include the data reported by the Netherlands and the UK (i.e. 2,799 analytical results, 87%)
and literature data reported for Europe (i.e. 406 analytical results, 13%). The origin of the samples
was not always the European country who reported the data, i.e. the data set also contained samples
originating from North and South America, Africa, Asia and Australia.
The LODs/LOQs of the MON data from the EFSA database and the scientiﬁc literature data varied
between laboratories and food matrices (i.e. LOD minimum–maximum 1–20 lg/kg, mean 5 lg/kg;
LOQ minimum–maximum 4–66 lg/kg, mean 41 lg/kg). The lowest mean LOQs were reported for the
FoodEx level 2 categories of ‘Snack, desserts and other foods’ (LOQ=10), ‘Fine bakery wares’
(LOQ=10), and ‘Grains for human consumption’ (LOQ = 18 lg/kg). A high percentage of results below
LOD/LOQ in combination with high LODs/LOQs with substantial differences between LB and UB
scenarios were observed, increasing the uncertainty associated with the dietary exposure estimations.
In order to reduce this impact, but also not to exclude data on foods mainly contributing to the
exposure to MON, an evaluation of LOQs was performed for those MON data for which the results
were considered to be suitable for the dietary exposure assessment. This evaluation was based on the
EFSA internal guidance on the application of LOD/LOQ cut-offs. A special attention was paid to food
categories which are considered to be potentially important contributors to the dietary exposure to
MON. Such a main food category identiﬁed was FoodEx level 1 ‘Grains and grain-based products’. The
analytical results were submitted to EFSA as corrected for recovery in all cases. Fifty-three per cent of
analytical results retrieved from the scientiﬁc literature were reported as being corrected for recovery.
Approximately, 99% of the data were obtained for samples collected within ofﬁcial monitoring
programs and 1% for samples from speciﬁc studies on occurrence on MON in food. Regarding the
sampling method, a minor part of analytical results (1%) were obtained from pooled samples meaning
that the result represented an average of a number of samples taken in equal parts from different
consignments/batches and pooled together for the laboratory analysis. Since the level of aggregation
for pooled samples matched the level of classiﬁcation of the individual samples (only similar food
matrices were pooled together) results from pooled samples were retained for further evaluation. To
ensure a proportionate representation of the individual samples, and thus an accurate use of
occurrence data in assessing the dietary exposure, the mean concentrations per food category were
calculated by weighting the reported analytical results for the number of samples pooled.
All analytical results were expressed on whole weight basis, thus no conversion had to be applied.
The MON occurrence data were available for 14 FoodEx level 1 food categories. An overview of the
number of data points available for exposure assessment, the percentage of results below LOD/LOQ,
the mean and 95th percentile concentrations of MON, are presented in Appendix B, Table B.2–B.4.
MON was quantiﬁed in the following FoodEx level 1 categories: ‘Grains and grain-based products’
(n = 1,457, LB/UB means of 32.2/56.7 lg/kg) and ‘Snacks, desserts, and other foods’ (n = 4, LB/UB
mean = 73/75.5 lg/kg).
Within FoodEx level 1 category ‘Grains and grain-based products’, quantiﬁed values were obtained
in a number of food categories at FoodEx level 2: ‘Grains for human consumption’ (LB/UB mean =
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47.1/60.4 lg/kg), ‘Grain milling products’ (LB/UB mean = 0.6/48.8 lg/kg), ‘Pasta (raw)’ (LB/UB mean
= 0.2/49.3 lg/kg), ‘Breakfast cereals’ (LB/UB mean = 1.5/49.4 lg/kg) and ‘Fine bakery wares’ (LB/UB
mean = 8.4/13.4 lg/kg). Overall, 99% of the quantiﬁed results were on ‘Grains and grain-based
products’ and in particular on ‘Grains for human consumption’. Therefore, the mean concentration for
the food category was strongly inﬂuenced by the results obtained on the samples of ‘Wheat grain’,
‘Barley grain’, and ‘Corn grain’ and ‘Oats grain’. These data were reported by 6 different countries.
3.3.2.3. Feed occurrence data used for the assessment
The 806 results for the feed samples analysed on MON were from four European countries,
including Austria (n = 380, 47%), Norway (n = 235, 29%), the Netherlands (n = 107, 13%) and
Germany (n = 84, 10%). The results from Austria and Norway were provided to EFSA and the data
from the Netherlands and Germany were collected from the published literature (see Section 2.3.1).
The origin of the data was not always the EU, i.e. the data set also contained samples of feed
imported from Turkey, Ukraine and Russia. The analytical results were from samples collected from
2006 to 2016, with the majority of the data collected between 2015 and 2016.
The LODs/LOQs of the MON data reported to EFSA varied between countries (i.e. Austria LOD = 4.8
and LOQ = 16.1 lg/kg; Norway LOD = 51.3 and LOQ = 171 lg/kg; Germany LOQ = 10 lg/kg; the
Netherlands LOQ = 6.6 lg/kg).
In the ﬁnal data set, MON occurrence data were available for three feed categories at the FoodEx
level 1. An overview of the number of data points available for exposure assessment, the percentage
of results below LOD/LOQ, the mean and 95th percentile concentrations of MON, are presented in
Annex A, Tables A5–A7.
The reported feed categories were ‘Cereal grains, their products and by-products’ (n = 739),
‘Forages and roughage, and products derived thereof’ (n = 65) and ‘Oil seeds, oil fruits, and products
derived thereof’ (n = 2). MON was quantiﬁed in all three feed categories.
In the category ‘Cereal grains, their products and by-products’ quantiﬁed values were reported
for a number of feed categories at FoodEx level 2: ‘Barley’ (LB/UB mean = 40.5/84.8 lg/kg),
‘Wheat’ (LB/UB mean = 9.7/46.9 lg/kg), ‘Maize’ (LB/UB mean = 69.6/73.7 lg/kg), ‘Oats’ (LB/UB
mean = 18.1/136.9 lg/kg), ‘Rye’ (LB/UB mean = 11.4/147.9 lg/kg), ‘Spelt’ (LB/UB mean = 0.0/171.0 lg/kg)
and ‘Cereal grains, their products and by-products, unspeciﬁed’ (LB/UB mean = 2.3/16.2 lg/kg). In the
category ‘Oil seeds, oil fruits, and products derived thereof’, the reported levels were LB/UB
mean = 3.9–11.9 lg/kg. In the category ‘Forages and roughage, and products derived thereof’,
quantiﬁed values were reported for ‘Maize silage’ (LB/UB = 15.9/20.9 lg/kg), ‘Cereals straw’
(LB/UB = 6.2/17.8 lg/kg) and ‘Grass, ﬁeld dried, [Hay]’ (LB/UB = 5.7/15.4 lg/kg).
3.3.2.4. Unprocessed grains of undeﬁned end-use occurrence data used for the
assessment
The category ‘Unprocessed grains’ comprised grains of undeﬁned end-use, deﬁned also as ‘Grains
as crops’. As the end-use of the grains at harvest is not established and because normally grains for
human and animal consumption undergo several processing steps before being used, it was
considered appropriate to report their concentrations separately.
An initial number of 504 results of ‘Unprocessed grains of undeﬁned end-use’ samples analysed for
MON reported to EFSA by Sweden were available for the assessment (Section 2.3.1). The origin of the
samples was not always the European country who reported the data, i.e. the data set also contained
samples originating from Asia, North America and Africa. Data were reported on samples collected
from 2010 to 2015. The LODs/LOQs of the MON data were LOD = 8 lg/kg and LOQ = 39 lg/kg.
In the ﬁnal data set, MON occurrence data were available for three categories at the FoodEx level
3. An overview of the number of data points available for exposure assessment, the percentage of
results below LOD/LOQ, the mean and 95th percentile concentrations of MON, are presented in
Annex A, Tables A8–A10.
The reported categories were ‘Wheat grain’ (n = 105), ‘Barley grain’ (n = 46), ‘Rye grain’ (n = 17),
‘Buckwheat grain’ (n = 4), ‘Millet grain’ (n = 2), ‘Oats grain’ (n = 139) and rice (n = 191). MON was
quantiﬁed in ‘Wheat grain’ (LB/UB mean = 102.4/109.6 lg/kg) and ‘Oats grain’ (LB/UB mean = 15.3/
39.0 lg/kg).
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3.3.3. Conclusions on the occurrence data
Twelve studies on the occurrence of MON in food (sampling years 2001–2014) and 12 studies on
the occurrence of MON in feed (sampling years 2006–2016) were published. For food, most data were
obtained for food grains, with the highest values reported for maize, wheat, barley and oats at 2,606,
2,078, 522 and 220 lg/kg, respectively. For asparagus, the highest reported value was 585 lg/kg,
while for ethnic food the highest reported value was 25.5 lg/kg. Mean values ranged from 89 to
1,127 lg/kg for maize, from 5.7 to 373 lg/kg for wheat, from < LOQ to 391 lg/kg for barley and
from < LOQ to 166 lg/kg for oats.
Twelve studies on the occurrence of MON in feeding stuffs sampled between 2000 and 2011 were
identiﬁed in the literature. For most of the studies, the data were obtained for whole feed grains, with
maximum levels for maize (corn), wheat, barley and oats of 3,330, 950, 380 and 210 lg/kg,
respectively. In two studies, MON was detected in maize cobs (maximum concentration 84 lg/kg) but
not in whole maize plants. In one study involving commercially manufactured compound feed for
poultry, a maximum of 1,214 lg/kg was reported.
For food, current occurrence data included data submitted to EFSA (n = 2,799 from two countries)
and data extracted from the scientiﬁc literature (n = 406 from ﬁve countries). Quantiﬁed values of
data submitted to EFSA and the ones extracted from the scientiﬁc literature were in the same range.
MON was quantiﬁed in ‘Grains and grain-based products’ (LB/UB mean = 32.2/56.7 lg/kg, 80%
left-censored) and in ‘Snacks, desserts, and other foods’ (LB/UB mean = 73.0/75.5 lg/kg, 25%
left-censored). For feed, 806 analytical results from four countries were available for three feed
categories (i.e. cereal grains, oil seeds, and forages and roughage). The levels ranged from LB/UB
mean = 9.7/46.9 lg/kg for ‘Wheat’ to LB/UB mean = 11.4/147.9 lg/kg for ‘Spelt’. The levels were
lower for ‘Oil seeds, oil fruits, and products derived thereof’ and ‘Forages and roughage, and products
derived thereof’. The 504 analytical results available from Sweden for unprocessed grains of undeﬁned
end-use were in a similar range.
Overall, although there was considerable variation in levels of MON reported in foods and feeds, the
data used to estimate exposure are broadly similar to those reported in the literature for foods and
feeds.
Furthermore, MON has been reported to co-occur with many other mycotoxins, in particular with
Fusarium toxins.
3.4. Food and feed processing
The extent to which cereals are processed depends on the cereal type and the ﬁnal feed/food
product. In general, it is known that processing reduces Fusarium toxin concentrations in products for
human consumption but may increase levels in food or feed by-products. This is because mechanical
cleaning of cereals (de-hulling) may lead to by-products (for the food and feed industry) in which
Fusarium toxins concentrate signiﬁcantly. While this may generally result in (much) higher
concentrations of Fusarium toxins in these materials than in the cereals before cleaning, scarce studies
on the effect of milling on MON show this may not be the case for this mycotoxin. The effects of
processing of cereals and cereal products, in ways common to the food and feed industry, on MON
have been investigated in a limited amount of studies, while the focus was sometimes in combination
with the effects of processing on other Fusarium toxins.
3.4.1. Food processing
3.4.1.1. Cleaning and sorting
Studies on the speciﬁc effect of cleaning and sorting on MON could not be identiﬁed. In general,
sorting of cereals by removing extensively damaged or infected kernels has the effect of lowering the
concentrations of mycotoxins in subsequently produced products (Abbas and Mirocha, 1985;
Scudamore and Patel, 2009).
3.4.1.2. Rolling and milling
Tittlemier et al. (2014) investigated the fate of MON during milling of durum wheat, as well as
during the production and cooking of spaghetti. Samples of clean durum wheat were fortiﬁed with
kernels contaminated by F. avenaceum, resulting in durum wheat samples containing MON ranging
from 0.16 to 0.90 mg/kg. After milling in a laboratory mill, semolina, bran, shorts, ﬂour and feed ﬂour
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were analysed for MON, showing concentrations of MON at 57–135, < 4–8, < 4–11, 56–106 and
24–31%, respectively, of the initial concentrations. Semolina, ﬂour and feed ﬂour not only contained
the highest concentrations of MON, but they also represented the largest compartment of MON in the
milling mass balance. On average semolina, ﬂour and feed ﬂour contained 85%, 6.8% and 1.4% of
the MON in the whole wheat prior to milling, respectively. The authors indicated that this association
between MON and endosperm was different from what has been observed with other Fusarium
mycotoxins, such as DON, which has been associated with outer bran layers of wheat. They explained
the differences in distribution between MON and DON in milling products to be due to the
translocation of MON from mycelium to endosperm, because physical characteristics of MON suggest it
could be more mobile than DON within a kernel.
3.4.1.3. Cooking and baking
Scott and Lawrence (1987) investigated the stability of MON in cereal grains during heating.
Ground maize and ground wheat both spiked at a level of 1 mg MON/kg were held at 50, 100 and
150°C for 0.5–2 h in a constant-temperature cabinet. Heating at all temperatures led to losses of MON
and the reductions were correlated with increases in temperature. At 50°C, approximately 80% and
approximately 60% of MON remained in the maize and in the wheat, respectively. At 100°C, 38% of
MON remained in the maize and 22% in the wheat, while at 150°C these percentages were 38% and
15%, respectively.
Castelo (1999) studied the fate of MON during extrusion cooking. Food grade yellow maize grits
were spiked with MON at 5 mg/kg grits (dry basis). The moisture content of the grits was raised to
26% by adding water. Samples were extruded at different temperatures (140, 160, 180 and 200°C)
and screw speeds (40, 80, 120 and 160 rpm). Extrusion cooking resulted in statistically signiﬁcant
losses of MON. The percentage loss of MON ranged from 24% to 34%. Statistical analysis showed no
signiﬁcant differences between the different screw speeds and no signiﬁcant differences between the
different temperatures. The study showed that MON is a relatively heat-stable compound that can
largely survive most conditions used in thermally processed food.
A complete reduction (100%) of MON was observed by Pineda-Valdes et al. (2002), when a
naturally contaminated maize sample containing 1.4 mg MON/kg was used in a pilot-scale alkaline
tortilla manufacturing process. In the ﬁrst step with alkaline cooking of maize, the concentration of
MON was already reduced by 97%, while MON was not detected in any steps after alkaline cooking,
including the rinsing water (study did not report the results for the remaining 3% of MON). A parallel
experiment performed at laboratory scale, using a maize sample containing 17.6 mg MON/kg, resulted
in a reduction of 71% from the initial concentration in the maize to the ﬁnal product. The greatest
reduction of MON (54%) resulted from the alkaline cooking step. Based on these ﬁndings, the authors
concluded that MON was reduced signiﬁcantly by the nixtamalisation process, probably due to both
heat and the alkaline pH. This conﬁrms the earlier ﬁnding (see also Section 1.3.1) that heating at pH
10 caused a major reduction of the concentration of MON (Pineda-Valdes and Bullerman, 2000).
Pineda-Valdes et al. (2003) investigated the effects of common commercial food processing methods,
including baking, autoclaving, extrusion, frying and roasting, on reduction of MON in maize-based food
products. Maize mufﬁn baking from maize meal, spiked with 5 mg MON/kg (dry basis) at 204°C and
218°C led to MON concentration decreases by 38% and 42%, respectively. Autoclaving at 121°C for
65 min of creamed maize for infants and cream style maize, both spiked with 5 mg MON/kg (wet
basis), showed MON reductions of 10% and 23%, respectively. Extrusion cooking of maize grits mixing
screw (with 18% moisture content and spiked with 5 mg MON/kg (dry basis)) at 180°C decreased
MON concentration by 27%. Frying of maize masa spiked with 5 mg MON/kg (dry basis) at 190°C for
10 min for maize chips production reduced MON concentration by 30%. Roasting of maize meal spiked
with 5 mg MON/kg (dry basis) at 218°C for 15 min had the most signiﬁcant effect of the food
processing methods on reduction of MON, inducing a 45% decrease in its concentration.
Tittlemier et al. (2014) studied the fate of MON during production and cooking of spaghetti.
Spaghetti was processed from 3 samples of semolina with MON concentrations 0.14, 0.52 and
1.02 mg/kg using a customised microextruder, and dried in a pilot-scale pasta dryer. Dried uncooked
spaghetti was placed into boiling water and cooled down for 10 min followed by water removal. The
cooked spaghetti was air dried for approximately 60 h at room temperature prior to MON analysis.
There was a large decrease in the amount of MON measured, when raw spaghetti was prepared. MON
could only be measured in raw spaghetti obtained from the two semolina samples with the highest
levels of MON and 27% of MON measured in semolina appeared to be retained in the raw spaghetti
from these two samples. During the cooking process, a further reduction of the MON concentration in
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the cooked spaghetti of approximately 50% was observed, with a part of the water-soluble MON
leaching into the cooking water. A balance study revealed an overall increase in the amount of MON in
the cooked spaghetti plus cooking water as compared to the uncooked spaghetti. The authors
hypothesised that the loss of MON from semolina to raw pasta is due to the binding or conjugation of
MON during dough formation, which is then released into the cooking water during the cooking of
spaghetti.
3.4.1.4. Malting process
Studies were not identiﬁed.
3.4.2. Feed processing
Except for one study in which it was reported that the occurrence of MON in the dust released
during wheat threshing was greater than in the original grains (Krysinska-Traczyk et al., 2001), no
information on impact of feed processing on MON concentrations in feed materials has been identiﬁed.
However, cereal grains intended for use as an animal feed are usually subject to some of the
processes used for processing grains for human consumption (cleaning, sorting, drying, rolling/grinding
and/or extrusion) before being fed to livestock, and therefore many of the effects reported above for
food (Section 3.3.1) apply equally to cereal grains for animal feed. In addition, by-products of
processing grains for human consumption are widely used as feeds for livestock. Ensiling is extensively
used as a way of preserving forages which allows them to be stored for long periods without
deteriorating. Forage maize is widely grown and ensiled as feed for livestock in Europe, and in view of
the relatively high levels of MON reported in maize grains it might be expected that whole maize plants
intended for silage are also potential sources of exposure for ruminant livestock. Moreover, Fusarium
mycotoxins, produced before ensiling, are highly stable substances and usually are not affected by
ensiling (Scudamore and Livesey, 1998; Dorn et al., 2009). Few data are available on the presence of
MON in maize silage. Sorensen et al., 2007, did not detect MON in whole plants intended for ensiling
and in the current occurrence data on feed (see Section 3.3.1.2) the maximum concentration was
44 lg MON/kg in maize silage, while in 31% of the 42 samples of maize silage levels were below LOD.
3.4.3. Conclusions
Published studies on the effect of food and feed processing on MON were limited, which requires
caution in drawing ﬁrm conclusions. During cleaning of grains the majority of infected kernels are
removed, which is expected to result in lower MON concentrations in subsequently produced products.
Milling of grains leads to a redistribution of MON into different fractions. Semolina, ﬂour and feed ﬂour
contain the highest concentrations of MON and they represent the largest compartment of MON in the
milling balance. Due to its physical characteristics, MON appears to be associated with endosperm,
while other Fusarium toxins are merely associated with outer bran layers of grains. Cooking and baking
generally lead to reductions of MON concentrations, where the observed reductions are higher at
increased temperatures. MON is unstable under high temperatures in combination with alkaline
conditions, such as during the nixtamilisation process. There is limited information on the effects of
processing of animal feeds on levels of MON, particularly in cereals and cereal by-products although it
may be reasonable to assume that the effects are similar to those for food. There is some evidence
that MON may be present in maize silage, but little appears to be known on the effect of ensiling on
MON.
3.5. Human exposure assessment
3.5.1. Exposure assessment for humans
3.5.1.1. Mean and 95th percentile acute dietary exposure
The mean and 95th percentile of acute exposure estimates at the UB to MON obtained for different
age groups are shown in Table 7. The range represents the minimum (Min) to the maximum (Max)
from the different countries and the number in the brackets are the 95% conﬁdence intervals (for
more detail see Section 2.7.1.1). The mean and 95th percentile of acute exposure to MON obtained for
different age groups is shown in Annex A, Table A11.
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Infants (< 12 months)
The mean acute dietary exposure ranged from 121 to 300 ng/kg bw per day, and the 95th
percentile from 506 to 1,489 ng/kg bw per day.
Toddlers (≥ 12 months to < 36 months old)
The mean acute dietary exposure ranged from 293 to 506 ng/kg bw per day, and the 95th
percentile from 757 to 1,480 ng/kg bw per day.
Other children (≥ 36 months to < 10 years old)
The mean acute dietary exposure ranged from 228 to 530 ng/kg bw per day, and the 95th
percentile from 566 to 1,455 ng/kg bw per day.
Adolescents (≥ 10 years to < 18 years old)
The mean acute dietary exposure ranged from 145 to 337 ng/kg bw per day, and the 95th
percentile ranged from 384 to 821 ng/kg bw per day.
Adults (≥ 18 years to < 65 years)
The mean acute dietary exposure ranged from 94 to 219 ng/kg bw per day, and the 95th
percentile ranged from 278 to 656 ng/kg bw per day. Acute dietary exposure in ‘Pregnant women’ and
‘Lactating women’ were within the range of exposure estimates in the adult population.
Elderly and very elderly (≥ 65 years old)
The mean dietary exposure ranged from 82 to 253 ng/kg bw per day for the elderly and very
elderly, and the 95th percentiles ranged from 202 to 675 ng/kg bw per day.
3.5.1.2. Mean and 95th percentile chronic dietary exposure
Table 8 shows summary statistics of the chronic dietary exposure assessment to MON using the
available occurrence data. Detailed mean and 95th percentile dietary exposure estimates calculated for
each dietary survey are presented in Annex A, Table A12.
Table 7: Summary statistics of probabilistic acute dietary exposure assessment to moniliformin
(at the upper bound) across European dietary surveys (ng/kg bw per day) by age group
Age group(a) n
Mean dietary exposure
(ng/kg bw per day)
95th percentile dietary exposure
(ng/kg bw per day)
Min Max Min Max
Infants(a) 6 121 (81–287) 300 (294–304) 506 (487–530) 1,489 (1,313–1,596)
Toddlers(a) 11 293 (265–360) 506 (409–848) 757 (635–853) 1,480 (1,096–2,201)
Other children 20 228 (220–239) 530 (460–625) 566 (530–615) 1,455 (1,138–1,572)
Adolescents 20 145 (138–158) 337 (321–359) 384 (363–406) 821 (785–873)
Adults 22 94 (89–100) 219 (212–231) 278 (273–284) 656 (639–673)
Elderly 16 82 (76–96) 253 (246–263) 202 (179–229) 675 (645–708)
Very elderly(a) 14 88 (83–95) 196 (189–207) 212 (187–240) 552 (503–627)
bw: body weight; n: number of surveys; Min: minimum; Max: maximum.
Note: The corresponding 95% conﬁdence intervals are presented in the brackets.
(a): One dietary survey for infants, and three dietary surveys for toddlers and very elderly had less than 60 survey participants
and therefore could not be included in calculation of the 95th percentile exposure.
Table 8: Summary statistics of the chronic dietary exposure to moniliformin (ng/kg bw per day)
across European countries
Age group(a) n
Minimum Median Maximum
LB UB LB UB LB UB
Mean dietary exposure in total population (ng/kg bw per day)(b)
Infants 6 0.06 11 9.2 73 38 106
Toddlers 10 0.10 20 6.7 73 51 196
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Infants (< 12 months)
The mean chronic dietary exposure ranged from 0.06 to 106 ng/kg bw per day (minimum LB and
maximum UB) and the 95th percentile dietary exposure from 0.54 to 489 ng/kg bw per day (minimum
LB to maximum UB).
Toddlers (≥ 12 months to < 36 months old)
The mean chronic dietary exposure ranged from 0.10 to 196 ng/kg bw per day (minimum LB to
maximum UB) and the 95th percentile dietary exposure from 0.34 to 528 ng/kg bw per day (minimum
LB to maximum UB).
Other children (≥ 36 months to < 10 years old)
The mean chronic dietary exposure ranged from 0.04 to 226 ng/kg bw per day (minimum LB to
maximum UB) and the 95th percentile dietary exposure from 0.39 to 406 ng/kg bw per day (minimum
LB to maximum UB).
Adolescents (≥ 10 years to < 18 years old)
The mean chronic dietary exposure ranged from 0.04 to 116 ng/kg bw per day (minimum LB to
maximum UB) and the 95th percentile dietary exposure from 0.08 to 280 ng/kg bw per day (minimum
LB to maximum UB).
Adults (≥ 18 years to < 65 years)
The mean chronic dietary exposure to MON ranged from 0.20 to 78 ng/kg bw per day (minimum
LB to maximum UB) and the 95th percentile dietary exposure estimate from 0.22 to 265 ng/kg bw per
day (minimum LB to maximum UB). Chronic dietary exposure in ‘Pregnant women’ and ‘Lactating
women’ were within the range of exposure estimates in the adult population.
Elderly and very elderly (≥ 65 years old)
The mean dietary exposure to MON ranged from 0.20 to 93 ng/kg bw per day (minimum LB to
maximum UB), the 95th percentiles dietary exposure estimate from ranged from 0.10 to 267 ng/kg bw
per day (minimum LB to maximum UB).
3.5.1.3. Contribution of different food groups to the exposure
The contribution of individual food groups to chronic dietary exposure to MON (see Annex A,
Table A13) varied between the dietary surveys. This is explained by the speciﬁc food consumption
patterns in the individual European countries and even in the different regions of one country. The
contribution to chronic dietary exposure to MON for the individual food groups was assessed
Age group(a) n
Minimum Median Maximum
LB UB LB UB LB UB
Other children 18 0.04 15 6.4 74 23 226
Adolescents 17 0.04 18 3.4 43 11 116
Adults 17 0.20 12 1.3 31 8.0 78
Elderly 14 0.20 7.7 0.69 24 5.8 93
Very elderly 12 0.28 7.9 0.72 24 22 78
95th percentile dietary exposure in total population (ng/kg bw per day)(b)
Infants(a) 6 0.54 144 54 278 123 489
Toddlers(a) 10 0.34 213 61 383 135 528
Other children 18 0.39 79 35 238 63 406
Adolescents 17 0.08 72 14 150 35 280
Adults 17 0.22 57 7.5 99 33 265
Elderly 14 0.10 44 3.8 61 23 267
Very elderly(a) 12 0.06 44 2.6 68 16 201
bw: body weight; LB: lower bound; UB: upper bound.
(a): One dietary survey for infants, and three dietary surveys for toddlers and very elderly had less than 60 survey participants
and therefore could not be included in calculation of the 95th percentile exposure.
(b): Rounded to the ﬁrst or second decimal place or to a whole number.
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separately for each survey and age group. The results are reported as a number of surveys for the
following contribution ranges: < 1, 1–5, 5–10, 10–25, 25–50, 50–75, > 75%. ‘Cereal ﬂakes’ made the
largest contribution to the dietary exposure to MON in all age groups.
3.5.1.4. Dietary exposure to MON for speciﬁc groups
Dietary exposure to MON for vegetarian diets includes more cereal and cereal-based products and
therefore it was considered that the exposure in this consumer group could be higher. The
Comprehensive Database contains only limited data on food consumption of vegetarians. Dietary
exposure was calculated and compared to the exposure of all subjects included in the respective
dietary study. Generally, for acute and chronic exposure, higher or marginally higher means were
observed compared to the general population for infants (based on one study), toddlers, other children
and the elderly (Tables 9 and 10). Thus, the limited data on vegetarians do not indicate a substantial
difference in the dietary exposure to MON between the vegetarians and the general population.
Conclusions
Mean acute dietary exposure to MON across 23 European countries in different age groups, using
UB concentrations, ranged from 82 ng/kg bw per day in the elderly to 530 ng/kg bw per day in other
children. The 95th percentile ranged from 202 ng/kg bw per day in the elderly to 1,489 ng/kg bw per
day in infants. Infants, toddlers and children had the highest estimates of chronic dietary exposure to
MON (mean exposure 0.04–226 ng/kg bw per day, 95th percentile 0.34–528 ng/kg bw per day). This
Table 9: Summary statistics of probabilistic acute dietary exposure assessment to MON (at mean,
the lower and upper bound) (ng/kg bw per day) by age group in vegetarians. The
corresponding 95% conﬁdence intervals are presented in the brackets
Age group(a)
Mean dietary exposure
(ng/kg bw per day)
95th percentile dietary exposure
(ng/kg bw per day)(a)
n Min Max Min Max
Infants 1 240 (182–461) – –
Toddlers 3 402 (305–701) 1,010 (688–1,126) – –
Other children 2 173 (108–286) 673 (504–1,083) – –
Adolescents 4 182 (150–240) 256 (224–389) – –
Adults 10 132 (95–249) 258 (217–337) 371 (318–443) 594 (411–714)
Elderly 7 42 (14–71) 219 (172–266) – –
Very elderly 4 50 (39–65) 178 (147–207) – –
bw: body weight; n: number of surveys; Min: minimum, Max: maximum.
(a): Not calculated for the other age groups because estimates were only available from one dietary survey.
Table 10: Summary statistics of the mean chronic dietary exposure to MON (ng/kg bw per day) by
age group in vegetarians
Age group(a) n
Minimum Median Maximum
LB UB LB UB LB UB
Mean dietary exposure in total population (ng/kg bw per day)(b)
Infants 1 15 162 15 162 15 162
Toddlers 3 0.02 4.5 13 131 14 379
Other children 2 12 41 16 150 19 260
Adolescents 4 2.2 47 2.3 72 7.9 102
Adults 8 0.01 23 1.6 54 4.4 86
Elderly 7 < 0.01 < 0.01 1.3 17 11 42
Very elderly 3 < 0.01 < 0.01 < 0.01 48 15 77
95th percentile dietary exposure in total population (ng/kg bw per day)(b)
Adults 8 10 10 10 165 165 165
n: number of surveys; bw: body weight; Min: minimum, Max: maximum.
(a): Not calculated for the other age groups because estimates were only available from one dietary survey.
(b): Rounded to the ﬁrst or second decimal place or to a whole number.
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can be explained by the higher intake of food per kg bw in younger age groups. Acute and chronic
dietary exposure in ‘Pregnant women’ and ‘Lactating women’ were within the range of exposure
estimates in the adult population.
The highest contributions to the exposure of MON were from grain-based products across all age
groups. Other relevant contributions were found in food for infants and small children, fruit and fruit
products in infants and toddlers, and composite foods in adults.
The limited consumption data on vegetarians do not indicate a major difference in the acute and
chronic dietary exposure to MON between vegetarians and the general population.
3.6. Exposure assessment for farm and companion animals
Exposure estimates at the 95th percentile and mean concentrations for farm and companion
animals are reported below (see also Appendix B). The farm and companion animal exposure
estimates22 were calculated by using the occurrence data set which comprised the data on feed
(Section 3.3.2.3) and the grains reported as ‘Unprocessed grains of undeﬁned end-use’
(Section 3.3.2.4). The feed consumption is reported in Section 2.6 and in Appendix B. For the
methodology of exposure calculations for farm and companion animals, see Section 2.7.
No data on levels of MON in species-speciﬁc compound feeds have been reported, and therefore
exposures to MON have been based on concentrations in individual feed materials and their levels of
inclusion in the diets. For non-forage feeds, information on levels of MON was only available for cereal
grains. For forages, data on concentrations of MON in 42 samples of maize silage were provided for
the EFSA database (see Section 3.3.2.3). Limited data were provided for cereal straws (n = 18), and
these have been used to estimate mean LB and UB exposure for certain ruminant livestock.
It should be noted that in contrast to human exposure, in which estimates of exposure are
presented as ng/kg bw per day, the exposure estimates in this section for farm and companion
animals are presented as lg/day or lg/kg bw per day.
3.6.1. Ruminants and horses
Two scenarios have been considered in estimating exposure by dairy cows to MON. The ﬁrst
reﬂects diets in which grass – fresh or conserved – is supplemented with compound feeds containing
cereals as described in Appendix B, Section B.1. In this scenario, it is assumed that the forages make
no contribution to exposure. In the second scenario, maize silage is assumed to be the sole forage,
supplemented with maize grain. In view of the relatively small number of samples of maize silage in
the database (n = 42), 95th percentile estimates of exposure have not been made.
For fattening beef cattle, four different feeding systems have been considered, namely (a) grass
(fresh or conserved) supplemented with cereals, (b) fattening beef cattle on a maize silage-based diet,
(c) beef cattle on a cereal straw-based diet and (d) intensively reared beef cattle on a ‘cereal beef’
diet. Details of the levels of maize silage, cereal straw and cereals in these different rations are given
in Appendix B, Section B.1.
For lactating sheep and goats, and for horses, diets have been assumed to be predominantly grass-
based (fresh or conserved) supplemented with cereals, the quantities of which are given in
Appendix B.
Estimates of exposures for ruminants and horses are given in Table 11.
22 Dietary exposures assume a 12% moisture content in the feed (i.e. they are expressed on an 88% dry matter (DM) basis).
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3.6.2. Pigs and poultry
Estimates of 95th percentile and mean exposure by pigs and poultry to MON were derived from
data for assumed inclusion rates of cereal grains in their diets, and are given in Table 12. Details of
assumed inclusion rates of cereals are given in Appendix B.
Table 11: Mean and 95th percentile (P95) moniliformin concentration in the diet of ruminants and
horses derived from concentrations in individual feed materials and their relative
proportions in their diets and the corresponding estimated exposure (lg/day and ng/kg
bw per day)
Animal species (diet) LB/UB
Diet
concentration
lg/kg dry
matter
Exposure
lg/day
Exposure
ng/kg bw
per day
P95 Mean P95 Mean P95 Mean
Dairy cows (grass-based diet) LB 23 4.5 483 94 740 140
UB 25 9.9 518 205 800 320
Dairy cows (maize silage-based diet)(a) LB – 36 – 979 – 1,500
UB – 37 – 1013 – 1,600
Beef cattle (grass silage-based diet) LB 11 1.8 106 17 270 40
UB 11 4.5 106 43 270 110
Beef cattle (cereal-based diet) LB 94 15 941 148 2,400 370
UB 94 38 941 383 2,400 960
Beef cattle (maize silage-based diet)(a) LB – 12 – 78 – 260
UB – 16 – 102 – 340
Beef cattle (straw-based diet)(a) LB – 19 – 152 – 510
UB – 50 – 396 – 1,300
Lactating sheep LB 27 5.2 75 15 1,200 180
UB 29 11 80 32 1,300 400
Lactating goats LB 15 9.7 52 33 860 550
UB 15 32 52 108 860 1,800
Horses LB 16 3.2 141 29 310 60
UB 34 14 307 122 680 270
LB: lower bound; UB: upper bound.
(a): Insufﬁcient samples were available to undertake 95th percentile exposure estimates
(b): Rounded to the ﬁrst or second decimal place or to a whole number.
Table 12: Mean and 95th percentile (P95) moniliformin concentration in the diet of pigs and poultry
derived from concentrations in individual feed materials and their relative proportion in
diets and the corresponding estimated exposure (lg/day and ng/kg bw per day)(a)
Animal species LB/UB
Diet concentration
lg/kg dry feed
matter
Exposure
lg/day
Exposure
ng/kg bw per day
P95 Mean P95 Mean P95 Mean
Pig starter LB 98 22 98 22 4,900 1,100
UB 111 43 111 43 5,600 2,200
Pig ﬁnisher LB 105 24 317 70 3,200 700
UB 119 46 357 138 3,600 1,400
Lactating sow LB 92 22 552 129 2,800 650
UB 106 41 634 245 3,200 1,200
Fattening chickens LB 160 40 19 4.8 9,700 2,400
UB 171 53 21 6.3 10,000 3,200
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3.6.3. Farmed ﬁsh (salmonids and carp), farmed rabbits and farmed mink
In the absence of any data on concentrations of MON in species-speciﬁc compound feeds,
estimates of exposure were made by using example rations and concentrations in individual feed
materials (see Appendix B for details of rations used) and are reported in Table 13.
3.6.4. Dogs and cats
No data on levels of MON in proprietary feeds for dogs and cats were available, and therefore
exposure was estimated using example rations (see Appendix B for details) and concentrations MON in
cereal grains used. The estimated exposures are reported in Table 14.
Animal species LB/UB
Diet concentration
lg/kg dry feed
matter
Exposure
lg/day
Exposure
ng/kg bw per day
P95 Mean P95 Mean P95 Mean
Laying hens LB 107 35 13 4.2 6,500 2,100
UB 149 45 18 5.4 9,000 2,700
Fattening turkeys LB 107 21 43 8.5 3,600 710
UB 115 46 46 18 3,900 1,500
Fattening ducks LB 92 21 13 2.9 4,300 980
UB 104 41 15 5.7 4,900 1,900
LB: lower bound; UB: upper bound.
(a): Rounded to the ﬁrst or second decimal place or to a whole number.
Table 13: Mean and 95th percentile (P95) MON concentration in the diet of farmed rabbits, farmed
ﬁsh and farmed mink derived from concentrations in individual feed materials and their
relative proportions in diets and the corresponding estimated exposure (lg/day and ng/
kg bw per day)(a)
Animal species LB/UB
Diet concentration
lg/kg dry feed
matter
Exposure
lg/day
Exposure
ng/kg bw per day
P95 Mean P95 Mean P95 Mean
Salmonids LB 19 4.9 0.76 0.19 380 100
UB 23 8.6 0.90 0.34 450 170
Carp LB 62 16 1.4 0.34 1,400 340
UB 69 23 1.5 0.51 1,500 510
Farmed rabbits LB 33 5.3 5.0 0.79 2,500 390
UB 33 14 5.0 2.0 2,500 1,000
Farmed mink LB 27 6.6 2.0 0.50 1,000 240
UB 29 9.1 2.2 0.68 1,100 330
LB: lower bound; UB: upper bound.
(a): Rounded to the ﬁrst or second decimal place or to a whole number.
Table 14: Mean and 95th percentile (P95) MON concentration in the diet of cats and dogs derived
from concentrations in individual feed materials and their relative proportions in diets and
the corresponding estimated exposure (lg/day and ng/kg bw per day(a)
Animal species LB/ UB
Diet concentration
lg/kg dry feed
matter
Exposure
lg/day
Exposure
ng/kg bw per day
P95 Mean P95 Mean P95 Mean
Cats LB 50 15 3.0 0.9 750 220
UB 50 18 3.0 1.1 750 260
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3.7. Risk characterisation
3.7.1. Human health risk characterisation
3.7.1.1. Acute human health risk from the dietary exposure to MON
Since the available data were not sufﬁcient to derive an ARfD for MON, the CONTAM
Panel characterised the acute human health risk associated with acute dietary exposure to MON by
comparing the mean and 95th percentile probabilistic acute dietary exposure estimates across
European dietary surveys and the age groups as summarised in Table 7 (see Section 3.5.1.1) with the
NOAEL of 6 mg MON/kg bw (i.e. 6,000,000 ng MON/kg bw) for cardiotoxicity identiﬁed based on a
subacute study in rats (see Section 3.2.1.2).
Estimated exposure levels to MON across the surveys and age groups varied at the mean UB from
82 to 530 ng/kg bw, with smallest lower and largest upper conﬁdence bounds of 76 and 848 ng/kg
bw. At the 95th percentile, UB exposure varied from 202 to 1,489 ng/kg bw, with smallest lower and
largest upper conﬁdence bounds of 179 and 2,201 ng/kg bw. The resulting MOE values (rounded
down) ranged from 11,000 to 73,000 at the mean and from 4,000 to 29,000 at the 95th percentile
dietary exposures, respectively, see Table 15. The CONTAM Panel concluded that these MOE values
were sufﬁciently large to indicate a low health concern for humans from current acute dietary
exposure to MON.
The data on dietary habits of vegetarians were available from only ﬁve European countries and four
of them had only very few subjects. These limited data did not indicate notable differences in acute
dietary exposure between the vegetarians and the general population. Therefore, the conclusions on
the general population remained valid also for the subpopulation of vegetarians.
3.7.1.2. Chronic human health risk from the dietary exposure to MON
Since the available toxicity data were not sufﬁcient to establish a chronic HBGV for MON, the
CONTAM Panel assessed the risk from chronic dietary exposure to MON by comparing the mean and
95th percentile acute dietary LB and UB exposure estimates across European dietary surveys and the
age groups as summarised in Table 8 (see Section 3.5.1.2) with the lowest BMDL05 of 0.20 mg
Animal species LB/ UB
Diet concentration
lg/kg dry feed
matter
Exposure
lg/day
Exposure
ng/kg bw per day
P95 Mean P95 Mean P95 Mean
Dogs LB 55 19 20 7.0 800 280
UB 56 23 20 8.1 800 330
LB: lower bound; UB: upper bound.
(a): Rounded to the ﬁrst or second decimal place or to a whole number.
Table 15: Margins of exposure (MOE) values based on the NOAEL of 6 mg MON/kg bw identiﬁed in
a subacute study in rats and the acute dietary exposure across age groups
Age group
MOE calculated from mean dietary
exposure
MOE calculated from 95th percentile
dietary exposure
Minimum Maximum Minimum Maximum
Infants 49,000 20,000 11,000 4,000
Toddlers 20,000 11,000 7,000 4,000
Other children 26,000 11,000 10,000 4,000
Adolescents 41,000 17,000 15,000 7,000
Adults 63,000 27,000 21,000 9,000
Elderly 73,000 23,000 29,000 8,000
Very elderly 68,000 30,000 28,000 10,000
NOAEL: no-observed-adverse-effect level.
Note: Minimum and maximum refer to the exposure scenarios.
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MON/kg bw per day calculated for haematological adverse effects (i.e. 200,000 ng MON/kg bw per
day) (see Section 3.2.1.2).
The mean chronic exposure to MON across the surveys and age groups varied at LB from 0.04 to
51 and at UB from 7.7 to 226 ng/kg bw per day. High exposure (95th percentile) varied at LB from
0.06 to 135 and at UB from 44 to 528 ng/kg bw per day. The MOE values (rounded down) ranged
from to 3,900 to 5,000,000 (LB) and from 880 to 25,000 (UB) at the mean exposure, and from 1,400
to 3,300,000 (LB) and from 370 to 4,500 to (UB) at the 95th percentile exposure estimates, see
Table 16.
The CONTAM Panel concluded that these MOE values were sufﬁciently large to indicate a low health
concern for humans from current chronic dietary exposure to MON.
However, the CONTAM Panel stresses that in the absence of quantitative dose–response data on
cardiotoxicity this risk characterisation was based on haematological effects from very limited toxicity
database.
The data on dietary habits of vegetarians were available from only ﬁve European countries and four
of them had only very few subjects. These limited data did not indicate notable differences in chronic
dietary exposure between the vegetarians and the general population. Therefore, the conclusions on
the general population remained valid also for the subpopulation of vegetarians.
3.7.2. Animal health risk characterisation
Because of the limited knowledge on the effects of MON on farm and companion animals and on
the absence of a comprehensive database on feed consumption by livestock in the EU, it has not been
possible to properly assess the risk of MON for animal health. However, the exposure estimates at the
LB and UB concentrations for MON in diets have been estimated for most relevant farm livestock and
companion animal categories, based on expected feed intakes and example diets and these have been
compared with the species-speciﬁc BMDL for pigs or NOAELs for poultry and farmed mink only, see
Table 17. In particular, the CONTAM Panel took into account the dietary exposure assessment of MON
using recent analytical results on the occurrence of MON in feed as described in Sections 2 and 3.3.2
and the diet composition and feed consumption of farm and companion animals as described in
Sections 2.6 and Appendix B. The estimates of exposure to MON are presented in Section 3.6.
For pigs, the CONTAM Panel characterised the health risk associated with dietary exposure to MON
by comparing the estimated exposures at the UB mean and UB 95th percentile dietary concentrations
Table 16: Margins of exposure (MOE) values based on the BMDL05 of 0.20 mg MON/kg bw per day
for haematological effects identiﬁed in a 28-day study in pigs and the chronic dietary
exposure across age groups
Age group
Minimum Median Maximum
LB UB LB UB LB UB
MOE calculated from mean dietary exposure
Infants 3,300,000 18,000 21,000 2,700 5,200 1,800
Toddlers 2,000,000 10,000 29,000 2,700 3,900 1,000
Other children 5,000,000 13,000 31,000 2,700 8,600 880
Adolescents 5,000,000 11,000 58,000 4,600 18,000 1,700
Adults 1,000,000 16,000 153,000 6,400 25,000 2,500
Elderly 1,000,000 25,000 289,000 8,300 34,000 2,100
Very elderly 700,000 25,000 277,000 8,300 9,000 2,500
MOE calculated from 95th percentile dietary exposure
Infants 370,000 1,300 3,700 700 1,600 400
Toddlers 580,000 930 3,200 520 1,400 370
Other children 510,000 2,500 5,700 840 3,100 490
Adolescents 2,500,000 2,700 14,000 1,300 5,700 710
Adults 900,000 3,500 26,000 2,000 6,000 750
Elderly 2,000,000 4,500 52,000 3,200 8,600 750
Very elderly 3,300,000 4,500 76,000 2,900 12,000 990
BMDL: Benchmark dose lower conﬁdence limit; LB: lower bound; UB: upper bound.
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for MON (see Section 3.6 and Appendix B), with the identiﬁed reference point BMDL05 for
haematological hazard) of 0.20 mg MON/kg bw per day (see Table 17).
For poultry and farmed mink, the CONTAM Panel characterised the health risk associated with
dietary exposure to MON by comparing the estimated exposures at the UB mean and UB 95th
percentile dietary concentrations for MON (see Section 3.6 and Appendix B), with the identiﬁed
NOAELs and calculating MOE values rounded down to the next lower unit of 10 or 100, see details in
Table 17 and Appendix D.
For all other farm and companion animal species where a speciﬁc reference point could not be
identiﬁed, the CONTAM Panel applied a conservative approach and characterised the health risk
associated with dietary exposure to MON by comparing the estimated exposures at the UB mean and
UB 95th percentile dietary concentrations for MON (see Section 3.6 and Appendix B), with the lowest
indicative reference point of 0.20 mg MON/kg bw per day, identiﬁed for pigs.
3.7.2.1. Pigs
The dietary exposure for fattening pigs at the UB mean and 95th percentile ranged between 0.1%
and 0.2% of the NOAEL of 1.2 mg/kg bw per day and was slightly higher than for lactating sows. The
MOE values comparing the UB mean and 95th percentile dietary exposure with the reference point of
0.20 mg MON/kg bw per day ranged from 90 to 160 (mean) and from 35 to 60 (95th percentile) for
fattening pigs and lactating sows, respectively, see Table 17 and Appendix B. Therefore, the risk for
adverse health effects from feed containing MON was considered low for pigs at the estimated
exposure levels under current feeding practices.
3.7.2.2. Poultry
Amongst the poultry species, the highest dietary exposure was for broiler chickens, for which the
exposure at the at the UB mean and 95th percentile ranged between 0.2% and 0.7% of the NOAEL of
1.4 mg/kg bw per day (see Table 17). The MOE values comparing the UB mean and 95th percentile
dietary exposure with the NOAELs identiﬁed as 1.4, 3.8, 1.6 and 2.3 lg/kg bw for broiler chickens,
laying hens, fattening turkeys and fattening ducks, respectively, ranged overall between 430 and 1400
for the mean and between 140 and 460 at the 95th percentile exposure – see Table 17 and
Appendix D. Therefore, the risk for adverse health effects from feed containing MON was considered
as negligible for poultry species at the estimated exposure levels under current feeding practices.
3.7.2.3. Farmed mink
For farmed mink, the dietary exposure estimates at the UB mean and 95th percentile ranged
between 0.03 and 0.1% of the NOAEL of 0.92 mg/kg bw per day. The MOE values comparing the UB
mean and 95th percentile dietary exposure with the NOAEL were 2,700 and 830 – see Table 17 and
Appendix D. Therefore, the risk for adverse health effects from feed containing MON was considered
as negligible for farmed mink at the estimated exposure levels under current feeding practices.
3.7.2.4. Other farm and companion animals
The CONTAM Panel noted that the margin between the estimated mean and 95th percentile
exposures and the assumed indicative reference point of 0.20 mg MON/kg bw adopted for other
animals (see Section 3.2.2) was not smaller than those observed for animals for which data on
adverse effects were available. Speciﬁcally the MOEs between the UB dietary exposure estimates and
the NOAELs for the other farm and companions animals for which data on adverse effects were not
available or insufﬁcient ranged between 90 and 2,700 for the mean and 35 and 800 for the 95th
percentile exposure, respectively – see Table 17 and Appendix D. Therefore, it seems reasonable to
conclude that the incidence of adverse health effects from feed containing MON is unlikely for them at
the levels of exposure estimated for current feeding practices. The CONTAM Panel noted that the
conclusion on animals other than poultry, pigs and farmed mink would be affected by a higher degree
of uncertainty than that on the animal species for which toxicity data were available.
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4. Uncertainty analysis
Evaluation of the inherent uncertainties in the assessment of exposure to MON has been performed
following the guidance given in the Opinion of the Scientiﬁc Committee related to Uncertainties in
Dietary Exposure Assessment (EFSA Scientiﬁc Committee, 2006). In addition, the report on
‘Characterizing and Communicating Uncertainty in Exposure Assessment’ has been considered (WHO/
IPCS, 2008). According to the guidance provided by EFSA, 2006, the following sources of uncertainties
have been considered: assessment objectives, exposure scenario, exposure model and model input
(parameters). In addition to the EFSA opinion, 2006, the CONTAM Panel also considered other
uncertainties.
4.1. Assessment objectives
The objectives of the assessment were deﬁned in the terms of reference and no uncertainty was
associated in the objectives.
4.2. Exposure scenario and model
The results of the samples collected in 2001–2016 on the occurrence of MON in food, feed and
grains of undeﬁned end-use reported to EFSA, identiﬁed suitable for evaluation, were limited. These
data were augmented by the results extracted from the published literature collected between 2001
and 2015 for food, and between 2006 and 2016 for feed. For the ﬁnal data set, analytical results for
food were available from six European countries and for feed, including the grains of undeﬁned-end
use, from ﬁve European countries. However, these samples of food/feed did not always originate from
the European country who reported the data. The data showed a high percentage of left censored
results and about 90% and 60% of the results available to assess human exposure and farm and
companion animal exposure, respectively, were left censored. Non-targeted sampling was reported
only for the samples submitted to EFSA and this was assumed also for the other contributing data in
the absence of further information. Therefore, the evaluation data set may not be fully representative
at the European level, which adds to the uncertainty for the exposure assessments for humans and
animals. The use of LB values tends to underestimate, while the use of UB values tends to
overestimate dietary exposure.
Table 17: Margins of exposure (MOE) values based on NOAEL or BMDL05 identiﬁed in relevant
studies and the estimated UB in mean and 95th percentile dietary exposure across
animal species
Species
MOE calculated from
mean dietary exposure
MOE calculated from 95th
percentile dietary exposure
Highest UB Highest UB
Ruminants 120 80
Pig
– Fattening pig 90 35
– Lactating sow 160 60
Poultry
– Broiler chicken 430 140
– Laying hens 1,400 420
– Fattening turkey 1,000 410
– Fattening duck 1,200 460
Horse 740 290
Farmed rabbit 200 80
Farmed mink 2,700 830
Dog 600 250
Cat 760 260
UB: upper bound.
Note: values were rounded down (to hundreds above 1,000 or to sets of ten).
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The lack of analytical methods formally validated through interlaboratory studies hampered a
reliable conclusion on the uncertainty of the currently available results on MON. The lack of certiﬁed
reference materials for MON (as calibrants and in particular matrix materials) is an additional limitation
that hampered an uncertainty estimate for individual laboratories. Both issues contribute to the overall
uncertainty of occurrence data and are equally valid for the chemical analysis used in toxicokinetic and
toxicity studies. Available information on correction/non-correction for recovery was not complete and
contributes to that uncertainty.
There were considerable differences in the number of analytical results across the food categories
with high prevalence of grains and grain-based foods and only few or no samples for other food
categories, except for asparagus, adding to overall uncertainty of the human exposure estimates.
For several food categories, the estimation of the highest reliable percentile was not possible due to
the small numbers of samples. There was a lack of dietary surveys on the consumption data for
infants and for vegetarians adding to the uncertainty of exposure estimates for these subgroups in
human population.
The CONTAM Panel noted a wide range between the LB and UB values of the chronic dietary
exposure of humans across European countries and the age groups which clearly indicate the
considerable uncertainty of these estimates.
Regarding the exposure of animals through feed consumption, only data on the major cereal grains
(wheat, barley, oats, rice and maize), and limited data for maize silage and cereal straw, were
available to assess exposure. As cereal by-products are typically used for animal feeding, the absence
of data on MON concentrations in these products led to a likely underestimation of exposure. A large
variety of feed materials are used to formulate diets for farm and companion animals in Europe, and
the lack of information on levels of MON in these feeds needed for reliable estimation of exposure
added to the overall uncertainty of the animal exposure.
4.3. Other uncertainties
Data on toxicokinetics were missing for humans and were very limited for experimental animals,
while the fate of more than 50% of ingested MON remains unknown. For farm and companion
animals, no data on toxicokinetrics were identiﬁed. Distribution and metabolism are unknown and
more information is needed on the potential crossing of the blood-brain barrier for MON. Therefore,
the uncertainty of the toxicokinetics of MON is large.
There is a lack of long-term toxicity studies and reproduction toxicity studies for MON in
experimental animals. There is also a lack of information on general toxicity, haematotoxicity and
cardiotoxicity of MON in experimental animals and most farm and companion animals. In particular,
studies on quantitative dose–response data for key cardiac endpoints, such as cardiomegaly, muscular
distress of the heart and heart failure in both well-designed short-term and long-term studies, are
lacking. In addition, available in vitro and in vivo data on the mode of action of MON are currently too
limited and the relationship between cardiotoxicity and mortality of MON in key animal species needs
to be based on a sufﬁciently large toxicity database, such that a convincing dose–response relationship
would be evident. The CONTAM Panel also noted that the dose–response data on the acute adverse
effects of MON in rats of Jonsson et al. (2015) and on chronic effects in pigs of Harvey et al. (2001)
may not fully inform on the critical endpoints chosen. The mechanism for the in vitro genotoxic effects
is unknown, and whether the observed positive in vitro results are relevant for the situation in vivo,
where data are so far lacking. For these reasons, both acute and chronic risk characterisation remains
incomplete and the hazard characterisation of MON remains highly uncertain.
Overall, the CONTAM Panel considered that the uncertainty, particularly resulting from the lack of
toxicity data on MON, prevented reliable risk assessment for humans and most farm and companion
animals.
4.4. Summary of uncertainties
In Table 18, a summary of the uncertainty evaluation is presented, highlighting the main sources of
uncertainty and indicating an estimate of whether the respective source of uncertainty might have led
to an over- or underestimation of the exposure or the resulting risk.
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The CONTAM Panel considered the impact of the uncertainties on the risk assessment of animal
and human exposure to MON and concluded that overall uncertainty is large.
5. Conclusions
Moniliformin (MON) is a mycotoxin with low molecular weight typically, but not exclusively,
produced by several plant pathogenic Fusarium species. It has mainly been detected in cereal grains
and cereal-based food and feed. Naturally occurring modiﬁed forms of MON have not been reported.
Methods of analysis
• Analytical methodology for MON in foods, feeds and biological samples has been mostly based
on LC-UV and LC–MS/MS. Currently, LC–MS/MS is the most widely used and preferred
technique.
• None of the applied analytical methods for MON have been formally validated in interlaboratory
studies.
• Rapid immunochemical test kits, able to detect MON, have not been developed.
• Certiﬁed reference materials (both reference matrices and reference calibrants) are not
available for MON but calibrants are commercially available.
Occurrence
• MON has mainly been reported to occur in various cereal grains, such as maize, wheat, barley
and oats, and in cereal products.
• MON has been found to co-occur with other mycotoxins, in particular with trichothecenes,
enniatins, beauvericin and zearalenone.
• A total of 3,205, 806, and 504 analytical results of MON for food, feed and unprocessed grains
of undeﬁned end-use, respectively, sampled between 2001 and 2016 fulﬁlled the quality
criteria applied by EFSA.
• The proportion of left-censored data in the data set (results below the LOD or LOQ) were 90%
for MON in food, 60% for MON in feed and 70% for MON in unprocessed grains of undeﬁned
end-use.
• The highest mean concentrations of MON were recorded for food in the categories ‘Grains for
human consumption’, ‘Snack food’ and ‘Breakfast cereals’, for feed in the categories ‘Cereal
grains’ (i.e. maize and barley) and for unprocessed grains of undeﬁned end-use in the category
‘Grains as crops’ (i.e. wheat and oat grain).
Table 18: Summary of qualitative evaluation of the impact of uncertainties on the risk assessment
of the human and animal dietary exposure to MON
Sources of uncertainty Direction(a)
Assuming non-targeted sampling for literature data used for exposure +
Uncertainty of the analytical measurements +/
Effects of food and feed processing +/
No data for most grain-based products and other foods and no data on other feed than grains +/
High variability of the composition of feedstuffs used and feeding systems for farm animals in
Europe
+/
Use of UB occurrence data in the exposure estimations +
Use of LB occurrence data in the exposure estimations 
Limited data on exposure of infants +/
Use of Fusarium culture materials in the toxicity studies +/
Lack of toxicity data on general toxicity in experimental and farm and companion animals +/
Limited data on toxicokinetics +/
Lack of data on in vivo genotoxicity and carcinogenicity 
Limited data on the mode of action +/
(a): + = uncertainty with potential to cause over-estimation of exposure/risk;  = uncertainty with potential to cause under-
estimation of exposure/risk.
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Effects of processing
• Cleaning and sorting of grains resulted in a reduction of MON in subsequently produced products.
• Milling of grains led to a redistribution of MON into different fractions. Semolina, ﬂour and feed
ﬂour contained the highest concentrations of MON.
• Cooking and baking generally led to reductions of MON concentrations in contaminated samples.
• MON was unstable under high temperatures in combination with alkaline conditions.
• In the absence of studies with feed materials, the CONTAM Panel considered the effects of the
processing of animal feeds were similar to those reported for food.
• Although the effects of ensiling on MON appeared not to have been studied so far, in view of
the relatively high levels of MON reported in maize grains, plants intended for silage were
considered as also potential sources of exposure for ruminant livestock.
Human exposure
• The estimates of mean acute exposure to MON across 39 different dietary surveys and all age
groups using the UB concentrations ranged from 82 to 530 ng/kg bw per day. The estimates
of 95th percentile acute exposure ranged from 202 to 1,489 ng/kg bw per day. The highest
acute dietary exposures were for infants, toddlers, and other children.
• The estimates of mean chronic exposure to MON across 33 different dietary surveys and all age
groups using the minimum LB and the maximum UB concentrations ranged from 0.04 to 226 ng/kg
bw per day. The estimates of 95th percentile chronic exposure ranged from 0.06 to 528 ng/kg bw per
day. The highest chronic dietary exposures were for infants, toddlers, other children and adolescents.
• The most important contributors to the chronic dietary exposure to MON were ‘Grains and
grain-based products’, especially ‘cereal ﬂakes’.
• The limited available consumption data on vegetarians do not indicate a major difference in
the dietary exposure to MON between them and the general population.
Farm and companion animal exposure
• Animal exposure to MON was primarily from consuming cereal grains and cereal by-products.
Levels in forages were generally low.
• For ruminants, the estimated lowest LB and highest UB mean dietary exposures were 0.04 and
1.6 lg/kg bw per day, and the 95th percentile exposures were 0.27 and 2.4 lg/kg bw per day,
respectively.
• For pigs, the estimated lowest LB and highest UB mean dietary exposures were 0.65 and
2.2 lg/kg bw per day, and the 95th percentile exposures were 2.8 and 5.6 lg/kg bw per day,
respectively.
• For poultry, the estimated lowest LB and highest UB mean dietary exposures were 0.71 and
3.2 lg/kg bw per day, and the 95th percentile exposures were 3.6 and 10 lg/kg bw per day,
respectively.
• For horses, the estimated LB and UB mean dietary exposures were 0.06 and 0.27 lg/kg bw
per day, and the 95th percentile exposures were 0.31 and 0.68 lg/kg bw per day, respectively.
• For farmed ﬁsh (salmonids and carp), the estimated lowest LB and highest UB mean dietary
exposures were 0.10 and 0.51 lg/kg bw per day, and the 95th percentile exposures were 0.38
and 1.5 lg/kg bw per day, respectively.
• For farmed rabbits, the estimated LB and UB mean dietary exposures were 0.39 and 1.0 lg/kg
bw per day, and the 95th percentile exposures were 2.5 lg/kg bw per day (LB and UB).
• For farmed mink, the estimated LB and UB mean dietary exposures were 0.24 and 0.33 lg/kg bw
per day, and the 95th percentile exposures were 0.99 and 1.05 lg/kg bw per day, respectively.
• For dogs and cats, the estimated lowest LB and highest UB mean dietary exposures were 0.22
and 0.33 lg/kg bw per day, respectively. The 95th percentile exposures ranged between 0.80
and 0.75 lg/kg bw per day.
Toxicokinetics
• In experimental animals, a large portion of MON was absorbed and excreted rapidly after
administration with no apparent accumulation in any tissue. However, the fate of at least half
of the amount ingested remains unknown.
• No data on toxicokinetics were identiﬁed for farm and companion animals considered in this
opinion.
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• The only available study on the transfer of MON from feed to food products of animal origin
was identiﬁed for broiler chickens, and no transfer was found.
Toxicity of MON in experimental animals
• Acute toxicity of MON was identiﬁed in rats, with oral LD50 values ranging from 19 to 25 mg
MON/kg bw in experiments using 99% pure MON. The oral acute toxicity in mice was lower
with LD50 values of about 50 mg MON/kg bw.
• Acute toxicity was accompanied by muscular weakness, respiratory and cardiovascular
changes, the latter including faint heart beats and cardiac arrhythmia.
• Prominent acute adverse health effects in experimental animals were presence of
ultrastructural lesions in the myocardium, reduction of contractility in aorta, pulmonary artery
and terminal ileus, decreased myocardial contractile force and ventricular arrhythmia and
congestive heart failure.
• The CONTAM Panel identiﬁed only one subacute study of MON in rats that allowed
identiﬁcation of a NOAEL of 6 mg/kg bw per day. Cardiotoxicity was observed at 15 mg/kg bw
per day and indications of cardiotoxicity were seen at 9 mg MON/kg bw per day.
• Only one subchronic study with a limited number of rats was identiﬁed. MON induced
cardiotoxicity and mortality at 32.5 mg MON/kg bw per day and higher, while no adverse
effects were observed at the lowest dose tested (16.6 mg MON/kg bw per day) which was
identiﬁed as a NOAEL for mortality for male rats. Data on haematotoxicity or myelotoxicity and
on immunotoxicity were too scarce to conclude on the hazard of MON in experimental animals.
• No chronic studies or any carcinogenicity study on MON were identiﬁed in animals.
• For developmental and reproductive toxicity of MON, only one study in mink was identiﬁed
from which the lowest dose of 0.92 mg MON/kg bw per day was identiﬁed as a NOAEL.
Exposure to 1.94 mg MON/kg bw per day, the other dose tested, resulted in signiﬁcant
neonatal mortality and reduced offspring body weights.
• There was no evidence that MON induces bacterial reverse mutation. MON has been shown to
be clastogenic in vitro inducing chromosomal damage.
• No data were identiﬁed to conclude on whether in vitro genotoxicity is caused by a direct or
indirect mechanism.
• No data were available on genotoxicity of MON in vivo.
• No relevant human epidemiological data on MON were identiﬁed.
• Although it has been hypothesised in published literature that dietary exposure to MON was
involved in past prevalence of KD in some regions in China, the CONTAM Panel noted that the
evidence for a causal relation between dietary exposure to MON and the incidence of KD was
too weak and insufﬁcient to be considered for human hazard characterisation.
• The mode of action of MON is unclear and only a limited amount of data was available. The
inhibition of enzymes involved in glucose metabolism could lead to cellular energy deprivation
and may partially explain the respiratory stress, including myocardial effects.
• The available database of possible effects of combined exposure to MON and other mycotoxins
was weak and insufﬁcient for establishing the nature of combined effects.
Considerations on derivation of human health-based guidance values (HBGV)
• Since the toxicological database of MON for experimental animals was scarce, and only one
subacute study and one subchronic study were available to characterise the hazard of MON,
the CONTAM Panel also examined the toxicological data for farm animals to augment the
database for human hazard characterisation.
Acute adverse health effects
• The CONTAM Panel could not establish an ARfD for MON due to the limitations of the available
acute and subacute toxicity data.
• The CONTAM Panel identiﬁed cardiotoxicity as a critical adverse health effect of acute and
subacute exposure to MON and identiﬁed a NOAEL of 6.0 mg/kg bw from a subacute study in
rats as reference point for the acute exposure of humans to MON.
Chronic adverse health effects
• The CONTAM Panel could not establish a TDI for MON due to limitations in the available
toxicity data on chronic effects.
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• The CONTAM Panel identiﬁed haematotoxicity as the critical chronic adverse effects of MON in
pigs and identiﬁed the lowest BMDL05 of 0.20 mg MON/kg bw per for the decrease of the
haematocrit and haemoglobin levels as reference point for chronic exposure of humans.
Adverse effects and reference points in farm and companion animals
• Data on adverse health effects in farm and companion animals were lacking for most of the
animal species. Information was available on poultry and, however limited, for pigs, farmed
ﬁsh and farmed mink.
• Mortality and reduced body weight gain were identiﬁed as chronic adverse effects both in pigs
and poultry.
• From the few available studies on the toxicity of MON in pigs, reduced weight gain, adverse
haematological effects, cardiotoxicity and mortality accompanied with lesions in heart were
identiﬁed as sensitive adverse health effects.
o The NOAEL for reduced body weight gain ranged between 50 and 100 mg MON/kg feed,
corresponding to 1.2 and 2.2 mg MON/kg bw per day.
o For haematological adverse effects, a NOAEL of 25 mg MON/kg feed, corresponding to
1.0 mg MON/kg bw per day, was identiﬁed. A lowest BMDL05 of 0.20 mg MON/kg bw per
day was calculated on the decrease of haematocrit and haemoglobin levels and this was
the most sensitive endpoint for pigs exposed to MON.
o Mortality was observed at a dose as low as 4.2 mg MON/kg bw per day.
o A study in miniature pigs showed cardiotoxicity at 3 mg MON/kg bw per day.
• In poultry, the heart was the main target organ and MON caused heart failure after acute
dosing. Repeated dietary exposure to MON generated cardiomegaly but also changed
haematological parameters and affected body weight gain and egg production.
o For day-old chickens, oral LD50 values of 4.0 and 5.4 mg MON/kg bw were reported.
Ascites with oedema of the mesenteries and small haemorrhages in the proventriculus,
gizzard, small and large intestine, and skin were observed in surviving chickens.
o For 7-day-old ducks, an oral LD50 value of 3.7 mg MON/kg bw, and increasing heart rates
followed by arrhythmia and ultimately cessation of contraction were reported.
o In broiler chickens, the dose of 2.8 mg MON/kg bw per day resulted in reduced body
weight gain, cardiomyopathy, changes in the major haematological parameters and
increased mortality rates, while at the dose of 1.4 mg MON/kg bw per day no adverse
effects were observed.
o In the only available study on laying hens, the dose of 8.5 mg MON/kg bw per day
reduced egg production and body weight gain, while the dose of 3.8 mg MON/kg bw per
day did not generate any adverse effects.
o In turkeys, no adverse effects were observed at 1.6 mg MON/kg bw per day, while a dose
of 3.2 mg MON/kg bw per day induced cardiomegaly.
o Based on two studies on ducks, the dose of 2.8 mg MON/kg bw per day generated
cardiomegaly, while no adverse effects were observed at 2.3 mg MON/kg bw per day.
• Only two studies on farmed ﬁsh were identiﬁed. Reduced weight gain was reported for channel
catﬁsh at the lowest dose of 0.8 mg MON/kg bw per day. Nile tilapia appeared to be more
resistant and no effects were observed at 1.8 mg/kg bw per day in this species.
• In farmed mink, the dose of 1.94 mg MON/kg bw per day resulted in signiﬁcant neonatal
mortality and reduced offspring body weights and was identiﬁed as the LOAEL. The NOAEL
was 0.92 mg MON/kg bw per day.
• No toxicity data suitable for hazard characterisation of MON were identiﬁed for ruminants,
farmed rabbits, horses, farmed ﬁsh, dogs and cats. Therefore, the CONTAM Panel considered
the BMDL05 of 0.20 mg MON/kg bw identiﬁed for pigs as an indicative reference point.
• The CONTAM Panel noted that the conclusion on animals other than poultry, pigs and farmed
mink would be affected by a higher degree of uncertainty than that on the animal species for
which sufﬁcient toxicity data were available.
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Human health risk characterisation
Acute risk
• Since an ARfD could not be established, and in order to get an indication of the risk from MON
exposure, the CONTAM Panel calculated the MOE between the NOAEL of 6.0 mg/kg bw from a
subacute study in rats and the acute UB dietary exposure estimates.
• The MOEs ranged across age groups and consumption studies from 11,000 to 73,000 at the
mean and from 4,000 to 29,000 at the 95th percentile dietary exposures, respectively,
indicating a low risk for human health.
Chronic risk
• Since a TDI could not be established, and in order to get an indication of the possible chronic
risk from MON exposure, the CONTAM Panel calculated the MOE between the lowest BMDL05
of 0.20 mg MON/kg bw per day calculated for haematological hazards from a 28-day study in
pigs and the chronic dietary human exposure estimates.
• The MOEs ranged across age groups and consumption studies from 3,900 to 5,000,000 (LB)
and from 880 to 25,000 (UB) at the mean exposure, and from 1,400 to 3,300,000 (LB) and
from 370 to 4,500 (UB) at the 95th percentile exposure estimates.
• The CONTAM Panel concluded that these MOE values were sufﬁciently large to indicate a low
risk for human health from current chronic dietary exposure to MON.
• However, the CONTAM Panel stressed that in the absence of quantitative dose–response data
on cardiotoxicity this risk characterisation was based on haematological effects from very
limited toxicity database.
• The limited data on exposure among vegetarians did not indicate notable differences in acute
or chronic dietary exposure between the vegetarians and the general population. Therefore,
the conclusions on the general population remained valid also for vegetarians.
Farm and companion animal health risk characterisation
• The margins between the UB estimates of the dietary exposure and the reference point for
adverse health effects ranged for pigs between 90 and 160 for the mean and 35 and 60 for
the 95th percentile exposure, for poultry between 430 and 1400 for the mean and 140 and
460 for the 95th percentile and it was 2,700 for the mean and 800 for the 95th percentile
exposure, respectively, in the farmed mink.
• The CONTAM Panel concluded that the MOE calculated for pigs, poultry and farmed mink
indicated overall a low or even negligible risk for these animal species at the estimated
exposure levels of MON under current feeding practices.
• The MOEs for the other farm and companion animals for which no toxicity data suitable for
hazard characterisation of MON were identiﬁed, ranged between 120 and 760 for the mean
and 80 and 290 for the 95th percentile exposure, respectively.
• The CONTAM Panel noted that these MOEs were similar to those observed for animals for
which data on adverse effects were observed and conclude that the risk for the other farm and
companion animals were therefore also low or even negligible at the estimated exposure levels
of MON under current feeding practices.
• The CONTAM Panel noted that the conclusion on animals other than poultry, pigs and farmed
mink would be affected by a higher degree of uncertainty than that on the animal species for
which sufﬁcient toxicity data were available.
6. Recommendations
• A well-designed 90-day toxicity study in rats using puriﬁed MON performed according to
relevant OECD guidelines with special focus on the assessment of haematotoxicity,
myelotoxicity and cardiotoxicity, is needed.
• Furthermore, in vivo studies on the genotoxicity of MON and more data on its mode of action
are needed.
• Well-designed studies of the toxicokinetics of MON in experimental, farm and companion
animals are required.
• Studies on adverse effects of MON in farm animals and companion animals other than poultry
are needed.
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• Depending on the outcome of the above recommended toxicity studies, more occurrence
data on MON in foods and feed with state-of-the-art validated analytical methods, such as
LC–MS/MS, might be required to enable a comprehensive risk assessment for humans and
farm and companion animals to be undertaken.
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AFRC Agricultural and Food Research Council
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ARfD acute reference dose
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BMDL Benchmark dose lower conﬁdence limit
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bw body weight
CA chromosome aberration
CAS Chemical Abstract Service
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DDT dichlorodiphenyltrichloroethane
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ECB European corn borer
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FEFAC European Feed Manufactures Federation
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LOD limit of detection
LOQ limit of quantiﬁcation
KD Keshan disease
MCH Mean concentration haemoglobin
Max Maximum
Min minimum
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MN micronucleus
MS mass spectrometry
NDV Newcastle disease vaccine
NOAEL no-observed-adverse-effect levels
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OECD Organisation for Economic Co-operation and Development
PCBs polychlorinated biphenyls
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PCDD/Fs polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans
PCDFs polychlorinated dibenzofurans
RBC red blood cell count
SCE sister chromatid exchange
SD Standard deviation
SEM Standard error of the mean
TBAH tetra-n-butyl ammonium hydroxide
TBAHS tetra-n-butyl ammonium hydrogen sulfate
TCDD tetrachlorodibenzo-p-dioxin
TDI tolerable daily intake
TEQ TCDD Toxic equivalents
TLC thin-layer chromatography
UB upper bound
UDS unscheduled DNA synthesis
UV ultraviolet
VKM Norwegian Scientiﬁc Committee for Food Safety
WG Working group
WHO World Health Organization
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Appendix A – EFSA guidance documents applied in the assessment of MON
in food and feed
The CONTAM Panel applied the general principles of the risk assessment process for chemicals in
food as described by WHO (2009), i.e. hazard identiﬁcation and characterisation, exposure assessment
and risk characterisation. The following EFSA guidance documents were applied in the assessment of
MON in food and feed:
EFSA (European Food Safety Authority), 2006. Guidance of the Scientiﬁc Committee on a request from EFSA
related to uncertainties in Dietary Exposure Assessment. EFSA Journal 2007;4(12):438, 54 pp. https://doi.org/
10.2903/j.efsa.2007.438
EFSA (European Food Safety Authority), 2009. Guidance of the Scientiﬁc Committee on transparency in the
scientiﬁc aspects of risk assessments carried out by EFSA. Part 2: General principles. EFSA Journal 2009;6
(5):1051, 22 pp. https://doi.org/doi org/10.2903/j.efsa.2009.1051
EFSA (European Food Safety Authority), 2010. Management of left-censored data in dietary exposure assessment
of chemical substances. EFSA Journal 2010;8(3):1557, 96 pp. https://doi.org/10.2903/j.efsa.2010.1557
EFSA (European Food Safety Authority), 2011. Scientiﬁc opinion on genotoxicity testing strategies applicable to food
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Appendix B – Feed intakes and diet composition (farm and companion
animals)
To estimate exposure to moniliformin (MON), information on both the amount of feed consumed
and the concentration of MON in the feed is required. This Appendix gives details of the feed intakes,
live weights and diet compositions for different livestock, ﬁsh and companion animals used as the basis
to estimate exposures. These are based on published guidelines on nutrition and feeding (e.g.
Carabano and Piquer, 1998; NRC 2000, 2007a,b, Leeson and Summers, 2008, OECD, 2009; McDonald
et al., 2011; EFSA FEEDAP Panel, 2012) and information provided by European feed manufacturers.
They are therefore estimates of the Panel on Contaminants in the Food Chain (CONTAM Panel), but
agree with common practice. In Annex A, Table A5, the concentrations of MON in feeds used to
estimate exposure are presented. It should be noted that the farm and companion animal exposure
estimates were calculated by using the occurrence data set which comprised the data on feed
(Section 3.3.2.3 and Annex A, Table A5) and the grains reported as ‘Unprocessed grains of undeﬁned
end-use’ (Section 3.3.2.4 and Annex A, Table A8 (crops)).
B.1. Feed intakes
B.1.1. Cattle, sheep, goats and horses
Dairy cows
The amounts of feed given to lactating dairy cows varies according to the amount and quality of
forages and other feeds available, the milk yield and the size of the cow. Two scenarios have been
considered in estimating exposure by dairy cows to MON. The ﬁrst reﬂects diets in which grass – fresh
or conserved – is supplemented with cereal grains. In this scenario, it is assumed that the forages
make no contribution to exposure, and that non-forage feeds are fed at the rate of 0.3 kg/kg of milk
produced (Nix, 2010). Exposures to MON have been estimated for a 650-kg dairy cow, with a milk
yield of 40 kg per day, reﬂecting a relatively high milk yield. Assumptions on the amounts of forages
and non-forage feed are given in Table B.1. In the second scenario, maize silage is assumed to be the
sole forage, supplemented with maize grain (amounts given in Table B.4). In view of the relatively
small number of samples of maize silage in the database (n = 42), the 95th percentile estimates of
exposure have not been made.
Beef cattle
There are a wide variety of beef production and husbandry systems in Europe. They may be
categorised broadly as forage-based or cereal-based systems, although combinations of these systems
are commonly found. In this opinion, four feeding systems are considered, in which the forages are
(1) grass hay or silage (in which case the forage is assumed to make no contribution to MON
exposure), (2) maize silage and (3) cereal straw with, in each case, appropriate supplementation with
non-forage feed materials. A fourth system, namely ‘cereal beef’, is also considered. For exposure
estimates, live weights of 300 or 400 kg, and feed intakes of between 6.6 and 10 kg dry matter/day
have been assumed, depending on the feeding regime, based on guidelines published by EBLEX
(2008, 2012) and details are given in Table B.1.
Sheep and goats
Many breeds and systems of management have been developed for sheep and goats to suit the
land, climate and husbandry conditions in the EU. As for other ruminants, forages may be the only
feeds used after weaning (NRC, 2007a). Common exceptions to this are pregnant and lactating
animals, whose feed is usually supplemented with non-forage feeds or commercial compound
(complementary) feeds (AFRC, 1993; NRC, 2007a). In this opinion, exposure estimates have been
made for lactating sheep and goats. The CONTAM Panel has used a daily dry matter intake of 2.8 kg
for an 80-kg lactating sheep feeding twin lambs to estimate the exposures. For lactating goats, the
CONTAM Panel has used daily dry matter intakes of 3.3 kg for a 60-kg goat for milking (4 kg milk/
day). No estimates of exposure have been made for fattening sheep and goats. For these livestock,
fresh or conserved forages are frequently the sole feed, and levels of MON in these feeds are generally
low or not reported.
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Horses
Horses are non-ruminant herbivores. They generally consume 2–3.5% of their body weight in feed
(dry matter) each day, of which a minimum of 50% should be as forage (pasture or hay) (NRC,
2007b). Mature horses with minimal activity can be fed forage alone, but for growing and active
horses supplementary feeding with cereal grains, cereal by-products (e.g. oats, barley and wheat bran)
and vegetable proteins is necessary. The CONTAM Panel has estimated the exposure for a 450-kg
horse, with a daily intake of 9 kg dry matter/day; as for ruminant livestock it is assumed that fresh
grass is the forage, and therefore makes no contribution to MON exposure (Table B.1).
B.1.2. Non-ruminant animals
Pigs
Although there is a considerable range of pig production systems in Europe, exposure estimates
have been made for piglets (pig starter), ﬁnishing pigs and lactating sows (using feed intakes
proposed by EFSA (2012)) (Table B.2)
Poultry
The CONTAM Panel applied the live weights and feed intakes reported for fattening chickens
(broilers), laying hens and turkeys proposed by EFSA (2012) and for ducks by Leeson and Summers
(2008) (Table B.2)
Farmed ﬁsh (salmonids and carp)
Commercially reared species include Atlantic salmon, rainbow trout, sea bass, sea bream, cod,
halibut, tuna, eel and turbot. In this Scientiﬁc Opinion, exposures to MON have been made for farmed
salmon and carp. Details of the body weights and feed intakes used are given in Table B.2.
Table B.1: Live weights, growth rate/productivity, dry matter intake for cattle, sheep, goats and
horses, and the proportions of the diet as non-forage
Animal species
(diet)
Live
weight
(kg)
Growth rate or
productivity
Dry matter
intake
(kg/day)
% of diet as
non-forage
feed
Reference
Dairy cows: grass-
based diet
650 40 kg milk/day 20.7 40 OECD (2009)
Dairy cows: maize
silage-based diet
650 40 kg milk/day 20.7 45 AFSSA (2009)
Beef cattle: grass
silage-based diet(a)
400 1 kg/day 9.6 15 AFRC (1993)
Beef cattle: cereal-
based diet
400 1.4 kg/day 10 85
Fattening cattle:
maize silage-based
ration
300 1.4 kg/day 6.6 25 Browne et al. (2004)
Fattening cattle:
cereal straw-based
diet
300 0.9 kg/day 8.0 68 EBLEX, 2008
Sheep: lactating 80 Feeding twin lambs 2.8 50 OECD (2009)
Goats: lactating(b) 60 6 kg milk/day 3.4 65 NRC (2007a)
Horses 450 Moderate activity 9.0 50 NRC (2007b)
(a): Housed castrate cattle, medium maturing breed.
(b): Months 2–3 of lactation.
Moniliformin in food and feed
www.efsa.europa.eu/efsajournal 85 EFSA Journal 2018;16(3):5082
B.1.3. Farmed rabbits
Feed intakes of 65–80 g/kg bw per day have been reported (Carabano and Piquer, 1998). For the
exposure estimates, the CONTAM Panel have assumed a live weight of 2 kg, and a daily feed intake of
75 g/kg bw (derived from Carabano and Piquer, 1998).
B.1.4. Farmed mink
For estimating exposure, the CONTAM Panel have assumed a live weight of 2.07 kg for a male mink
at pelting, and with a feed intake of 227 g/day (75 g dry matter) (NRC, 1982).
B.1.5. Dogs and cats
The amount of food consumed is largely a function of the mature weight of the animal, level of
activity, physiological status (e.g. pregnancy or lactation) and the energy content of the diet. In this
opinion, the CONTAM Panel assumed body weights (kg) and feed intakes (g dry matter/day) for dogs
and cats were 25/360 and 4/60, respectively (derived from NRC, 2006).
B.2. Diet compositions and inclusion of diet ingredients to the
exposure calculations
As reported in Section 3.3.2, most of the data on levels of MON provided to EFSA have been for whole
cereal grains, and therefore, estimates of exposure have been made using assumed levels of cereal
grains in the diets of farmed animals (including ﬁsh) and companion animals. In addition, levels of MON in
maize silages (n = 42) and cereal straw (n = 18) have been reported and these, together with levels in
cereal grains, have been used to estimate mean LB and UB exposures to MON for dairy and beef cattle.
B.2.1. Cattle, sheep, goats and horses
For most ruminants and horses, forages (either fresh or conserved) are important ingredients in
their diet, but they are normally supplemented with non-forage feeds such as cereals, cereal by-
products, oilseed meals and by-products of human food production. These may be fed either as
individual feeds, mixtures of feed materials or as species-speciﬁc complementary feeds in the form of
compound feeds. In some situations, however, forages may represent the total diet.
Fresh (grazed) or conserved grass (as silage or hay) are the principal forages for ruminants and
horses in the EU, but in the absence of any data on levels of MON in these feeds, it has been assumed
that they make no contribution to exposure. For other maize silage and cereal straw, however, the
presence of MON has been reported. Therefore, two estimates of exposure have been reported for
ruminants and horses, the ﬁrst of which assumes no exposure from forages (i.e. the main forages are
fresh grass and/or grass silage). Exposures have also been estimated for diets in which maize silage or
cereal straw are the main forage. AFSSA (2009) have provided example intakes of dairy cows fed maize
silage supplemented with maize grain and soybean meal, while example diets of beef cattle on maize
silage or cereal straw-based diets are taken from EBLEX (2008, 2012), and these are given in Table B.4.
Table B.2: Assumed live weights and feed intake for pigs, poultry and ﬁsh
Live weight (kg)
Feed intake
(kg dry matter/day)
Reference
Pigs: starter 20 1.0 EFSA (2012)
Pigs: ﬁnishing 100 3.0 EFSA (2012)
Pigs: gilts 50 2.0
Pigs: lactating sows 200 6.0 EFSA (2012)
Poultry: broilers(a) 2 0.12 EFSA (2012)
Poultry: laying hens 2 0.12 EFSA (2012)
Turkeys: fattening turkeys 12 0.40 EFSA (2012)
Ducks: fattening ducks 3 0.14 Leeson and Summers (2008)
Salmonids 2 0.04 EFSA 2012
Carp 1 0.02 Schultz et al. (2012)
(a): Fattening chickens.
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Horses are non-ruminant herbivores, and their diet should contain a minimum of 50% forages
(NRC, 2007b). While mature horses with minimal activity can be fed forage alone, for growing and
active horses supplementary feeding with cereal grains, cereal by-products (e.g. oats, barley, and
wheat bran) and vegetable proteins is necessary. Although oats are the preferred cereal for many
horse owners, other cereal grains and cereal by-products are also routinely used. In this Opinion, the
CONTAM Panel has estimated the exposure for a 450-kg horse, with a daily intake of 9 kg dry
matter/day, of which half is in the form of non-forage feeds and where oat grains represent 40% of
the non-forage component of the daily ration.
B.2.2. Pigs and poultry
In the absence of data for species-speciﬁc compound feeds or pigs and poultry, estimates of
exposure to MON have been made using levels of MON in whole cereal grains and their inclusion in
diets for each category of livestock as given in Table B.3.
B.2.3. Farmed rabbits
Rabbits are usually fed a pelleted diet (in the form of complete feedingstuffs) consisting of dried
forages, cereals and vegetable proteins supplemented with minerals, vitamins and trace elements.
Lebas and Renouf (2009) reviewed diet formulations used in experimental studies: in 58 diets, cereals
and cereal by-products (mostly wheat brans represented 18–20%. Dried lucerne is a particularly
important ingredient in some diets, and has been included at levels of up to 65% (Lebas and Renouf,
2009). In this opinion, the cereal grain inclusion rates used in a typical French commercial rabbit
compound, as provided by T. Gidenne, (Personal communication, 2011) have been used, details of
which are given in Table B.3.
B.2.4. Farmed mink
Mink are carnivorous animals and are fed high protein diets, and therefore commercially
manufactured mink feed consists largely of ﬁsh and land animal by-products, with lesser amounts of
cereals and cereal by-products. The proportions of cereal grains used in estimating the exposure are
given in Table B.3, and are based on information translated from Finnish to English provided by the
Finnish Fur Breeders Association in 2015.23
B.2.5. Farmed ﬁsh (salmonids and carp)
Traditionally, the principal raw materials used for the manufacture of ﬁsh feeds in Europe have
been ﬁshmeal and ﬁsh oils, and although alternative sources of oil and protein (e.g. soybean meals
and vegetable oils) are increasingly being used ﬁsh-derived feeds remain the major ingredients.
For many ﬁsh species, digestion of complex carbohydrates and the metabolic utilisation of the
absorbed glucose is low, reﬂecting the scarcity of carbohydrates in the aquatic environment (Guillaume
et al., 2001). Instead, ﬁsh obtain much of their energy from protein in the diet. Where carbohydrates
are used, they generally require some form of pre-treatment (e.g. cooking, ﬂaking or toasting).
Berntssen et al. (2010) provided details of the composition of a diet for growing salmonids, and the
CONTAM Panel used this feed formulation to estimate the exposures (Table B.3).
In contrast, studies with the common carp (Cyprinus carpio) have demonstrated greater intestinal
amylase activity than in carnivorous ﬁsh, which accounts for the better utilisation of carbohydrates by
these ﬁsh. The optimum level of carbohydrates appears to be 30–40% (FAO, Aquaculture Feed and
Fertiliser Resources Information System24), which allows for higher levels of cereals than in diets for
salmonids. The CONTAM Panel have adopted the ingredients of commercial compound feeds for carp
reported by Schultz et al. (2012) to estimate exposure to MON.
B.2.6. Cats and dogs
Most small companion animals derive their nutritional needs from processed food, and in 2010 EU
annual sales of pet food products was approximately 8.3 million tonnes.25 Although a wide range of
23 www.profur.fi
24 http://www.fao.org/ﬁshery/affris/en/
25 Available online: www.Fedif.org.
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ingredients is used in commercial diets, most dog and cat diets contain cereals (predominantly wheat,
rice or maize), cereal by-products, vegetable proteins and by-products of human food production.
The European Pet Food Industry Federation (FEDIAF) has provided information on typical
ingredient compositions of dry cat and dog food,26 and in the absence of data on species-speciﬁc
manufactured complete feedingstuffs, this has been used to estimate exposure to MON (details given
in Table B.3). However, these should be regarded as indicative only, since actual ingredients will vary
depending both on the availability of feed materials and the nutrient requirements of the animals.
Table B.3: Estimated example diet composition (%) for farmed species and companion animals
(cats and dogs)
Feeds Wheat Barley Oats Maize
Ruminants and horses
Dairy: high yielding 15 20 ni ni
Beef: intensive cereal ni 60 ni ni
Beef: fattening ni 40 ni ni
Sheep: lactating 14 18 ni ni
Goats: lactating ni 25 35 ni
Goats: fattening ni 20 40 ni
Horses ni ni 40 ni
Pigs and poultry
Pig starter 48 16 ni ni
Pig ﬁnisher 48 20 ni ni
Lactating sow 50 11 ni ni
Broilers: starter 32 ni ni 35
Broilers: grower 38 ni ni 38
Laying hens 30 ni ni 35
Turkeys: grower 30 35 ni ni
Ducks: grower 45 15 ni ni
Farmed ﬁsh
Salmonids 13 ni ni ni
Carp 24 ni ni 10
Farmed rabbits and mink
Rabbits ni 18 ni ni
Mink 6 1 ni 6
Cats and dogs
Cats 10 ni ni 5
Dogs 10 ni 0.5 6
ni: not included in the diet formulations.
Table B.4: Feed intakes of high yielding lactating dairy cows (40 litres/day) and beef cattle fed
diets based on different forages with non-forage feeds adjusted for milk yield, and beef
cattle
Ruminants
Quantities of feed consumed
(kg dry matter/day) Reference
Forage Maize grain Barley grain
Lactating dairy cows: maize silage-based diet 15.0 9.5 ni AFSSA (2009)
Fattening beef cattle: maize silage-based diet 4.9 ni ni EBLEX (2012)
Beef cattle: cereal straw-based diet 2.5 ni 4.1 EBLEX (2008)
Beef cattle: ‘Cereal beef’ 1.5 ni 5.5 EBLEX (2005)
ni: not included in the diet formulations.
26 FEDIAF, Personal communication by email, May 2016
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Appendix C – Benchmark dose modelling
This Appendix provides details on the calculation of the LD50 for female rats of the study by Abbas
et al. (1990) and BMDL values from the dose–response evaluation of pigs reported by Harvey et al.
(2001) using the BMD approach (EFSA Scientiﬁc Committee, 2017). Further details on the application
of BMDS and Proast software are provided as supplementary information in its Appendix A.
For the quantal response data from Abbas et al., all models available in the BMDS software were
selected using the default benchmark response (BMR) of 10% extra risk. For the quantitative response
data of Harvey et al. (2001), the BMR was deﬁned as a percent change of the magnitude of the
response when compared to that predicted at background, i.e. a relative deviation from background.
The default value of 5% (BMR = 0.05) was used as recommended by EFSA Scientiﬁc Committee
(2017) in the absence of statistical or toxicological considerations supporting a deviation from that
default value. The BMD analyses of quantitative data were based on means and standard errors of the
mean available from the reports of the selected studies. For interpreting the graphs and tables
obtained by PROAST, it should be noted that the data of each dose group are assumed to be
log-normally distributed such that the means are geometric means and the whiskers are based on
geometric standard deviations.
C.1. Calculation of the LD50 for female rats reported by Abbas et al.
(1990)
The dose–response data on female rats reported by Abbas et al. (1990) were analysed using the
BMD approach to calculate a LD50 and its lower 95% conﬁdence limit. Doses of MON, number of
animals per dose group and mortality are shown in Table C.1.
Minimum BMDL approach for BMD = 50% – female rats
The CONTAM Panel modelled the acute toxicity data of female rats of Abbas et al. (1990) (Table C.1)
to calculate an LD50 using the BMD approach with a BMR of 50% using the BMDS software accounting the
EFSA guidance (EFSA Scientiﬁc Committee, 2017). Thereby, the CONTAM Panel estimated the LD50 of
18.52 mg/kg bw with a lower 90% conﬁdence bound LDL50 of 13.08 mg/kg bw. The results of the BMD
analysis are presented in Table C.2. The multistage model in its default form in BMDS and the Weibull and
Gamma models could not be ﬁtted. The probit and logistic as well as the log-probit and log-logistic
models were saturated models. The AIC of the full model was AICFull = 23.00 with AICFull +2 = 25.00. All
models selected for the BMD analysis showed an AIC < AICFull +2 = 25.00. The AIC of the null model was
AICNull = 64.18 with AICNull 2 = 62.18. No selected model showed an AIC > AICNull 2 = 62.18. The
AICMIN = 7.00 was obtained by the log-logistic model and all other models, except the multistage cancer
and the quantal linear model, showed AIC values not larger than AICMIN +2 = 9.00 and were accepted.
The lowest BMDL50, denoted here as LDL50, of the accepted models was 13.08 mg MON/kg bw per day
obtained with the log-logistic model. The ﬁt is shown in Figure C.2 and more details of the analysis are
given in Supplementary Information Abbas et al. (1990)
Table C.1: Doses of MON, number of animals per dose group and incidences for the acute toxicity
of rats by Abbas et al. (1990)
Dose (mg MON/kg bw) Number of animals Incidence
0 5 0
2.5 5 0
5 5 0
10 5 0
20 5 4
40 5 5
60 5 5
80 5 5
100 5 5
MON: moniliformin; bw: body weight.
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Model averaging – female rats
Model averaging (MA) implemented in the EFSA tool based on the two-stage, probit, logistic, log-
probit, log-logistic, two-stage, Weibull, Gamma models and the exponential and hill model modiﬁed for
quantal data provided the BMC conﬁdence interval (MA-BMC-CI) of 13.5–17.6 mg/kg bw per day (for
details see in Supplementary Information Abbas et al., 1990). The corresponding Bootstrap plot of MA
is shown in Figure C.2.
Table C.2: Summary of dose–response analysis of acute toxicity data in female rats of Abbas et al.
(1990)
Models
Number of
parameters
Minus Log-
likelihood
p-value AIC
LD50 LDL50
Comment(mg/kg bw
per day)
Full model 9 2.50 na 23.00 na na
Null (reduced) model 1 31.09 64.18 na na
Probit 2 2.50 1 9.00 18.71 14.09 Accepted
Logistic 2 2.50 1 9.00 19,32 14.09 Accepted
LogProbit 2 2.50 1 9.00 18.32 13.14 Accepted
LogLogistic 2 2.50 1 7.00 18.52 13.08 Accepted
Multistage No ﬁt
Multistage Cancer 1 4.57 0.85 11.14 16.54 11.69 Accepted
Quantal-Linear 1 8.32 0.17 18.63 14.04 8.80 Not accepted
Weibull No ﬁt
Gamma No ﬁt
BMD50: benchmark dose response of 50%; BMDL50: 95% lower conﬁdence limit for the benchmark dose response (BMR) of
50%; bw: body weight; na: not available, including cases where the BMD/Ls were not calculated, the ﬁt was incomplete, or
serious or conﬂicting comments were noted (e.g. parameters reaching boundaries).
Note: The models with the lowest AIC among the accepted models and the model with the lowest LDL50 (corresponding to a
BMDL50) are in bold.
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Figure C.1: Dose–response curve of the ﬁtted model of lowest BMDL50 on the acute toxicity data
reported by Abbas et al. (1990) (see Table C.1). The (red) curve is the ﬁtted dose–
response curve and the dotted line curve indicates the 95% lower conﬁdence limit of the
calculated BMDL
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C.2. Calculation of BMDL values for haematological effects of MON in
pigs reported by Harvey et al. (2001)
Concentration–response data on the haematotoxicity of MON in barrows abotaine in two
consecutively conducted 28-day experiments, each designed for n = 6 animals per group, were
reported by Harvey et al. (2001). Concentrations of MON in feed, mean body weights and number of
animals per dose group and haematological effects of MON are shown in Table C.3. The CONTAM
Panel calculated for each dose group of the two experiments a mean body weight based on the
reported mean body weights of the pigs at start and after 28 weeks. Based on that and assuming a
1.2 kg feed intake per day, doses were calculated as shown in Table C.3.
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Figure C.2: Dose–response curves for the modelling averaging of the ﬁtted models of the data of
Abbas et al. (1990)
Table C.3: Concentrations of MON, samples sizes (N) body weights, calculated doses and
haematological effects of MON in pigs (means with s.e.m.) of the two experiments of
Harvey et al. (2001)
Experiment
Concentration
mg MON/kg feed
N
bw at
start
bw at
90 days
Mean bw
dose (kg)
mg MON/kg
bw per day
1 0 6 17.9 42.0 29.95 0
1 25 6 17.8 41.6 29.70 1.00
1 50 6 17.8 39.8 27.05 2.22
1 100 6 17.8 36.3 28.80 4.17
2 0 6 15.3 37.2 26.25 0
2 50 6 15.1 34.9 25.00 1.2
2 100 6 15.3 32.0 23.65 5.07
2 200 6 15.3 26.5 20.90 11.48
RBC HCT Hb MCH
6.22 (0.06) 40.7 (1.1) 13.6 (0.5) 21.9 (0.6)
5.98 (0.09) 39.8 (0.7) 12.9 (0.3) 21.6 (0.7)
5.01 (0.27) 33.8 (1.2) 11.3 (0.5) 22.5 (0.6)
5.48 (0.45) 28.2 (1.9) 9.3 (0.5) 17.3 (2.5)
5.02 (0.36) 41.0 (0.5) 14.1 (0.2) 28.4 (2.5)
3.29 (0.33) 31.8 (1.9) 10.6 (0.2) 33.1 (3.0)
3.05 (0.32) 29.2 (2.3) 9.4 (0.6) 31.3 (3.1)
2.96 (0.0) 25.0 (0.0) 8.4 (0.0) 28.4 (0.0)
MON: moniliformin; bw: body weight; Hb: haemoglobin; HCT: haematocrit; MCH: mean concentration haemoglobin; RBC: red
blood cell count.
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Figure C.3: Result of the dose–response evaluation the two experiments of Harvey et al. (2001)
combined for haemoglobin (Hb)
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Figure C.4: Result of the dose–response evaluation the two experiments of Harvey et al. (2001)
combined for haematocrit (HCT)
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Figure C.5: Result of the dose–response evaluation the two experiments of Harvey et al. (2001)
combined for the red blood cell count (RBC)
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Appendix D – Margin of exposure (MOE) values based on the NOAEL or
BMDL identiﬁed in relevant studies and the estimated UB or LB 95th
percentile and mean dietary exposure across animal species
Table D.1: Margin of exposure (MOE) values based on upper bound (UB) 95th percentile and mean
dietary exposure across animal species
Animal species
NOAEL/
BMDL
lg/kg bw
95th percentile
dietary exposure (UB)
Mean percentile
dietary exposure (UB)
Exposure lg/kg
bw per day
MOE value
Exposure lg/kg
bw per day
MOE value
Ruminants£ 200* 2.4 83 1.6 125
 Dairy cows 200* 0.8 250 0.32 625
 Beef cattle 200* 2.4 83 1.3 154
Lactating sheep 200* 1.3 154 0.4 500
Lactating goat 200* 1.8 111 0.86 233
Fattening pig (starter) 200* 5.6 36 2.2 90
Lactating sow 200* 3.2 62 1.2 166
Poultry
 Broiler chicken 1,400 10 140 3.2 438
 Laying hens 3,800 9.0 422 2.7 1407
 Fattening turkey 1,600 3.9 410 1.5 1067
 Fattening duck 2,300 4.9 469 1.9 1211
Horse 200* 0.68 294 0.27 741
Farmed ﬁsh 800# 1.5 533 0.51 1569
Farmed rabbit 200* 2.5 80 1 200
Farmed mink 920 1.1 836 0.33 2788
Dog 200* 0.8 250 0.33 606
Cat 200* 0.75 267 0.33 769
NOAEL: no-observed-adverse-effect levels; BMDL: benchmark dose lower conﬁdence limit; bw: body weight; UB: upper bound.
*: based on pig BMDL05;
#: reduced body weight gain reported in catﬁsh, £: based on various types of ruminants
For ‘ruminants’, it is reported the lowest calculated value from the various diets (as listed in Table 11 in the body of the opinion).
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Table D.2: Margin of exposure (MOE) based on lower bound (LB) 95th percentile and mean dietary
exposure across animal species
Animal species
NOAEL/ BMDL
lg/kg bw
95th percentile dietary
exposure (LB)
Mean percentile dietary
exposure (LB)
Exposure lg/kg
bw per day
MOE
values
Exposure lg/kg
bw per day
MOE
values
Ruminants 200* 0.27 741 0.04 5,000
 Dairy cows 200* 0.74 270 0.14 1,429
 Beef cattle 200* 0.27 741 0.04 5,000
Lactating sheep 200* 1.2 167 0.18 1,111
Lactating goat 200* 0.86 233 0.55 364
Fattening pig (starter) 200* 4.9 40.8 1.1 181.8
Lactating sow 200* 2.8 71 0.65 308
Poultry
 Broiler chicken 1,400 9.7 144 2.4 583
 Laying hens 3,800 6.5 585 2.1 1,810
 Fattening turkey 1,600 3.6 444 0.71 2,254
 Fattening duck 2,300 4.3 535 0.98 2,347
Horse 200* 0.31 645 0.06 3,333
Farmed ﬁsh 800# 0.38 2,105 0.1 8,000
Farmed rabbit 200* 2.5 80 0.39 513
Farmed mink 920 0.99 929 0.24 3833
Dog 200* 0.8 250 0.28 714
Cat 200* 0.75 267 0.22 909
NOAEL: no-observed-adverse-effect levels; BMDL: benchmark dose lower conﬁdence limit; bw: body weight; LB: lower bound.
*: based on pig BMDL05;
#: reduced body weight gain reported in catﬁsh.
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Annex A – Supporting tables on food and feed occurrence and human
exposure
Annex A can be found in the online version of this output (‘Supporting information’ section): http://
onlinelibrary.wiley.com/doi/10.2903/j.efsa.2018.5082/abstract
Description: Supporting tables on food and feed occurrence and human exposure
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